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ABSTRACT
In West Africa, the Acquired Immunodeficiency Syndrome (AIDS) is caused 
by both types of Human Immunodeficiency Virus HIV-1 and HIV-2 and the majority 
of people infected with HIV-2 remain healthy for over 15 years.
The major goal of this work was to determine and describe genetic variants 
associated with phenotypic changes at the population level and study their role in 
pathogenesis and immune response. Studies presented in this thesis were carried 
out in two well established HIV-2 cohorts in Guinea Bissau and Gambia. Using 
recent tools in molecular medicine i.e. sequence-based techniques (SBT) (Chapter 
2), we determined and comprehensively described variations at the two most 
polymorphic regions of the human genome: HLA and KIR gene complexes located 
on chromosomes 6 and 19, respectively, in these cohorts (Chapters 3 and 6). The 
data showed high heterogeneity in allele and genotype frequencies between the 
studied populations. Furthermore, we related the presence of gene variants to 
HIV-2 antibody status and study their effect on markers of disease progression, 
notably CD4+ T cell count and viral load (Chapter 4). Here we showed for the first 
time that HLA-B*1503 associates with poor prognosis after HIV-2 infection and 
HLA-B*0801 with susceptibility to HIV-2 while the compound genotypes 
KIR2DL2+HLA-C1 and KIR2DS2+HLA-C1 protect against HIV-2 acquisition in the 
Manjako ethnic group. None of the HLA class I alleles/haplotypes and KIR gene 
profiles was found to influence HIV-2 infection in the second cohort, which was of 
mixed ethnic origin (Chapter 5).
In general, we observed that alleles previously shown to be associated with 
HIV-1 disease in western populations showed no effect in HIV-2 infection. This 
emphasizes the need to study HLA and HLA/KIR combinations in different 
populations in order to better inform subsequent vaccine design and evaluation in 
target populations.
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CHAPTER 1 : INTRODUCTION
This chapter describes the epidemiology of the human immunodeficiency 
virus type 1 (HIV-1) and type 2 (HIV-2) with particular reference to the spread of 
HIV-2 in West Africa and other parts of the world. The structure and genomic 
organisation and life cycle of both viruses are discussed. A review of host 
immunity in HIV infection is presented with information on the role of Human 
Leukocyte Antigens (HLA) and Killer Immunoglobulin-like Receptors (KIR) genes 
in the control of HIV from previous epidemiological studies. The structure and 
functions of the major histocompatibility complex (MHC) in humans and those of 
the genes encoding KIR molecules are also described. The interaction between 
KIR and HLA, which governs to an extent the activity of NK cells, is an important 
part of the innate immune response to pathogens.
HIV epidemiology
The Acquired Immunodeficiency Syndrome (AIDS) is the most devastating 
pandemic of our times (Figure 1.1). It is caused by two closely related 
retroviruses of the family retroviridae namely: Human Immunodeficiency Virus 
(HIV) type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 was first isolated in 1983 in 
France and United States of America (USA)12, and three years after, the second 
retrovirus (HIV-2) was isolated from two West African patients3 one from the Cape 
Verdes Islands and the other from Guinea Bissau. By 2007 it was estimated that 
more than 33 million people have been infected with both viruses4. While HIV-1 is 
present in nearly every country, HIV-2 remains geographically confined primarily to 
West Africa since its discovery in 1986. Both viruses have caused substantial 
morbidity and mortality worldwide.
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Figure 1.1: The global distribution of HIV infection in adults
(Reproduced from Report on the Global AIDS Epidemic, UNAIDS/WHO, 2008)
HIV epidemic in Africa
Africa remains the epicentre of HIV/AIDS and is the continent most affected 
since the start of the pandemic in the 1980’s. Sub Saharan Africa harbours more 
than 2/3rd of all people affected by this scourge and accounts for three quarters of 
all AIDS related deaths4. Although the global proportion of people living with the 
disease has levelled off in most parts of the world since the year 2000, the 
proportion of African living with HIV/AIDS in Sub Saharan Africa is continually 
rising as well as are the number of new infections (Figure 1.2). Of the 2.7 million 
new HIV infections recorded in 2007, 1.9 million were from Sub Saharan Africa. 
There are, however, regional differences with regards to the prevalence and 
incidence of HIV in this part of the world. For example, in most West African 
countries the prevalence of HIV infection is less than 2%, whereas it is greater 
than 20% in many Southern African countries4. Similarly, the epidemic varies 
significantly from one country to another even within the same region probably due 
to many complex reasons including but not limited to population genetic diversity,
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social behaviour and environmental factors, and differences in the circulating 
strains/type of virus predominating.
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Figure 1.2 An estimate of the number of people living with HIV from the adult 
populations in Sub Saharan Africa for a 17 years period (1990-2007).
Black squares represent the number of people living with HIV; Red circles represent the percent 
HIV prevalence among adults aged 15-49 years; Bars indicate the range around the estimate 
(Reproduced from Report on the Global AIDS Epidemic, UNAIDS/WHO, 2008)
HIV epidemic in West Africa
AIDS in West Africa is caused by two closely related retroviruses HIV-1 and 
HIV-2, which differ greatly in pathogenesis5. Clustering analyses of sequences of 
Simian Immunodeficiency Virus (SIV) from chimpanzees (Pan troglodytes 
troglodytes) (SIVCpz) and sooty mangabeys (Cercocebus torquatus atys) (S IVsm) 
and those of HIV isolated from people living in close proximity to these animals in 
Sierra Leone, Liberia and Ivory Coast suggest that HIV-1 and HIV-2 entered the 
humans in Africa through separate cross-species transmission events67. HIV-2 is 
believed to have resulted from at least eight distinct cross-species transmissions 
of SIVsm in West Africa8'12 and is thought to have been in the region prior to the 
war of independence in Guinea Bissau in the 1960’s1314. However, it was first 
described to have infected healthy commercial sex workers in Dakar Senegal15 in
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1985 and isolated the following year from two West African patients: one from 
Guinea Bissau and the other from the Cape Verdes Islands3. Since then, HIV-2 
remained confined to the West African sub region. Only a few incident cases of 
HIV-2 infections have been reported outside West Africa. Interestingly, most of 
these cases have been linked to history of previous contacts with West Africa or 
countries with economic ties with the sub region (Figure 1.3). Examples of 
countries where occasional cases of HIV-2 infection have been reported include 
Mozambique, Angola, France and Portugal. Guinea Bissau has reported one of 
the highest frequencies of HIV-2 infection in the world, reaching 20% amongst 
adults aged 40 years and above living in urban areas1617. For the past decade or 
so, the prevalence of HIV-2 in West Africa has been stable or declining in most 
countries while that of HIV-1, which was recently introduced in many of these 
countries, is steadily rising and overtaking HIV-2.
Seroprevalence of HIV2 for Low-Risk Populations 
in West Africa
/  O'JjIYlO
j  & u rkinj {
Pet. Seropositive
% 5.0-9.9
O  10.0-19.9
O 20 0 +
| Benin 
Togo
U.S. Gctct u t  Bureau P c **JJ lc r i D v ls lo n  
If-Yfc+rdlcrdl Center.
IfV.'A IDS S urve illance C u lj B « C  J u w 2 » 1 .
Figure 1.3: Map of West Africa
Showing the distribution of HIV-2 in the sub region (Source: The U.S. Census Bureau Population 
Division)
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The Genetic structure and organisation of HIV
Morphology
The mature HIV virion has 2 strands of RNA (Figure 1.4), measures on 
average between 100-120nm in diameter and is roughly circular in shape. HIV 
particles surround themselves with a coat of fatty material known as the viral 
envelope. Projecting from the envelope are the gp120 and gp41 (collectively 
known as gp160) proteins. Just below the viral envelope is a layer of matrix 
proteins (p17). The viral core (or capsid) is found within the cytoplasm and 
constitutes the p24 proteins. Three vital enzymes are a prerequisite for HIV 
replication: reverse transcriptase, integrase and protease. They are located inside 
the viral capsid as are the viral genetic materials (RNA).
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Figure 1.4: Structure of an HIV virion
(Adapted from Structural Biology of HIV (Felix Voigts Hoffmann), http://spider.iwr.uni- 
heidelberq.de/teachinq/wes/2005/03 Structural Biology of HIV (Felix Voiqts-Hoffmann).pdf)
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Genomic organization
HIV-2 genome sequences are much closer to that of SIVsm than those of 
HIV-1. HIV-2 genome is made up of about 9700 nucleotide compared to 9500 
nucleotides in HIV-118. The difference arises from the difference in the length of 
long terminal repeats (LTR), which are slightly longer in HIV-2. But in general, the 
genetic layout of HIV-2 genome is similar to that of HIV-1: 5’LTR -  gag -  pol -  
central region -  e n v -  orfF -  3’LTR (Figure 1.5).
HIV has nine genes: three of them (gag, pol and env) contain the 
information needed to make structural proteins for new viral particles, the other six 
genes, known as accessory/regulatory genes: tat, rev, nef, vif, vpr and vpu (or vpx 
in HIV-2), code for proteins that control the ability of the virus to successfully infect 
a cell, replicate, assemble and bud-off new virions. The function of tat, rev and nef 
is to regulate viral gene expression. The tat gene is very important in maintaining 
the infectivity of the virus. Studies have shown that any mutation or deletion in the 
tat gene abolish viral infectivity and that the control of HIV gene expression 
depends on the interaction between the tat and rev genes19 20. On the other hand, 
the nef gene mediates the enhancement of viral infectivity and replication, 
downregulates CD4 and MHC class I molecules from the cell surface of the 
infected cell, and also modulates cellular activation pathways.
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Figure 1.5: HIV-1 and HIV-2 genomic organization
(from http://www.hiv.lanl.QOv/content/seauence/HlV/COMPENDIUM/1995/INTRO.Ddf)
The HIV replication cycle
The HIV life cycle can be divided into two phases: early phase and late 
phase (Figure 1.6). The former begins when a virus particle attaches to a CD4 
receptor and one of two co-receptors (CCR5 or CXCR4) on the surface of a CD4+ 
T lymphocyte. This interaction subsequently allows the viral envelope to fuse with 
the host cell membrane. The contents of the HIV particle containing the genetic 
material (RNA) are then released into the cell, leaving the envelope behind. Upon 
entry into the cell, an HIV enzyme (reverse transcriptase) converts the single 
stranded viral RNA into a double stranded HIV DNA, which is then transported into 
the cell's nucleus. Once in the nucleus, the enzyme integrase splices and 
integrates the viral DNA into the host DNA. The integrated HIV DNA is known as 
a provirus and may lie dormant within a cell for a long time (several years) 
awaiting cell activation. When the cell is activated the provirus uses the host 
enzyme (RNA polymerase) to make copies of itself. The human DNA (including 
the proviral DNA) is converted into messenger RNA, which is transported outside
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the nucleus, and used as a blueprint for producing long chains of HIV proteins and 
enzymes. Among the strands of messenger RNA produced by the cell are 
complete copies of HIV genetic material. Another HIV enzyme (protease) cuts the 
long chain of HIV proteins into smaller individual HIV proteins. These gather 
together with the newly made copies of HIV RNA and enzymes to form new viral 
particles which eventually get out of the host cell, develop further into mature 
viruses and attach to other CD4 molecules and co-receptors to infect other CD4+ 
cells.
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Figure 1.6: Features of HIV replication cycle.
The early phase begins with CD4 recognition and ends with integration of the HIV DNA into the 
host genome: the late phase includes all other events from transcription of the integrated DNA to 
virus budding and maturation (Reproduced from: Turner et al. 1999 Structural Biology of HIV, JMB 
285:1-32).
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Comparison of HIV-1 and HIV-2 infection
HIV-1 and HIV-2 share between 30-60% similarities in most genes. 
However the viruses differ in many aspects. The HIV-2 genome contains the vpx 
gene that takes the place of the vpu gene in the HIV-1 genome18. The ease of 
transmission and pathogenicity of HIV-2 are reduced compared to HIV-121. HIV-2 
uses a broad range of chemokine receptors such as CCR5, CXCR4, CCR1, 
CCR3, CCR2B, BOB and BONZO2223. The proviral genomes of HIV-1 and HIV-2 
are approximately 10 kb in length. The error rate of the virus reverse transcriptase 
is likely to be higher in HIV-1 than in HIV-2. A number of studies have estimated 
the rate of base substitution errors to range between 1:2000 to 1:4000, suggesting 
a value between 5 and 10 misincorporation per virus genome in each round of 
reverse transcriptase and as a result, no two virus isolates are genetically 
identical24 25.
Natural history of HIV infection
HIV can be transmitted through blood, blood products, bodily fluids, breast 
milk, sexual contact with an infected person, and vertically from a mother to her 
infant in utero or during delivery26. A successful HIV infection is largely dependent 
on the interaction between the host and viral factors. A balance between the host 
factors and those of the virus is also a major determinant of the outcome of the 
infection. HIV targets are specific host cells carrying receptors and co-receptors 
necessary for binding and entry into the host cell. HIV infection activates the host 
immune system causing a wide pool of cell death (apoptosis). As a result, there is 
depletion of CD4+ T lymphocytes and a contest for power between the virus and 
the immune system. Some people, however, are able to mount a better immune 
response to control the rate at which the virus multiplies. Such individuals, 
commonly known as long-term non-progressors (LTNP), may remain chronically
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infected for many years with minimal loss of CD4+ T cells and very low or 
undetectable plasma viral load. In contrast, other people succumb to the disease 
within a very short time following infection when their immune systems are unable 
to keep the virus under check by failing to control its replication successfully. 
Following infection, the clinical course of HIV can be divided into three phases: 
acute/primary, asymptomatic/latent and AIDS (Figure 1.7).
Acute/primary phase of HIV infection
The initial/acute infection with HIV is subclinical and may be clinically 
undetected. Within 2-3 weeks the infected individual may develop a rash followed 
by fever and lymphadenopathy. Opportunistic infections are generally not seen at 
this stage and a large majority of patients remain asymptomatic.
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Figure 1.7: Phases of HIV infection and CD4+ T cell and viral load dynamics
(Reproduced from Paranjape RS, Indian J Med Res 2005 121:240-55)
The primary phase of HIV infection begins soon after seroconversion -  the 
time when the HIV antibody test becomes positive for the first time. 
Seroconversion usually takes place four to eight weeks after primary infection with
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HIV27 28. Symptoms are rare during the acute phase of HIV infection but some 
15% of individuals at this stage experience some syndromes including sore throat, 
headache, mild fever, fatigue, muscle and joint pains, swelling of the lymph nodes, 
rash, and (occasionally) oral ulcers, lasting between one and two weeks27.
The initial burst of HIV, releasing up to 107 HIV RNA copies per ml of 
plasma27 takes place during the acute phase of infection and because of the high 
level of circulating virus after the burst, there is a rapid systemic dissemination of 
the virus throughout the body. This stimulates the immune system to respond 
vigorously to the attack, with both humoral and cell mediated immune responses 
coming into play to curtail the spread of the virus29 30. Consequently, a dramatic 
downregulation of viraemia and virus expression in peripheral blood mononuclear 
cells (PBMC) follows the vigorous immune pressure mounted against the virus3132. 
Unfortunately, this reduction in viral load in the peripheral blood does not 
completely eliminate viruses from the body but only drives them to an equilibrium 
level termed the ‘viral set point’ (Figure 1.7). This is an indication that the control 
of virus expression by the immune response is ineffective and can not completely 
arrest viral replication during acute/primary infection. However successful 
downregulation of the amount of circulating virus to a low level that can be 
tolerated by the body (viral set point) is usually associated with resolution of the 
acute viral syndrome. In the majority of HIV-1 infected individuals this occurs six 
to eight weeks after the onset of the symptoms and coincides with the first 
appearance of HIV-specific immune responses27 32.
The immunologic events that take place during the course of acute/primary 
HIV infection are complex and the role played by the various arms of the immune 
system immediately after primary infection to control the spread of the virus is 
currently unclear. Several studies have demonstrated that vigorous HIV-specific 
humoral and cell-mediated immune responses can be detected very early during
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the primary phase of HIV infection in the large majority of HIV-1 infected 
individuals30 32'34, and they are likely to contribute to the suppression of the initial 
burst of viral replication27. High titres of anti-HIV antibodies are found at the time 
of peak viraemia and at the point of downregulation of viraemia32 but these 
antibodies produced during the primary phase of infection are non-protective and 
lack neutralising activity needed to reduce the amount of free living viruses from 
the periphery30 33. It is surprising and still not well understood why neutralising 
antibodies are not produced during the acute/primary phase of HIV infection but 
appear rather late during the course of the disease.
The CD8+ T lymphocyte count increases dramatically during acute/primary 
phase of HIV infection (up to 20-fold above normal in many patients) while the 
CD4+ T cell count drops significantly. The appearance of HIV-specific CD8+ T cell- 
mediated cytotoxicity also known as the cytotoxic T lymphocyte (CTL) function that 
are readily detected in peripheral blood mononuclear cells (PBMC) correlate well 
with the downregulation of the high viraemia observed following primary HIV 
infection30 34. It is proposed that CD8+ T cells contribute to the downregulation of 
viraemia from the initial viral burst by directly killing cells in which active virus 
replication is taking place (a cytotoxic mechanism) or by secreting cytokines and 
other soluble factors to mediate the suppression effect27 34.
A panel of cytokine expressions have been detected during primary 
infection by many investigators35'37. IFN-y expression predominates with the level 
remaining constant throughout the primary phase of infection in certain individuals 
while in others, its peaks very early post infection35. It is expressed predominantly 
by the CD8+ T cell population. In contrast, the levels of TNF-a and IL-10 peak late 
during the course of primary infection35. The levels of other cytokines including IL- 
2, IL-4, and IL-6, measured during the acute/primary phase of HIV infection are 
usually very low or barely detectable in many subjects35.
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The reason(s) associated with lack of clearance of HIV from the system by 
the vigorous and specific immune responses observed in most HIV infected 
subjects during the acute/primary phase of HIV infection remain speculative. 
Some have suggested that this could be due to the formation of a large pool of 
latently infected cells that succeeded in avoiding the HIV-specific CTL responses36 
38 while others proposed that the trapping of infected cells and viral particles in 
different body compartments not readily accessible by specific CTLs serves as 
reservoir for de novo infection39 40.
It is however well documented that high viral turnover leading to complete 
changes in virus phenotypes and genotypes helps HIV to escape from host 
immune responses .
Asymptomatic/latent/chronic phase of HIV infection
This phase begins immediately after the reduction of viraemia and the 
resolution of the primary syndrome. In the majority of HIV infected individuals, the 
asymptomatic phase spans over many years, on average 10 and 15 years for HIV- 
1 and HIV-2 infected individuals, respectively. The virus load is at its set point but 
active viral replication persists at much slower rate41 compared to that observed 
following primary infection.
Variegated and broad HIV-specific CTL responses are continually detected 
over the latent period in a good proportion of HIV infected individuals targeting 
envelope, gag, pol and some of the regulatory proteins including nef and tat27 42. 
In addition, CD4+ T cell responses to a variety of HIV proteins have also been 
observed in many subjects27, but their role in any attempt to control viral replication 
is not clear.
Neutralising antibodies are active in reducing the numbers of free virions 
but are less effective in blocking cell-to-cell transmission43-45. The activities of
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neutralising antibodies are detected for a very long time during the latent phase of 
infection, but rarely neutralise the currently circulating strain as viral escape 
through envelope mutation occurs rapidly. In addition, a variety of other antibodies 
against HIV proteins are also detected during this phase27.
AIDS phase of HIV infection
AIDS defining illnesses and a significant drop of CD4+ T cell count (< 200 
cells per pi of blood) characterise this stage of infection. The virus load increases 
dramatically and continuously as will all other virologic parameters in the 
peripheral blood and lymphatic system2740.
A profound immunosuppressive state with decline of HIV-specific cytotoxic 
activity is observed at this last stage of the disease42. Antibody titres against most 
of the HIV proteins significantly decrease and neutralising antibodies are rarely 
detected. In contrast, the level of production of certain cytokines including IFN^y 
and IL-10 mainly by CD8+ T lymphocytes remains high suggesting that CD8+ T cell 
activity remains the only protective mechanism at the AIDS stage, since most of 
the CD4+ T cells are either infected or destroyed27.
Why should HIV target CD4+ T cells: the function of T helper 
lymphocytes in the immune system
HIV (both type 1 and type 2) primarily targets a subgroup of lymphocytes (a 
type of white blood cells) that carry the CD4 molecules on their cell surface for 
destruction. These cells are collectively known as CD4+ T cells and are not known 
to have significant cytotoxic activity28. The destruction of a particular category of 
CD4+ T cells known as T helper (Th) cells, brings about the immunodeficiency 
syndrome observed in all HIV infected individuals at the last stage of disease. Not 
all T cells with CD4 molecules on their cell surface are helper cells. In line with
this, some natural killer T cells, and regulatory T cells express CD4 but do not
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perform the same function as Th cells. Helper T cells are particularly important to 
the immune system as they help in maximising the ability of other immune cells to 
deal with invading pathogens. The role of Th cells is to activate and direct other 
immune cells in carrying out their function and preserve the integrity of the body.
During the course of HIV infection, CD4+ T cells are massively infected after 
the initial burst of the virus at the primary phase of infection and a good proportion 
of them are destroyed leading to a sudden drop in CD4+ T cell counts in the 
peripheral blood. But this event is short lived since the body quickly 
accommodates, probably by producing more T helper cells from the thymus to 
help other immune cells bring the situation to normal. It has been proposed that 
during the latent phase of HIV infection, the viruses present have low affinity for T 
cells (but high affinity for other CD4+ antigen presenting cells (APCs), such as 
dendritic cells (DCs) and macrophages) and as such, the rate at which CD4+ T 
cells are destroyed is minimised while the body compensates for loss of Th cells by 
generating more cells from the thymus. Towards the end of the latency period, 
viruses gain tropism for T lymphocytes, probably by switching co-receptor usage. 
Early in infection, the virus tropism is predominantly for CCR5, which is expressed 
on APCs and memory Th cells, but later in infection the virus usually switches to 
use the CXCR4 receptor, which is widely expressed in the naTve T-cell pool. Once 
these viruses become lymphotropic, they begin to infect CD4+ T cells more 
effectively such that the body’s replenishment mechanism becomes exhausted 
and overwhelmed. This coincides with the time that the much-needed help from 
Th cells gradually becomes unavailable, probably because the CD4+ T cell 
population pool is diminishing progressively. Other immune cells such as CD8+ T 
cells and B cells that depend on getting help from Th cells to carry out their 
immunologic functions28 become inert and no longer able to protect the body from 
invading pathogens, including newly generated HIV virions. Various pathogens
escaping the immune surveillance then cause opportunistic infections that 
gradually increase in severity, leading to the collapse of the immune system and 
death.
Th cells produce a wide range of cytokines. The pro-regulatory (type 1) 
cytokines they produce include IFN-y and IL-12; and the pro-inflammatory 
cytokines (type 2) include IL-4, IL-5, IL-10, and IL-13. These cytokines are very 
important in activating and maintaining the effector function of other immune cells 
such as phagocytes (e.g. macrophages). The profile of cytokines produced by Th 
cells during HIV infection and the fine balance between these cytokines in terms of 
qualities and quantities have been shown to correlate with the stage of infection46 
47. For example, a strong CD4+ T cell response during the primary phase of HIV-1 
infection was found to correlate with slow disease progression and better control of 
viral replication46. Recently, Ostrowski et al. and Imami and colleagues 
independently demonstrated that impaired production of cytokines predicted 
mortality in HIV-1 infected individuals while preserved capacity to produce the 
correct cytokine profile was associated with prolonged survival and LTNP4849.
In HIV-2 infection, unlike HIV-1, the large majority of patients maintain a 
healthy CD4+ T cell population with a strong HIV-2-specific Th cell response that is 
highly polyfunctional (producing both IFN-y and IL-2) with high proliferative 
capacity for a long time post infection50. Duvall and colleagues proposed that the 
maintenance of a well-preserved and functionally heterogeneous population of 
HIV-specific Th cell response can significantly delay disease progression; a 
phenomenon frequently observed in the majority of HIV-2 infected subjects in 
West Africa.
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The role of cytotoxic T lymphocytes in HIV infection and disease
The cytotoxic T (Tc) cells are a subgroup of leukocytes that are vested with 
the ability to defend the body against intracellular pathogens (e.g. certain bacteria 
and viruses). Tc cells express a wide variety of T cell receptors (TCR) that interact 
with target cells presenting specific antigenic peptides bound to MHC class I 
molecules at their cell surfaces.
Following HIV infection, CD8+ T cells are exposed to virally infected cells. 
Tc cells recognise HIV infected cells when they express HIV antigens on the cell 
surface bound to a specific HLA class I molecule. Tc activity is dependent on cell- 
to-cell contact. During the cell-to-cell interaction, the Tc enzyme known as 
perforin, perforates the cell membrane of the infected cell and allows granzyme 
(another enzyme) to penetrate into the infected cell. The presence of granzyme in 
the cytoplasm of the infected cell results in the activation of a series of enzymes 
that eventually lead to apoptosis (programmed cell death)28.
During the acute phase of HIV infection, the HIV-specific CD8+ T cell 
response is detected after the initial viral burst and is thought to contribute 
significantly to the decline in viraemia29 30, a process that influences disease 
progression5152. HIV-1 Gag- and Nef-specific CTLs have been reported to appear 
very early post HIV infection but during the course of the disease HIV-specific CTL 
responses to most of HIV antigens would normally be detected. In HIV-2 infection, 
Gag-specific CTL responses are readily detected at a higher magnitude in people 
who control the viraemia better53. However, it is not yet well understood why these 
CTL responses are incapable of preventing further infection of CD4+ T cells or 
completely stop viral replication in the same individual54 55. The progressive loss 
of CTL activity observed as the disease progresses has been attributed to the 
gradual loss of CD4+ T cell population and particularly to the decrease in the
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number of T helper cells46 56. Some defects in enzyme expression and cytokine 
production have been reported to also affect CTL activities5758.
Immunogenetic factors that influence susceptibility to infectious 
diseases in Africa.
Infectious diseases are a huge health problem worldwide and account for 
most of the deaths in developing countries particularly those in Sub Saharan 
Africa. In this part of the world, a combination of pathogen and human genetic 
factors, complexes with environmental factors to determine the susceptibility to 
and the outcome of any infectious disease. For many years, great efforts have 
been made by researchers to identify and characterise relevant genes that 
influence susceptibility to bacterial, viral and parasitic diseases59-64.
Given the complex nature of infectious diseases that prevail in Sub Saharan 
Africa, the high inter-population heterogeneity, and the complex immune 
responses that follow exposure to an infectious agent, it seems likely that several 
human genes may collectively and/or individually play a role in determining 
susceptibility to infection. In addition, the outcome of the infection might also 
depend on the genetic profiles of the infected individuals65 66.
Genes of the HLA loci are particularly important in the initiation and 
regulation of immune responses to diverse range of pathogens. Their role in the 
susceptibility and progression to several infectious diseases have been thoroughly 
investigated in cohorts and large population studies59 60 62 67-71. In Africa, one of 
the largest HLA association studies in an infectious disease was done in malaria in 
The Gambia60. The results of that study showed for the first time that there were 
strong HLA associations with the outcome of infection by demonstrating that HLA- 
B*5301 and HLA-DRB1*1302 independently associated with protection against 
severe malaria in young African children5972.
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Genetic factors that influence susceptibility to HIV infection and 
progression to AIDS.
Since the onset of HIV pandemic, a number of approaches have been used 
to estimate the role of host genetic polymorphisms, with particular interest 
accorded to genes of the MHC region, in the susceptibility to HIV infection and 
disease progression. A few cohort studies have clearly demonstrated the 
differential susceptibility to HIV acquisition in “at risk” groups such as the 
commercial sex workers (CSW) in The Gambia and Kenya73"75. The control of 
CD4+ T cell depletion by virus specific cytotoxic T cells (CTL) is an important 
immunogenetic response protecting individuals from both infection and rapid 
disease progression76 71. The most frequently studied phenotypes in large 
population and cohort studies have been “time to AIDS” and “time to death” 
following HIV infection65.
An increasing number of chemokine and cytokine genes and their receptors 
have also been identified from association studies to have some impact on HIV 
outcomes (reviewed in ref 7878). Of note is the association of a variant of CCR5 
(CCR5A32) with acquisition of HIV-1 and progression to AIDS. People who carry 
two copies (homozygotes) of this variant of CCR5 gene are protected against 
heterosexual acquisition of HIV-1 while HIV-1 infected individuals carrying only 
one copy of CCR5A32 (heterozygotes) progress very slowly to AIDS79 80. This 
mutation has not yet been found in people of Sub Saharan Africa descent81 
implying that the slow progression to AIDS observed in the majority of HIV-2 
infected individuals in West Africa can not be attributed to the presence of this 
mutant in West African patients. One study showed that a single nucleotide 
polymorphism (SNP) in the CCR5 ligand RANTES has been linked to more rapid 
disease progression82. Others have demonstrated that an amino acid change in
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CCR2 gene from Valine to Isoleucine (CCR2V64I) disrupts the interaction with 
CXCR4 and reduces its expression, leading to a delay in the onset of AIDS in HIV- 
1 infected individuals83. Winkler and colleagues found in a large multi-cohorts 
study that a single mutation in stromal derived factor 1 (SDF-1), the ligand for 
CXCR4, considerably delays the onset of AIDS in HIV-1 patients84. 
Polymorphisms in other cytokine genes such as IL-2, IL-4, IL-10, NRAMP1, IFN^y, 
and TNF -a have been inconsistently associated with HIV outcomes in different 
populations85'87. A summary of some of these polymorphic genes with specific
mutations that affect the outcome of HIV infection is presented in Table 1.1 
Table 1.1: Human Genes that affect HIV/AIDS
Gene Allele Mode Effect Mechanism of action
HIV entry
CCR5 A32 Recessive Prevent infection Knockout CCR5 expression
A32 Dominant Prevent lymphoma (L) Decrease available CCR5
A32 Dominant Delay AIDS Decrease available CCR5
CCR5 P1 Recessive Accelerate AIDS (E) Increase CCR5 expression
CCR2 I64 Dominant Delay AIDS Interact with CXCR4
CCL5 In1.1c Dominant Accelerate AIDS Decrease RANTES expression
CXCL12 3'A Recessive Delay AIDS (L) lmpedeCCR5-CXCR4 transition
CXCR6 E3K Dominant Accelerate PCP (L) Altered T-cell activations (?)
CCL2-CCL7-CCL11 H7 Dominant Enhance infection Stimulate immune response
Cytokine anti-HIV
IL10 5'A Dominant Limit infection Decrease IL10 expression
5'A Dominant Accelerate AIDS Decrease IL10 expression
IFNG -179T Dominant Accelerate AIDS (E)
Acquired immunity, cell mediated
HLA A.B.C Homozygous Accelerate AIDS
Decrease breadth of HLA class 
I epitope recognition
B*27 Codominant Delay AIDS Delay HIV-1 escape
B*57 Codominant Delay AIDS Delay HIV-1 escape
B*35-Px Codominant Accelerate AIDS Not clear
Acquired immunity, innate
KIR3DS1 3DS1
Epistatic with 
HLA-Bw4
Delay AIDS Not clear
E, acts early in AIDS progression; L, acts late in AIDS progression; PCP, Pneumocystis carinii 
pneumonia; ?,plausible mechanism of action with no direct empirical support. All other 
mechanisms have quantitative expression differences among alternative alleles that suggest a 
mechanism. (Adapted from: 0 ”Brien SJ and Nelson GW, Nature genetics 2004 36(6):565)
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A number of HLA alleles have been identified that may influence HIV 
outcomes but consistent associations are rare probably due to lack of power to 
detect particularly strong associations. One other reason could be that of 
inadequate sample sizes and inappropriate selection of controls in multiethnic 
groups of subjects participating in these association studies.
It is important to note that innate antiviral immunity is an ancient defense 
mechanism, reflecting the struggle of multicellular organisms such as humans to 
survive. A wide variety of other innate defences against HIV other than HLA and 
KIR have been reported for ecample APOBEC-3G and Trim5 alpha.
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The HLA system
Genes of the major histocompatibility complex (MHC) in humans govern the 
expression of proteins on the surface of cells, which were originally described in 
the recognition of ‘self and ‘non-self in tissue transplantation and are key 
elements of the immune response to infection. This complex in man is called the 
“Human Leukocyte Antigen” (HLA) system. It comprises a set of highly 
polymorphic genes located on chromosome 6 (6p21.31) that encode cell surface 
molecules, vested with the ability to present short peptides to T cells for 
recognition, resulting in the initiation of an adaptive type of immune response.
The HLA system was described in the early 1960’s88"90, following earlier 
work in murine transplantation models on histocompatibility antigens 2 (H-2)91. 
This discovery was facilitated by observations made at the start of the last century 
by scientists interested in knowing why inbred mice could accept tumour grafts 
that were usually rejected. A group of genes from a number of loci that were 
contributing to graft/tissue rejection were later identified. These loci were 
collectively called histocompatibility loci. The locus that contributed most to graft 
compatibility was named the major histocompatibility complex while the remainder 
was called the minor histocompatibility complex.
Further research demonstrated that genes of the MHC encode polymorphic 
molecules that differ between strains and were the main targets for alloantibodies 
made against them by the recipient immune system. In this respect, these 
polymorphic molecules were considered to be ‘alloantigens’ (proteins occurring in 
a member of a species, which when introduced into members of that species who 
lack it, will induce an immune response by stimulating the production of 
alloantibodies). In the past, serological techniques were used to define distinct 
classes of MHC antigens in both human and mouse, but with the advent of
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molecular (DNA-based) techniques, previous classifications have been refined and 
the discovery of new antigens has been simplified.
In mice, alloantigens are present in abundance on the surfaces of both red 
and white blood cells (RBC and WBC, respectively) but in humans, these antigens 
are expressed only on the leukocyte cell surface and absent on RBC, thus the 
name “human leukocyte antigens” (HLA). So far, three distinct classes or regions 
of HLA have been defined mapping to genes on the short arm of chromosome 6 in 
humans (Figure 1.8). These regions contain several genes that have repeatedly 
been implicated in immune responses to “non-self including pathogens that have 
successfully breached the host innate barriers and gained entrance into the body.
Because of its great diversity and pivotal role in modulating host immune 
responses to pathogens, the HLA system has been frequently investigated both in 
biological and anthropological studies. The constant probing of this region of the 
human genome, coupled with the advent of molecular techniques in the 1980’s led 
to a rapid rate of discovery of new HLA antigens in different populations and ethnic 
groups around the world. The number of known alleles at these loci continues to 
grow exponentially (Figure 1.9) as more and more populations are investigated 
aided by the availability and affordability of newer typing techniques to researchers 
in low-income countries.
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Figure 1.8: The HLA region on human chromosome 6
The class I region is nearest the telomere while class II genes are closer to the centromere. The 
third region comprises genes encoding the complement factors (C2, C4 and factor B (Bf)) and is 
sandwiched between classes I and II. (Reproduced from ref. 92)
More than 200 genes have been mapped to the HLA region spanning about 
4 Mb of the human genome but only 20% of them code for leukocyte antigens 92 93 
that are involved in regulating host immunity. Those directly involved in immune 
regulation are called the “classical HLA genes”, which can broadly be divided into 
two main classes: HLA class I (A, B, and C) on one hand and HLA class II 
including HLA-DR, -DQ, -DP, -DO, and -DM among others.
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Figure 1.9: Classical HLA class I and class II antigen discoveries
(Reproduced from The IMGT/HLA database94)
HLA class I: molecule, structure and gene organisation
HLA class I antigens are proteins encoded by the class I genes and consist 
of two polypeptides chains: a heavy chain called alpha (a) and a non-covalently 
linked light chain known as beta-2 microglobulin (fern).
The a-chain is a glycoprotein measuring about 45 kDa with five distinct 
domains namely the extracellular domains (a1, a2, and a3), the transmembrane 
region and the cytoplasmic tail (Figure 1.10). The two membrane-distal domains 
(a1 and a2) fold in a special way to form the peptide-binding groove, which 
accommodates and holds a short pathogen- or self-derived fragment (8-10 amino 
acid long) for presentation to cytotoxic (CD8+) T lymphocytes. Changes in the 
amino acid sequence of the binding groove determine the binding efficacy and 
stability of peptides delivered from the processing cascade with major impact on T 
cell recognition. Most of the polymorphisms in the class I genes lie in specific 
exons coding for proteins that form the peptide-binding groove.
8822
Plasma
membrane
Class I Class II
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Figure 1.10: HLA class I and II molecules on the cell surface
(Reproduced from ref. 92)
The light chain (P2m) is a water-soluble protein measuring 12 kDa in weight 
that constitutes an integral part of all HLA class I molecules and some class l-like 
molecules. Beta-2 microglobulin is encoded by a monomorphic gene located on 
chromosome 15 and is thus not classified as part of the HLA family because it is a 
product of a gene that is not located within the MHC. Although (32m is not 
polymorphic, it constitutes an important component of all HLA class I molecules. 
Several reports have demonstrated that soluble (32m in the serum or plasma is a 
good marker of immune activation. Its levels are abnormally high in people 
infected with persistent viruses such as HIV, cytomegalovirus (CMV), and hepatitis 
B virus (HBV)95'97 to name a few.
There are over 20 genes within the class I region that are ubiquitously 
expressed but only three are considered to be highly polymorphic (HLA-A, HLA-B,
r
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and HLA-C). Each class I gene encodes a heavy chain (a-chain) and each 
domain is coded by a separate exon (Figure 1.11). The leader sequence is 
encoded by exon 1; the extracellular domains are encoded by exons 2, 3 and 4 
respectively; the transmembrane region by exon 5; and the cytoplasmic tail by 
exons 6 and 7. Variations in exons 2 and 3 are the basis of the antigenic 
polymorphisms observed in the classical class I genes (HLA-A, -B, and -C).
The number of HLA class I alleles currently described in the 
immunogenetics database is 3007 alleles94. HLA-B is by far the most polymorphic 
with 1431 known alleles (Table 1.2) followed by HLA-A and HLA-C (893 and 569 
alleles, respectively). The other non-classical class I genes (including HLA-E, -F, 
and -G) are less polymorphic.
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I I I I
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Figure 1.11: The HLA class I gene organisation
HLA class II: molecule, structure and gene organisation
Class II molecules are heterodimers consisting of two heavy chains: a 35 
kDa a-chain and a (3-chain measuring 28 kDa98. Each of these heavy chains 
anchors on the cell membrane and has four domains - two extracellular domains 
(a1, a2; (31, and (32 for alpha and beta chains, respectively), a transmembrane
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region and a cytoplasmic tail (Figure 1.10). The two membrane-distal 
extracellular domains (a1 and (31) are referred to as the peptide-binding domains 
because they fold in an interactive manner to form the peptide-binding groove with 
similar function as described above for HLA class I molecules except that they 
present their fragments (peptides) to CD4+ T cells and have the ability to 
accommodate longer peptides (up to 14 amino acid long).
In contrast to HLA class I molecules that are ubiquitously expressed on 
nucleated cells, the products of HLA class II genes are expressed only on 
subpopulations of immune cells including B cells, macrophages, activated T cells, 
DCs and other APCs". Their levels of expression vary according to the tissue 
location (Table 1.3).
Table 1.2: Number of alleles at the HLA class I and HLA class II loci
Class Genes Number of alleles
A 893
B 1431
I C 569
E 9
F 21
G 45
DRA 3
DRB 814
DQA1 35
DQB1 106
II DPA1 28
DPB1 136
DMA 4
DMB 7
DOA 12
DOB 9
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There are five different class II isoforms: HLA-DM, -DO, -DP, -DQ  and -DR 
(Figure 1.8). Each of these types has a gene encoding an a-chain designated A 
(e. g. DQA1, DRA) and one or more corresponding genes encoding for p-chains 
designated B (e.g. DQB1, DRB1, DRB4, etc).
Table 1.3: The differential expression of classical HLA class I and HLA class II 
molecules on human cell surfaces
Cell type HLA class 1 HLA class II
B cells +++ +++
T cells +++ +/-
Macrophages +++ ++
Other APCs +++ +++
Thymic epithelial cells + +++
Neutrophils +++ -
Brain cells + -
Hepatocytes + -
Kidney cells + -
Red blood cells - -
The structural organisation of the genes encoding each class II heavy 
chains is similar to that of class I heavy chains, i.e. exon-intron organisation 
(Figure 1.12). With the exception of the transmembrane region of the a-chains, 
each domain of a class II protein is encoded by a separate exon100101. The leader 
sequence in both a  and p chains is encoded by exon 1; exons 2 and 3 encode for 
a1 and a2  domains (a-chains), and p1 and p2 domains (p-chains); the 
transmembrane region and the cytoplasmic tail in all class II a-chains are coded
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by exon 4; in contrast, the transmembrane region and the cytoplasmic tail of the p- 
chains are coded by exons 4 and 5, respectively.
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Figure 1.12: The HLA class II gene organisation
Most of the polymorphisms observed in HLA class II molecules accumulate 
around the peptide-binding groove especially on the membrane-distal extracellular 
domains (a1 and p1). The a-chain genes of certain class II isoforms are 
monomorphic or oligomorphic (with only a few variants), e.g. HLA-DRA, -DPA1 
and -DQA1, while in most cases the p-chain genes are highly polymorphic.
The number of known HLA class II alleles in the HLA database is 1154 
(Table 1.3), of which 814 are alleles of DRB genes94. There are 9 different DRB 
genes (DRB1-DRB9) but DRB1 is the most polymorphic of all with 722 alleles 
representing 89% of alleles encoded by the DRB family.
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HLA nomenclature
The WHO Nomenclature Committee for factors of the HLA system is 
responsible for assigning and publishing names of new HLA alleles102. Since 
1987, each HLA allele has been uniquely indentified using a four-, six- or eight­
digit number. The length of the allele designation depends on the sequence of the 
allele and that of its closest relative. The first two digits represent the type 
(serological antigen); the third and fourth digits correspond to the subtypes and are 
given serially based on the order of discovery. Alleles whose numbers differ in the 
first four digits have one or more nucleotide substitutions that change the amino 
acid sequence of the protein they encode. The fifth and sixth digits are used to 
distinguish between alleles that differ only by synonymous nucleotide substitutions 
(silent or non-coding substitutions) within the coding sequence. Furthermore, 
alleles that only differ by sequence polymorphisms in the intronic regions or in the 
5' untranslated region (5’ UTR) or in the 3' UTR are distinguished by the addition of 
seventh and eight digits. In addition to these unique allele identification numbers, 
suffixes are optionally added after the last digit to indicate the levels of expression 
of the protein encoded by that allele (see Table 1.4).
Given that the number of alleles for some HLA genes was fast approaching 
the maximum possible number that could be allocated with the current naming 
convention; a new naming convention has been proposed by the Nomenclature 
Committee for implementation in April 2010. All current HLA allele names will 
have to accommodate colons (:) to serve as field delimiters and alleles that were 
previously rolled over would be renamed. Examples of allele names under the 
new naming convention as of April 2010 will be as follows: A*01010101 will 
become A*01:01:01:01; A*02010102L will become A*02:01:01:02L; all other fields 
description remain as described above and shown on Table 1.4 below.
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Table 1.4: Nomenclature of the factors of HLA system
Nomenclature Indicates
HLA
HLA-DRB1
HLA-DRB1*13
HLA-DRB1*1301
HLA-DRB1*1301N
HLA-DRB1*130102
HLA-DRBV13010102
HLA-A*3014L
HLA-A *24020102L
HLA-B*44020102S
HLA-A*3211Q
the HLA region and prefix for an HLA gene 
a particular HLA locus i.e. DRB1 
a group of alleles which encode the DR13 antigen 
a specific HLA allele 
a null allele
an allele which differs by a synonymous mutation
an allele which contains a mutation outside the coding 
region
an allele encoding a protein with significantly reduced 
or 'Low' cell surface expression
an allele encoding a protein with significantly reduced 
or 'Low' cell surface expression, where the mutation is 
found outside the coding region
an allele encoding a protein which is expressed as a 
'Secreted' molecule only
an allele which has a mutation that has previously 
been shown to have a significant effect on cell surface 
expression, but where this has not been confirmed 
and its expression remains 'Questionable'
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HLA restriction and T cell maturation
T cell development takes place in the thymus gland where naTve T 
lymphocytes are educated and trained to interact with autologous (self) antigens 
such as HLA class I and II molecules. By the end of their educational period, each 
mature T cell will express either an ap receptor made up of one a  and one p chain, 
or the yS receptor comprising one y and one 8 chain103. Only those T cells 
expressing the ap-TCRs can effectively interact with the HLA-peptide complex.
A fundamental requirement for successful T cell development is the need to 
rearrange some of the genes necessary for the immune response in order to 
become functional. This process starts with the rearrangement of the p-chain 
genes, which when successful, initiates the rearrangement of the a-chain genes. 
The next step entails a positive or negative selection, which eliminates those cells 
that bind with high affinity to autologous class I or II allotypes (negative selection), 
while retaining those that bind with intermediate affinity to one class I or class II 
molecule (positive selection). Failure to bind or poor binding will result in 
termination of the maturation process and death104.
Each ap-T cell receptor only recognises peptides presented by one HLA 
class I or II allotype (the one that it was positively selected for in the thymus) and 
is said to be restricted to that HLA allotype. By virtue of their maturation, a given T 
cell clone is therefore functionally monoclonal. In addition, T cell restriction to a 
particular class of HLA is in part determined by other cell-surface proteins namely 
CD4 and CD8 molecules, which like TCRs also interact with HLA-peptide complex 
but at a membrane-proximal level (a3 domain on class I chain and p2 domain on 
class II chain, respectively). These cell surface proteins have been given the 
name “co-receptors”. CD4 and CD8 expression on T cells is generally mutually 
exclusive and T cells expressing the CD4 co-receptor primarily recognise peptides
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bound to HLA class II molecules while those positive for CD8 glycoprotein interact 
with peptides presented by HLA class I molecules105.
HLA and antigen presentation
HLA class I and II molecules are key components of the adaptive immune 
system. They present short fragments derived from endogenous and exogenous 
sources to cytotoxic (CD8+) and helper (CD4+) T lymphocytes. A successful 
presentation of peptides to T cells occurs when the T cells are able to recognise 
and interact with the peptide loaded onto the HLA molecule via T cell receptors 
(TCRs). For this to happen, T cells must have been primed or educated during 
their maturation in the thymus to restrict their scope of MHC interaction to a 
particular class I or II molecule. The interaction with T cells could lead to the 
initiation of a specific cell-mediated immune response against the source of the 
antigenic peptide or the organism from which the peptide was derived.
Presentation through HLA class I pathway
For the class I pathway, antigen processing begins with the assembly of the 
heavy chain (a) with the p2m within the lumen of the endoplasmic reticulum (ER), 
while protein degradation is taking place in the cytosol by proteasomes to 
generate antigenic peptides. The transporter protein associated with antigen 
processing (TAP) then moves the peptides from the cytosol to the lumen of ER 
where they are loaded onto class I heavy chains with the help of tapasin. Two 
chaperonins (calnexin and calreticulin) residing in the ER intervene with the 
stabilisation of newly assembled but very unstable class-l-heavy-chain/p2m 
complex. Tapasin then helps with the off-loading of peptides from TAP and 
loading them onto the class I binding groove (one peptide per groove). When the 
complex (a-chain + p2m + peptide) is stable enough, it leaves the lumen of the ER
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and passes through the Golgi apparatus to get to the plasma membrane where the 
peptide is presented to CD8+ T cells to initiate an appropriate immune response.
Presentation through HLA class II pathway
The heavy chains of HLA class II (a and p chains) molecules are also 
assembled in the lumen of the ER with help from chaperonins (calnexin and 
calreticulin) but they are not permitted to bind a peptide in this cellular 
compartment. During the assembly process, another polypeptide called the 
invariant chain (li) attaches itself to and occupies the class II binding groove 
thereby preventing any peptide loading within the lumen of the ER. This trimeric 
structure is stable enough to go through the Golgi body into endocytic vesicles 
where endocytosed or phagocytosed proteins are being degraded into small 
fragments (peptides). Once in the vesicles, the invariant chain is also degraded to 
free the binding groove but in some cases a small part of the invariant chain still 
remains. This small piece is called the class II associated invariant chain peptide 
(CLIP). When this happens, HLA-DM catalyses the release of CLIP and replaces 
it with a single peptide resulting from the degradation of extracellular proteins from 
endocytosed or phagocytosed organisms or non-self cells. The stable complex 
(class II molecule + peptide) leaves the endocytic vesicle also known as the MHC 
class II compartment (MHC) to the cell membrane where the antigenic peptide is 
presented to CD4+ T cells to stimulate and initiate a cascade of host immune 
response.
HLA polymorphism
The HLA system remains the most polymorphic genetic system ever 
studied, even though some of its non-classical loci are monomorphic or 
oligomorphic. Recent technologies (DNA-typing methods) such as sequence-
based techniques and crystallography have provided fine details of the HLA genes
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and molecules, and made the comparison of allele sequences from polymorphic 
loci possible. Furthermore, they have helped to demonstrate that nucleotide 
substitutions in polymorphic class I and II genes are concentrated in exons that 
encode the peptide binding groove, and sites that interact directly with TCRs on 
the membrane-proximal domains of the a-chain (class I) and p2-chain (class II).
The mechanisms that give rise to polymorphic variants in the HLA genes 
have progressively become clearer over the years. Natural selection combined 
with point mutation, gene conversion and recombination has contributed to the 
high level of diversity observed in some HLA class I and class II genes106. It is 
also believed that past exposures to infectious diseases by our ancestors have 
helped in selecting for variants conferring a survival advantage. A number of 
important scientific observations suggest that HLA allotypes are associated with 
functional differences that can be explained by differential natural selection107.
Generation and pattern of MHC diversity
Maximum overall heterozygosity for HLA determines the number of 
antigens an individual’s T cell population can respond to and is likely to give 
greatest selective advantage108. One of the characteristics of the HLA complex is 
the lack of a “wild type” phenotype probably because of the extensive number of 
known alleles resulting from polymorphisms at the MHC region106. It has been 
demonstrated that HLA genes generate their diversity through positive selection of 
alleles with coding mutations in key areas resulting in differences in the amino acid 
sequences of the peptide-binding site109.
Phylogenetic analyses of HLA sequences from different populations around 
the world have shown that the HLA region exhibits greater sequence divergence 
between loci than is observed in any other part of the human genome109. In 
keeping with this, the number of non-synonymous substitutions in the exons of
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HLA-B locus is by far the highest compared to those observed in HLA-A and -C 
loci, respectively. The mechanisms for the generation of distinct allelic forms 
within and between HLA loci are complex and have been a subject of debate in 
the scientific community for many years.
Gene duplication
Gene duplication is a hallmark of the MHC region and results in the 
formation of gene clusters. In higher primates, the MHC class I and class II genes 
undergo periodic expansion and contraction presumably in response to the 
changing range of pathogens. It is believed that gene duplication has played a 
significant role in the generation of polymorphisms in the HLA regions leading to 
the multiplicity of both functional and non-functional HLA genes. This is evident by 
the fact that groups of related genes and some times remnants of genes are found 
throughout the MHC region particularly in the class I region where a number of 
pseudogenes are found109.
It has been shown that about 5% of human genome can be attributed to 
segmental duplication - a common feature of the human genome that is not limited 
only to multi-gene families such as those of the human MHC that are involved in 
immune regulation110.
Point mutation
Point mutation is the introduction of a unique substitution within an allele. It 
may involve the loss of a nucleotide or the insertion of an additional nucleotide, or 
the substitution of one nucleotide for another. In combination with other forms of 
substitutions, point mutation has greatly contributed in HLA diversity109.
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Gene conversion and recombination
Gene conversion is another form of genetic recombination during which 
there is a non-reciprocal transfer of sequence motif from one allele to another at 
the same locus during which the transferred motif completely replaces the 
corresponding motif in the recipient allele109. Studies on germ-line mutations have 
suggested that inter-allelic gene conversions do contribute immensely to MHC 
polymorphism111. However, sequence comparison analyses have indicated that 
inter-locus conversion does not contribute substantially to the overall generation of 
diversity in the HLA region109. Multiple recombination or crossing-over events can 
occur at different sites between homologous chromosomes resulting in the 
exchange of DNA segments of varying length.
HLA haplotypes
A haplotype is a combination of alleles encoded by different loci of the 
same chromosome and within a certain chromosomal region. The resultant effect 
of HLA polymorphisms on an individual’s ability to elicit an effective immune 
response against a given antigen is determined by the individual’s phenotype, 
which is the combination of gene products contributed by two human 
chromosomes 6. The mechanisms for the generation of different haplotypes in 
HLA class I and HLA class II are similar and are likely to have been by gene 
duplication and recombination109. The presence of multiple Alu sequences (a 
marker for the origin of different genes) particularly within the class II genes 
indicates that most recombination events occurred through unequal crossing-over 
with gene misalignment leading to increased variability within the region112. 
Certain HLA haplotypes may predominate in particular populations due to 
advantageous recombination of alleles on those specific haplotypes.
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HLA and HIV infection and disease progression
Data demonstrating in vivo T cell-induced protective immunity to HIV are 
accumulating from cohort and large population-based studies around the world73 
113114. This function depends on the ability of the individual’s HLA molecules to 
present antigenic peptides more effectively to CD8+ and CD4+ T cells, a biological 
function that can be altered by genetic polymorphisms capable of generating 
structural changes in peptide-binding grooves.
HLA association with HIV transmission
Many large studies from Western populations and cohorts focusing on 
identification of the genetic determinants of susceptibility to HIV infection have 
implicated certain HLA class I genes with favourable or unfavourable HIV-1 
disease outcomes68'70 74 115'118. There is also considerable evidence, from a small 
number of studies targeting individuals who have been exposed to HIV but did not 
seroconvert after a long period of time, suggesting that natural immunity may 
protect against HIV acquisition and that HLA-restricted CTLs may be the mediator 
of such protection119. Some of the alleles that have been shown to influence HIV- 
1 transmissibility include HLA-A*02[U 120 with low transmissibility and HLA- 
A*2301, -A*29,-Cw*07, and - Cw*08 with high transmission114120.
HLA concordance between mother-child pair has also been shown to be a 
risk factor for HIV-1 transmission121 122. In another study, Winchester and co­
workers demonstrated that protection against transmission of HIV-1 to infants born 
to HIV-1 positive mothers was associated with the class II genes HLA-DRB1*1501 
and HLA-DRBV13123.
Comparative analyses using data from West Africa have shown that 
transmissibility is slow in HIV-2 compared to HIV-1124. Some have suggested that 
HIV-2 protects against HIV-1 acquisition but this issue remains controversial as
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data from Senegal, The Gambia and elsewhere in West Africa are not 
consistent125'127.
A number of HLA alleles have been found to increase substantially the 
susceptibility to HIV-1 in different epidemiological studies in Africa114, Argentina128, 
America129, and Australia130; while others were associated with resistance to HIV 
infection. For example in The Gambia, HLA-B*35 has been linked to resistance to 
HIV in a cohort of HIV-exposed but uninfected commercial sex workers (CSW) 
who demonstrated a strong B35-restricted CTL response to both HIV-1 and HIV-2 
peptide epitopes73. In a similar risk group in Nairobi, HLA class II (HLA-DRBV01) 
was found to mediate resistance to seroconversion observed in exposed but 
uninfected CSW in that part of East Africa.
HLA association with HIV disease progression
Homozygosity at any of the HLA loci decreases the number of epitopes that 
can be seen or targeted by host CTLs. This appears to be a selective advantage 
to a virus like HIV with a high replicative capacity. HLA homozygosity has been 
associated in a dose dependent manner with progression to AIDS following HIV-1 
infection in several epidemiological studies69118131. Specifically, homozygosity for 
HLA-B Bw4 is associated with slower rate of decline in CD4+ T cells132. In other 
cohort studies, HLA-B*35 has consistently been implicated with rapid HIV disease 
progression in a variety of risk groups69 115 116 133 134. The effect of B*35 seems to 
be co-dominant and subtype dependent69 133. Other HLA class I and II genes that 
have been marginally linked to rapid progression to AIDS include A*23, A*24, 
B*08, DRB3, and DRB5 genes and the ancestral haplotype A1-B8-DR3116130131135
On the other hand, several alleles have been found to associate with 
protection against progression to AIDS and include A*25, A*26, A*68, B*27, B*57, 
and DRB6. However, the most consistent findings have been those associating
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B*27 and B*57 with protection against rapid HIV-1 disease progression. HLA- 
B*27 and -B*57 are rare alleles in most populations but their effect on slowing HIV- 
1 disease progression has been consistently proven116131133_136. Heterozygosity at 
several of HLA class I loci is advantageous against rapid development of AIDS69 
118 and high HIV viral load137 in Caucasians.
In the past 20 years, most of the HLA associations with HIV disease 
outcomes resulted from candidate gene studies in which, suspected gene variants 
were analysed to discover their role in either the pathogenesis or immune 
response to HIV78 79 84 138. In recent past, new genome-wide approaches have 
been used in several studies (GWAS) to globally assess the influence of the host 
genome on HIV disease outcomes including viral load set point and progression to 
AIDS13914°. These studies have provided strong functional data supporting the 
central role of HLA genes in restricting HIV replication and have open up new 
perspectives in the understanding of the effect of human genetic variation on the 
individual response to HIV infection and disease progression.
Together, these data have provided valuable insights into the mechanisms 
of protective immunity against HIV infection, which still remain poorly understood. 
More recent insights have come from studies associating HIV disease outcome 
with genotypes of KIRs.
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Killer cell immunoglobulin-like receptors (KIR)
Given that both the humoral and adaptive immune responses are relatively 
ineffective against HIV when compared to other pathogens, innate immune 
mechanisms may play a particularly important role in governing susceptibility to 
infection and rate of disease progression. This may also result from the ability of 
several HIV genes to down regulate HLA expression, thereby reducing T-cell 
recognition of infected cells. HIV-1 disease tends to progress rapidly and very few 
people are able to control the infection for any length of time. In contrast HIV-2 
infection is characterised by stable viral load over the course of many years. Thus 
HIV-2 provides a good model for examining the mechanisms by which the immune 
system is able to control these viruses, potentially identifying better methods of 
influencing the natural history of HIV infection and informing vaccine development.
Overview of NK cells
Natural killer (NK) cells are essential components of the innate immune 
system, which serve as the first line of defence against invading pathogens 
including viruses. Morphologically, NK cells are a heterogeneous population of 
large granular lymphocytes representing 10-15% of circulating lymphocytes that 
contribute to the immune response against infection141. Derived from the bone 
marrow, NK cells share a common progenitor with T cells (key effector cells of the 
adaptive immune system), but unlike the latter they have the spontaneous ability 
to kill “abnormal” cells, which are recognised as ‘non-self without prior 
sensitisation -  hence the name “natural killer”. They further differ from T and B 
cells in that they are thought not to express antigen-specific cell surface receptors, 
although recent evidence suggests that at least in some cases the interaction 
between NK cells and target cells may be peptide specific142. Genes encoding NK
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cell surface receptors are thought not to undergo clonal germ-line rearrangement 
as is common in other lymphocytes.
Phenotypically, mature NK cells do not express CD3 or CD4 molecules on 
their cell membranes. Some, however, do express the a/a form of CD8 molecules 
in addition to the common CD16 and CD56 markers that are expressed by all NK 
cells. Functionally, NK cells destroy their targets using a range of different 
mechanisms including: (1) secretion of regulatory cytokines including IFN-y, TNF- 
a, TGF-p, IL-1, IL-5, IL-10, and chemokines such as RANTES, MIP-1a and MIP- 
1 p143*145 to recruit other cells to the site of infection for concerted action against the 
pathogen; and (2) direct killing through antibody-dependent cellular cytotoxicity 
(ADCC). These activities are tightly regulated by a group of receptors collectively 
known as the “natural killer cell receptors” (NKCR) encoded by specific genes 
located on human chromosome 12 and within the leukocyte receptor complex 
(LRC) on human chromosome 19.
NK cell recognition and the “missing self hypothesis”
By nature of their education, NK cells are programmed to recognise and kill 
specific target cells (unhealthy non-self cells) and to produce a wide range of 
chemokines and cytokines. NK cell recognition differs from that of other immune 
cells in that NK cells must make no mistake in differentiating between “self and 
“non-self (altered self). A normal and healthy cell (self) is usually not attacked by 
NK cells but as soon as that cell gets infected or starts to undergo some 
transformation, NK cells immediately sense the change from self to non-self and 
destroy it. NK cells must therefore have the required receptors on their cell 
surface to enable them distinguish between self and non-self.
Unlike T cells, which are activated through the recognition of antigenic 
peptides presented by MHC proteins on cell surfaces, NK cells become functional
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by sensing the lost of MHC class I molecules on cell surfaces; a process termed 
the “missing self hypothesis”. NK cells are constantly probing other cell surfaces 
for the presence of their ligands. If the inhibitory KIR receptor on the NK cell 
surface comes in contact with its corresponding ligand (HLA class I molecules), 
NK cell cytolytic activity is inhibited but if the expression of the ligand is absence or 
reduced, NK cells become activated and destroy the target146. Their cytolytic 
activity is tightly controlled by an equilibrium between the activating and inhibitory 
signals mediated by their respective receptors expressed on the NK cell surface 
(Figure 1.13).
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Figure 1.13: KIR-HLA interaction and modulation of NK cell cytolytic activity.
NK cells are licensed to kill targets with altered MHC class I expression (Carrington M, personal 
communication).
NK cell receptors in humans
A variety of membrane-bound receptors are found on NK cell surfaces 
belonging to two main families; namely, the Immunoglobulin Superfamily and the 
C-type lectin family. Genes encoding the former include the leukocyte 
immunoglobulin-like receptors (LILR), leukocyte-associated inhibitory receptors 
(LAIR), leukocyte immunoglobulin-like receptors (LIR), Killer cell immunoglobulin­
like receptors (KIR), FcaR, and NKp46 among others mapping to the Leukocyte
Receptor Complex (LRC) on human chromosome 19 (19q13.4) (Figure 1.14). 
Genes encoding for the C-type lectin family are located at the centromeric end of 
human chromosome 12 and include the CD94 (also known as NKG2) gene.
KIR gene family
In humans, KIR molecules are encoded by a diverse and compact set of 
genes located within the LRC on chromosome 19. The family comprises 15 
functional genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, 
KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, 
KIR3DL2, KIR3DL3 and KIR3DS1) and 2 pseudogenes (KIR2DP1 and KIR3DP1). 
The expression and function of each of these genes influences the expression and 
function of other members of the gene family147. KIR molecules are glycoproteins 
that belong to the immunoglobulin superfamily and expressed as receptors on the 
surfaces of a subset of lymphoid cells (NK cells), a subpopulation of y5 T cells and 
some memory ap T cells148149.
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Figure 1.14: KIR genes within the Leukocyte Receptor Complex.
KIR molecules are structurally similar but can be divided on functional 
grounds into activating and inhibitory receptors based on the number of 
extracellular domains, the length of the cytoplasmic tail and the composition of the 
transmembrane region (Figure 1.15). Activating KIR molecules have two or three 
extracellular domains, a short (S) cytoplasmic tail with a positively charged residue 
in the transmembrane region, while the inhibitory KIR molecules have two or three 
extracellular domains, a long (L) cytoplasmic tail containing at least one immuno- 
tyrosine-based inhibitory motifs (ITIM)150. Those with two extracellular domains 
can further be classified as type I if they possess the D1 domain or type II if they
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instead have the membrane distal domain (DO) in addition to the common D2 
possessed by all KIR molecules.
The role the human KIR is to survey surfaces of other cells for the 
expression of appropriate human leukocyte antigens (HLA) class I molecules, 
which serve as their ligands. In the presence of intact ligands for the inhibitory 
receptors, NK cell-mediated cytolysis is inhibited whereas their absence or down 
regulation is associated with NK cell activation151.
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Figure 1.15: Structural characteristics of KIR gene products
Activating molecules have short cytoplasmic tails (S) and a positively charged residue that allows 
them to interact with an adapter molecule (DAP12), while the inhibitory receptors have long 
cytoplasmic tails (L) with one or two immuno tyrosine-based inhibitory motifs (ITIM). (Reproduced 
from ref152)
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KIR Nomenclature
Since 2002, naming of KIR genes is the responsibility of the HUGO 
Genome Nomenclature Committee (HGNC). KIR genes are named taking into 
accounts the structures of the molecules they encode. Each name then has five 
major divisions: the acronym KIR stands for “Killer-cell Immunoglobulin-like 
Receptor”; the first digit following the acronym corresponds to the number of Ig-like 
domains in the molecule encoded by that gene; the “D” is an abbreviation for 
“domain”; the D is either followed by an 'L' indicating that the protein encoded by 
that gene has a “Long” cytoplasmic tail, or an “S” indicating that the protein 
encoded by that gene has a “Short” cytoplasmic tail, or a “P” an abbreviation for 
pseudogenes. The last digit indicates the order in which the genes were 
discovered. For example KIR2DL2 is a KIR gene that encodes receptors having 
two extracellular Ig-like domains and a long cytoplasmic tail and the second of this 
type of 2DL family. In addition, when two or more genes have very similar 
structures and their sequences are not that much different, they are given the 
same last digit number but distinguished by a final letter (e.g. KIR2DL5A and 
KIR2DL5B genes).
KIR alleles are currently named in an analogous fashion as described for 
HLA above. Briefly, after the gene name (e.g. KIR2DL2) an asterisk is used as a 
name delimiter before a numerical allele designation is added. The first three 
digits following the asterisk are used to indicate alleles that differ in the sequences 
of their encoded proteins. Two other digits are added to distinguish alleles that 
only differ by synonymous (non-coding) differences within the coding region 
(exon). Two other digits are added to distinguish alleles that only differ by 
nucleotide substitutions in non-coding regions (e.g. intron, promoter, and others). 
An example of a KIR allele is KIR2DL2*0030101.
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KIR gene organization
All KIR genes are located within a 150 kb segment of human DNA on 
chromosome19q13.4. Although the region is extremely variable and has gone 
though several episodes of expansion and contraction due to gene duplication and 
unequal crossing-over153, KIR genes are arranged in a tightly organised manner 
within the region in a tail-to-tail fashion154. Each of the 16 KIR genes is about IQ- 
16 kb long and each pair of genes is separated by about 2 kb except for the pair 
KIR2DL4 -  KIR3DP1, which is separated by a 14 kb space.
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Figure 1.16: KIR genomic organisation
(Reproduced from ref. 152)
KIR genomic organisation is remarkably consistent across all genes. The 
basic arrangement is shown in Figure 1.16. Briefly the signal/leader sequence is 
encoded by exons 1 and 2; the 3 domains are encoded by exons 3, 4, and 5, 
respectively; the linker/stem and the transmembrane regions by exons 6 and 7,
respectively; and finally the cytoplasmic tail is encoded by exons 8 and 9. There is
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however, a pseudoexon 3 in all type I 2D KIR genes that may have arisen as a 
result of a three-base-pair deletion155 and as a result, all type I 2D genes encode 
for proteins lacking the DO domain. Similarly, the lack of D1 in all type II 2D 
molecules resulted from the complete absence of exon 4 in type II KIR2D 
genes156. These abnormalities (possessing a pseudoexon or missing an exon) are 
not limited to type II KIRs and are also found in other KIR genes and 
pseudogenes.
KIR polymorphism and diversity
Within the LRC, the 150 kb region that accommodates KIR genes is one of 
the most polymorphic regions of the human genome155. The latest release from 
the Immuno Polymorphism Database -  a centralised repository for human KIR 
sequences (IPD/KIR)157, shows 335 KIR alleles with KIR3DL3, KIR3DL1, 
KIR3DL2, KIR2DL1 and KIR2DL4 being the most polymorphic (55, 52, 45, 25 and 
25 alleles, respectively).
KIR haplotypes can be classified into 2 broad categories (A and B) based 
on the type and number of genes (activating or inhibitory) that constitute the 
haplotype (Figure 1.17). The group A haplotypes have a fixed gene content of 
seven expressed genes and two pseudogenes. These haplotypes strongly 
contribute to the polymorphic nature of the KIR gene complex as their genes are 
highly diversified and polymorphic. In contrast, the group B haplotypes are less 
polymorphic but highly polygenic. Group B gene contents vary greatly and contain 
several other genes and allelic forms that are absent in group A haplotypes. 
Another structural difference between A and B haplotypes is that the latter 
comprise a mixture of both activating and inhibitory KIRs while the former lack all 
activating genes with the exception of KIR2DS4, which is ubiquitously expressed 
by every NK cell.
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The frequency distribution of group A and B haplotypes varies from one 
population to another. For example, they are evenly distributed in Caucasians158, 
however in Japanese group A haplotypes predominate159 while the predominant 
group in Aboriginal Australians is B160. Overall, the group A haplotype is by far the 
most common haplotype in most studied populations154.
The number and type of haplotypes present in an individual constitute 
his/her KIR gene profile. Profile A (i.e. two copies of “A” haplotype in the same 
individual) is relatively homogeneous in terms of gene content and comprises 
mainly genes encoding inhibitory receptors (except K/R2DL2)161 with KIR2DS4. 
On the other hand, Profile B (which can either be AB or BB haplotypes) exhibits 
substantial variation in gene content and contains several activating and inhibitory 
genes155 162. Some KIR genes are common to both profiles, for example KIR3DL3, 
KIR3DP1, KIR2DL4, and KIR3DL2 - the so called “framework genes”.
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KIR evolution and rapid expansion
The high level of homology in both coding and non-coding regions of KIR 
genes is a consequence of their recent evolution and rapid expansion in numbers. 
This is evidenced by the observation that most of the KIR-associated Alu 
sequences are of the S subclass (a more recent evolutionary subclass)163. 
Furthermore, KIR orthologues are yet to be found in rodents but the receptors 
have been found in Chimpanzee164. KIR and Ly49 in humans and mice, 
respectively, are structurally unrelated and have independently evolved to be used 
as variable NK cell receptors for polymorphic MHC class I147.
Several investigators have demonstrated that the human KIR gene complex 
and mouse Ly49 gene complex are functional analogues163 165. Although genes of 
these complexes encode distinct protein families - Ly49 encodes C-type lectin- 
related proteins while KIR encodes Ig-related proteins, they have many features in 
common. For examples, some KIR as well as Ly49 genes code for inhibitory 
receptors that use MHC class I molecules as ligands. These inhibitory receptors 
all have different numbers of ITIMs within their cytoplasmic domain to help them 
mediate their inhibitory activities. Both KIR and Ly49 families contain pairs of 
inhibitory and stimulatory receptors with high degree of nucleotide homology in 
their extracellular domains.
Fahlen and colleagues have demonstrated that the acquisition of Ly49 
receptors by mouse NK cells is informed by interactions with cognate MHC class I 
ligands expressed on bone marrow cells, which reduces the frequency of receptor 
expressing cells166. Comparative studies between different populations and other 
species including mice have shown that some interactions between NK cell 
receptors and MHC class I are highly conserved while others are highly diverse 
and rapidly evolving under natural selection147. It is believed that over millions of 
years, natural selection, imposed by adaptations to new and short-lived pathologic
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challenges from microorganisms with high mutation rates, has provided some 
selective advantages leading to rapid evolution of modern day polymorphic KIR 
and MHC genes167.
KIR genes and diseases
HLA and KIR interactions have recently been documented to have a major 
effect in modulating the host immune responses to pathogens. A number of 
recent studies have demonstrated that different HLA-KIR  combinations, involving 
activating and inhibitory KIRs, impact on many diseases outcomes168'175. For 
example, the KIR2DS2 gene associates with diabetes in people with a subset of 
HLA-C having asparagine at position 80 (C1)170. The combination between HLA-C 
and KIR2DL1 in the absence of the corresponding activating gene is associated 
with pre-eclampsia173. In hepatitis C research, homozygosity for both HLA-C1 and 
KIR2DL3 is associated with resolution of HCV infection171 176. KIR2DS1 and 
KIR2DS2 genes in the absence of HLA-C gene that encodes for a ligand for the 
corresponding inhibitory receptors confer susceptibility to psoriatic arthritis177. In 
HIV/AIDS research, an epistatic interaction between KIR3DS1 and a subset of 
HLA-B Bw4 alleles has been shown to delay progression to AIDS in HIV-1 infected 
individuals169.
A number of viruses down regulate HLA class I expression from the 
surfaces of cells that they infect as soon as they gain entrance into and cease the 
host cell’s machinery. However, this leaves the cells open to attacks by NK cells. 
In trying to avoid NK cell attacks, some viruses target only specific HLA alleles for 
down regulation. For example, it has been reported that HIV selectively 
downregulates HLA-A and HLA-B but not HLA-C or HLA-E, which are major 
ligands for a significant number of NK cell receptors including KIR178.
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Rationale
The burden of HIV epidemic rests on developing countries, most of which 
are in sub Saharan Africa. Since its first report in 1986, HIV-2 remains largely 
confined to West Africa3 where it coexists with HIV-1 and other pathogens. HIV-2 
prevalence is high, reaching 20% among adults in Guinea Bissau. Since most 
people who are infected with HIV-2 control the virus well for many years this 
provides an excellent opportunity to investigate the mechanisms by which the 
immune system prevents disease progression. This information is likely to shed 
light on potential mechanisms to combat the more aggressive HIV-1 infection. A 
preventive vaccine that would curtail the spread of the HIV virus remains elusive. 
The main barrier to the development of an effective vaccine against HIV infection 
is a lack of understanding of the mechanisms that would confer protective 
immunity.
Immunogenetic studies in Western cohorts have provided considerable 
insights into potential mechanisms, for example by highlighting associations of 
particular HLA molecules and/or KIR genotypes with good or bad outcome in HIV- 
1 infection. These studies have strongly implicated aspects of the CD8+ and CD4+ 
T cells and NK cell responses as important in the control of HIV replication. Most 
current candidate HIV vaccines aim to stimulate a strong cellular immune 
response against the virus, for which knowledge of the most common HLA 
molecules and the epitopes they present is essential for both vaccine design and 
immune monitoring in vaccine trials. However, there is a paucity of information 
about the distribution of HLA molecules in vaccine target populations, particularly 
in Africa.
This study was designed to determine the distribution and nature of HLA
and KIR alleles, genotypes and gene profiles in two West African populations in
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The Gambia and Guinea Bissau. The effects of different KIR/HLA combinations 
on susceptibility to HIV-2 infection and disease progression using recognised 
markers such as the rate of CD4+ T cell decline and viral load were also studied.
Hypotheses
Main hypothesis
Specific HLA and KIR genes/alleles and/or KIR gene profiles associate with 
susceptibility or protection to HIV-2 infection and progression to AIDS assessed by 
decrease in CD4+ T cell counts and/or increase in HIV-2 viral load.
Secondary hypotheses
1. KIR and HLA frequencies in our study populations are similar to other 
populations in West Africa and other parts of the world.
2. KIR-HLA combinations associated with NK cell activation rather than 
inhibition are related to reduced susceptibility to HIV-2 and slower disease 
progression.
3. Homozygosity at one or more HLA class I loci is associated with 
susceptibility to HIV-2 infection and rapid progression in a dose dependent 
manner with increasing homozygosity.
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CHAPTER 2 : MATERIALS AND METHODS
This chapter describes the cohorts and techniques used for these studies. 
The Caio cohort is a community cohort established 20 years ago, which has had 
repeated follow up surveys. The cohort comprises an homogenous population 
(>95% Manjako) derived from a collection of 10 small isolated villages. The 
original aim of founders of this cohort was to study the natural history of HIV-2 
infection in a community with one of the highest prevalences of HIV-2 infection in 
the world. However a few years later, HIV-1 was introduced in that community 
and is now overtaking HIV-2 in prevalence. Anti-retroviral therapy (ART) was not 
available in Caio until April 2007.
The Fajara HIV cohort is a clinical cohort established by the Medical 
Research Council (MRC) (UK) Laboratories, The Gambia more than 24 years ago, 
which is located in Fajara on the The Gambian coast in the Greater Banjul Area. 
Members of the cohort belong to a variety of ethnic groupings including Fula, 
Mandinka, Wolof, Serahuli, Aku, Jola, Serer, and Manjako. The two cohorts are 
among the best well characterised HIV cohorts in West Africa.
This project is one in the series of projects designed at the MRC 
Laboratories in The Gambia to understand futher the natural history of HIV-2 
infection. In September 2005, EDCTP (European and Developing Countries 
Clinical Trial Parthnership) launched a call for application for two PhD training 
fellowships which I applied for. In March 2006, I was one of the two winners of 
that prestigious award and was awarded the grant in August 2006. With the help 
of my mentors, I then wrote three proposals for approval by the MRC SCC 
(Scientific Coordinating Committee) which approved the scientific merit of the 
project; the Joint MRC/Gambian Government Ethics Committee which approved
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that there were no ethical issues with the conduct of this project; and the Life and 
Biological Science Board of the Open University, UK which approved that the 
project was worthy of consideration for an award of a doctorate degree.
Caio community cohort
This is a unique, isolated community in the Cacheu region on the coast of 
Northwest Guinea Bissau (Figure 2.1), which is geographically characterised by 
lowlands of mangroves, rice fields, and palm groves. The inhabitants, numbering 
about 10,000, belong to the Manjako tribe and have a traditional way of life and 
strong beliefs in earth spirits and ancestral cults179. In the late 1980’s an 
observation was made by health workers in one sexually transmitted diseases 
(STD) Clinic in neighbouring Ziguinchor (Senegal), that the majority of the 
commercial sex workers visiting their clinic for routine check-ups were from the 
Caio sector in Guinea Bissau. At that time, the rate of HIV-2 infection among 
prostitutes of Bissau origin seen in clinics in Ziguinchor was 36% 180.
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Figure 2.1 Map of West Africa showing the study sites
(Source: Google Earth)
The first survey conducted in the Caio sector revealed an HIV-2 prevalence 
of 8.5% among sexually active adults181. Since 1989, the MRC (UK) Laboratories 
in the Gambia in collaboration with Professor Peter Aaby’s group at the “Projecto 
Saude Bandim” in Bissau have conducted three serological surveys in Caio. Many 
other studies have been done including case-control studies and extensive clinical, 
epidemiological and laboratory data have been gathered from this cohort to study 
the natural history of HIV.
Fajara HIV clinical cohort
The HIV cohort in Fajara recruits its members through the clinic and 
hospital of the MRC (UK) Laboratories in Fajara, The Gambia (Figure 2.1). 
Patients aged 15 years and above attending the outpatient department and
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suspected of having contracted a sexually transmitted disease are referred to the 
Genito Urinary Medicine (GUM) clinic for counselling, and a blood sample is 
collected for HIV antibody status if the patient consents to testing. Those 
confirmed to be infected with HIV are invited to join the cohort. For the purposes 
of this study, those testing negative were invited to participate as controls. The 
patient information and consent form used for recruitment into the Fajara HIV 
cohort is reproduced in Appendix 1. Social history information was randomly 
collected on every other patient who newly joined the cohort (see Appendices 2 
and 3 for male and female social history forms respectively).
Samples
I was responsible for coordinating the sample collection between 2004 and 
2005 in Caio and the collection of controls from the Genitory Urinary Medicine 
Clinic (GUM) in Fajara. This entailed designing appropriate forms including the 
patient information form, consent form and sample form that accompanied each 
sample to the laboratory. I made more than seven trips to and from Caio to 
provide the site with laboratory consumables and bring back the samples to Fajara 
for processing. At the Caio field station blood samples were collected by the field 
site medical doctor who provides free medical care for the research participants 
and their family members or relatives. In Fajara, I was responsible for providing 
the GUM (Genito Urinary Medicine) clinic with the materials needed for sample 
collection which was perfomed by trained phlebotomists. The samples were then 
taken to the Human Genetic laboratory for processing and DNA extraction as 
described below.
A total of 1113 DNA samples extracted from HIV-2 infected and uninfected 
individuals were used for this study: 513 came from the Caio community cohort 
and 600 from the Fajara HIV clinical cohort. Of these, 750 were archival samples
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from the MRC Laboratories Biobank and the remaining (363) were prospectively 
collected from HIV negative individuals through the same GUM clinic in Fajara 
from 30th October 2006 through 17th September 2007. This part of the study was 
performed prospectively because the Fajara clinical cohort did not initially recruit 
HIV negative individuals. The characteristics of the study participants are shown 
in Table 2.1 and Table 2.2 for Caio and Fajara cohorts, respectively. Individuals 
infected with both HIV-1 and HIV-2 viruses (dual status) were excluded from 
analyses because of their limited number and the potential for HIV-1 to confound 
our analyses.
Table 2.1: Characteristics of the study population (n=513), Caio, 2003-7
N (%) Median age (IQR)
HIV negative
Male 114(35) 36.2 (25.8-52.5)
Female 213(65) 46.2 (30.8-62.8)
HIV-2 infected
Male 49 (32) 53.7 (43.0-62.9)
Female 102 (68) 59.5 (49.5-69.4)
HIV-1 &-2 dually infected
Male 6(17) 37.0 (34.7-49.3)
Female 29 (83) 52.8(42.8-61.7)
Ethnic groups
Manjako 479 (93.4)
Pepel 15(3.0)
Mandinka 11 (2.1)
Others 8(1.5)
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Table 2.2: Characteristics of the Fajara study population (n= 600)
N (%) Median age (IQR)
HIV negative
Male 61 (17) 31 (25-38)
Female 302 (83) 27 (22-35)
HIV-2 infected
Male 71 (30) 44 (35-53)
Female 166 (70) 38 (30-44)
Ethnic groups (n = 493)
Mandinka 229 (46.5)
Fula 66 (13.4)
Jola 67 (13.6)
Wolof 52 (10.6)
Serer 18(3.6)
Manjako 18(3.6)
Serahuli 13(2.6)
Aku 3 (0.6)
Others 27 (5.5)
The participant information form and the consent form used for the 
recruitment of the control individuals in Fajara are shown in Appendices 4 and 5, 
respectively. The subject information/consent form used in Caio to recruit study 
participants into the Caio community cohort is reproduced in Appendix 6. The 
social history information was collected on every participant that consented to join 
the study as a control. The male and female social history forms were the same 
as in Appendices 2 and 3 mentioned above.
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HIV antibody testing by serological techniques
Each of the participants was pre-test counselled and a blood samples 
collected from consented individuals were placed into two containers: (1) a plain 
tube that allowed the blood to clot and (2) an EDTA (ethylenediaminetetraacetic 
acid) tube that prevented the blood from clotting. The plain tube was sent to the 
MRC HIV diagnostic laboratory (accompanied with a sample request form) where 
the serum was collected and screened for the presence or absence of HIV 
antibodies using a Murex ICE HIV-1.2.0 capture enzyme immunoassay - a 
commercial kit from Murex (Murex Diagnostics). Suspected positive or reactive 
sera were confirmed using a rapid differential Hexagon test (Human GmbH) - an 
immunochromatographic test capable of differentiating between HIV-1 and HIV-2. 
Weakly reactive HIV-1 or HIV-2 or suspected dually positive sera were further 
tested using Pepti-Lav 1-2 (Sanofi Diagnostics Pasteur) - a synthetic peptide- 
based strip that also discriminates between HIV-1 and HIV-2. Samples with 
positive HIV-1 or HIV-2 or dual (HIV-1 &2) status were excluded from this round of 
prospective recruitment of controls and only those with negative HIV antibody test 
results were retained. DNA was extracted as described below. Recruitment of 
HIV infected individuals into the Fajara cohort is routine and achieved using the 
same study sites (GUM clinics in Fajara) but using a different protocol where by 
patients are to be pre and post-test counselled before their consent is sought to 
willingly join the cohort. The sample request form used for this study is 
reproduced in Appendix 7.
Sample collection and DNA extraction
Two millilitres of venous blood were collected into an EDTA container and 
sent to the MRC human genetics laboratory for DNA extraction. The samples
were stored in -20 °C freezer awaiting the HIV status from the HIV diagnostic
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laboratory. Only samples confirmed to be HIV seronegative were processed. 
Genomic DNA was extracted from each blood samples using an in-house salting- 
out technique. Briefly, red blood cells (RBC) were lysed using a solution of Tris- 
EDTA buffer (TE-20-5) pH 8.0 and 20% sodium dedocyl sulphate (SDS) solution 
was used to lyse white blood cells (WBC) and release the nuclear material into 
solution. Unwanted proteins were digested using 10 mg/ml proteinase K and 7.5 
M ammonium acetate added to bind onto DNA. This complex was subsequently 
precipitated using ice cold absolute ethanol. TE 20-5-NaCI solution containing 0.2 
M sodium chloride was added into the mixture to replace the ammonium salt with 
sodium salt. The DNA-salt complex was again precipitated using ice cold absolute 
ethanol. The DNA was redissolved in TE 20-1, quantified and stored at -20 °C for 
future use. The DNA extraction protocol used for this study is described in 
Appendix 8.
KIR typing by PCR-SSP techniques
The techniques involved the use of 60 KIR specific primers (see list of KIR 
primers in Appendix 9) to amplify conserved regions of the gene of interest by 
PCR-SSP (sequence specific priming)182. Primers were synthesised by Metabion 
(Metabion International, Germany) as desalted and HPLC purified 
oligonucleotides. They were reconstituted to 100 pM in TE buffer pH 8.0 and used 
to prepare primer mixes as indicated on the worksheet in Appendix 10.
This technique detects 14 functional KIR genes (KIR2DL1, KIR2DL2, 
KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, 
KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and KIR3DS1) and 1 pseudogene 
(KIR2DP1). The template was designed to contain 30 PCR reactions per sample. 
Two pairs of primers annealing at two different positions (exons) of the KIR gene 
of interest were used to reduce the chance of missing the presence of a gene due
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to mutation at one of the primer binding sites. A pair of internal control primers 
was introduced into each PCR reaction (except for lane 6) to amplify a 796 bp 
fragment from the third intron of HLA-DRB1 gene to check the effectiveness of the 
PCR reactions. The master mix contained 200 pM dNTP, 500 nM primer, 1.5 mM 
MgCb, 20 mM Tris-HCI, pH 8.4, 50 mM KCI, and 0.5 U of Taq polymerase (Bioline 
Ltd, London, UK). Amplifications were performed using a PTC-200 (tetrad) 
Thermal Cycler (MJ Research, Inc., MA, USA) with the following conditions: 94 °C 
for 2 minutes followed by 5 cycles of 94 °C for 5 seconds, 65 °C for 15 seconds, 
and 72 °C for 30 seconds; then 21 cycles of 94 °C for 5 seconds, 60 °C for 15 
seconds, and 72 °C for 30 seconds; followed by 4 cycles of 94 °C for 5 seconds, 
55 °C for 1 minute, and 72 °C for 2 minutes; and finally 1 cycle of 72 °C for 7 
minutes. The PCR products were separated in a 3% agarose gel containing 
ethidium bromide at 220 volts for 30 minutes and gel picture taken for 
interpretation and analysis.
The protocol (SOPL2) used for KIR genotyping is reproduced in Appendix
11. In January 2008, I visited Dr. Mary Carrington’s laboratory in Frederick, MD, 
USA for 3 months for training on gel scoring techniques. All gel pictures 
generated during the course of this study were independently scored by two 
people. The second scoring was done by a senior scientist in Dr. Carrington’s 
laboratory at the National Cancer Institute, NCI-Frederick, USA. The scoring 
results were compared and any sample with discordant results re-typed. Most of 
the repeats were done in Dr. Carrignton’s laboratory particularly to confirm that the 
frequency of KIR3DS1 was correct since it has been previously reported to be low 
in people of African descent. A sample of the gel interpretation sheet is shown in 
appendix 12. The results were double entered into an Access database for 
analysis.
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HLA class I typing by sequence-based techniques
HLA typing was done following the sequence-based method as described 
fully elsewhere183. Briefly, genomic DNA from each individual was amplified using 
locus-specific primers that flanked exons 2 and 3 of HLA-A, -B, and -C loci. 
Sequence-specific primers were then used to sequence the amplified products in 
both directions as illustrated in Figure 2.2. The list of HLA primers used in this 
study is reproduced in Appendix 13. Primers were synthesised, desalted and 
HPLC purified by Metabion (Metabion International, Germany). They were 
reconstituted to 100 pM in TE buffer pH 8.0.
.Fwd
ex3l [3R
Exon 2
1 73 204 473 715 900 1570
PCR primer 
Sequencing primer 
Exonic region
Intronic region
Figure 2.2 HLA class I sequencing map with primer positions
Polymerase chain reaction (PCR)
Each locus was amplified by polymerase chain reaction (PCR) in a 20 pi 
reaction mixture consisting of 2 pi of 10X PCR buffer, 0.4 pi of 10 mM dNTPs, 0.8 
pi of 50mM MgCI2, 1.0 Unit of Taq polymerase (Bioline Ltd, London, UK), 0.4 pi of
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10 pM of each primer and 150 ng DNA. Amplifications were performed using a 
PTC-200 (tetrad) Thermal Cycler (MJ Research, Inc., MA, USA) programmed as 
follows: for HLA-A, 1 cycle of 96 °C for 2 minutes, 30 cycles of 96 °C for 25 
seconds, 60 °C for 25 seconds, and 72 °C for 1 minute, followed by 1 cycle of 72 
°C for 7 minutes and 4 °C for ever; HLA-B, 1 cycle of 96 °C for 2 minutes, 40 
cycles of 96 °C for 15 seconds, 62 °C for 15 seconds, and 72 °C for 1 minute, 
followed by 1 cycle of 72 °C for 7 minutes and 4 °C for ever; and HLA-C, 1 cycle of 
96 °C for 2 minutes, 30 cycles of 96 °C for 25 seconds, 70 °C for 25 seconds, and 
72 °C for 1 minute, followed by 1 cycle of 72 °C for 7 minutes and 4 °C for ever. 
The efficiency of the PCR reaction and the sizes of the amplified products were 
checked by electrophoresing 5 pi of the products in 2% agarose gel and staining 
with ethidium bromide. Gels were visualized using a UV transilluminator and a 
gel picture taken with a Kodak gel image documentation camera (DC120). The 
remaining 15 pi products were purified using either Exonuclease I and Shrimp 
Alkaline Phosphatase (GE Healthcare UK Ltd, Buckinghamshire, England) or 
AMPure kit (Agentcourt Bioscience Corporation, Beverly, USA).
Sequencing reaction and interpretation
The BigDye Terminator v3.1 Cycle Sequencing Ready Reaction kit (Applied 
Biosystems, Foster City, CA, USA) was used to sequence the purified products in 
both directions following the manufacturer’s instructions. Briefly, the mix contained 
(per reaction) 2.07 pi of 5X buffer, 0.25 pi of BigDye Terminator v3.1 (Applied 
Biosystems, Foster City, CA, USA), 5.36 pi of water, 0.32 pi of primer, and 2.0 pi 
of purified PCR products. The sequencing conditions were 1 cycle of 96 °C for 1 
minute; followed by 30 cycles of 96 °C for 10 seconds, 50 °C for 5 seconds, and 
60 °C for 4 minutes; and finally one cycle of 4 °C on hold.
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The sequencing products were purified using either Sephadex G-50 
superfine (Sigma-Aldrich, Dorset, UK) in Multiscreen HV 0.45 pm plates (Millipore 
Corporation, Watford, UK) or CleanSEQ 96 kit (Agentcourt Bioscience 
Corporation, Beverly, USA). Cleaned products were analysed using either ABI 
3130x1 or 3730x1 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). In 
June 2008, I re-visited Dr. Mary Carrington’s laboratory at the NCI-Frederick, MD, 
USA for another 3 months period to learn about sequence trace interpretation and 
analysis techniques. All sequence traces generated from this study were analysed 
by two independent readers using the “Assign 400” software (Conexio Genomics, 
Western Australia). The second reading was performed by a senior scientist in Dr 
Carrington’s laboratory at the National Cancer Institute, NCI-Frederick, USA. 
Results were compared and repeats done for samples with discordant results. 
The HLA typing protocol is reproduced in Appendix 14.
Statistical Analysis
Data were managed using Microsoft Access. HLA-A, HLA-B, and HLA-C 
alleles and genotype frequencies were calculated using SPSS v16 (SPSS Inc, 
Chicago, USA) and STATA v9.2 (Stata Corporation, Texas, USA). SAS 9.1 (SAS 
Institute) was used for statistical analyses. The %2 test was used to examine 
differences in allele and genotype frequencies between Caio, Fajara and other 
West African populations. PROC FREQ was used to compute frequencies on 
individual variables. PROC LOGISTIC was used for categorical analyses to obtain 
odds ratios and 95% confidence intervals. PROC GLM was used for analyzing 
continuous variables. Both logistic and linear regression models were adjusted for 
age and gender.
Allele frequency was calculated as a percentage of the total number of 
alleles in the locus of interest and the genotype frequency was estimated based on
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the number of individuals carrying the corresponding allele. The Hardy-Weinberg 
(HW) test of equilibrium and the two- and three-locus haplotypes estimates were 
performed using Arlequin v 3.11 based on the genotype data. All p-values are 
uncorrected for multiple comparisons and were considered significant when p was 
less than 0.05.
Although several comparisons (-90 ) were performed on these highly 
polymorphic loci, we only have power to detect significant changes in 32 
comparisons because of the small numbers in each of the HLA groups. However, 
since this is the first time a thorough examination of HLA and KIR has been done 
in a sizeable cohort of HIV-2 infected people, we considered it best to present 
uncorrected p-values at this preliminary stage. It is well known that for diseases 
that are being investigated for the first time with regards to HLA and KIR, it is 
generally best not to apply corrections that can result in false negative 
interpretations (i.e. an allele that actually show an effect may appear not to be 
significant). We recommend that these preliminary findings be taken cautiously 
pending replication in other HIV-2 cohorts. Subsequent HLA and KIR studies on 
these and other HIV-2 cohorts will need to adjust for multiple comparisons and 
some of the methods that can be used to correct for multiplicity testing include 
Bonferroni test and test for false discovery rate.
The Bonferroni test is one of the simplest and most conservative 
approaches to correct for multiple testing when several dependent or independent 
statistical tests are being performed simultaneously on a set of data. This is based 
on the assumption that an alpha level of 0.05 might not be appropriate for a set of 
multiple comparisons. The Bonferroni correction then reduces the alpha value for 
the comparisons in such a way that the probability of having a significant p-value 
by chance is much more reduced. This is achieved by multiplying 0.05 by the total 
number of comparisons.
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CHAPTER 3 : HLA CLASS I ALLELE, KIR GENE 
FREQUENCIES AND HIV-2 ANTIBODY STATUS IN CAIO, 
GUINEA BISSAU
This chapter describes the frequencies of individual genes/alleles at the 
HLA-A, -B and -C loci and the common HLA haplotypes found in the Caio 
population in Guinea Bissau. The relationship between HLA alleles and HIV-2 
status defined by antibody levels was examined with antibody positivity implying 
HIV infection. A well-validated diagnostic algorithm exists and is currently in 
routine use at MRC laboratories, The Gambia to distinguish between HIV-1 and 
HIV-2 and avoid false positive results from cross-reactivity as described in 
Chapter 2. Frequencies of KIR genes and gene profiles are given together with 
their relationship to HIV-2 status. The effect of HLA/KIR combinations was also 
investigated where KIR genes were paired with their respective HLA ligands.
HLA allele frequencies in the Caio population
Although 513 individuals consented to take part in the study, a small 
number were excluded from allele frequency (AF) analyses because their HLA 
results were non-conclusive. A sample was classified as indeterminate if the 
sequence trace deviated from a known HLA allele consensus by at least one 
mismatch. These indeterminate samples are likely to contain new HLA alleles that 
are yet to be described. Our future plan is to characterise these alleles further by 
designing new primers to sequence extensively the remaining exons. HLA-A data 
were available for 492 subjects, HLA-B and HLA-C for 406 and 462 individuals, 
respectively.
Table 3.1 summarises the allele frequency of classical HLA class I (A, B, 
and C) loci found in this sample of Manjako population from Caio. A total of 24
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HLA-A, 32 HLA-B and 21 HLA-C alleles were detected. Homozygosity was low in 
all three loci (HLA-A: 0.134; HLA-B: 0.140; and HLA-C: 0.134) and decreased with 
increasing number of loci (HLA-AB: 0.038; HLA-AC: 0.027; HLA-BC: 0.043; and 
HLA-ABC: 0.019) (data not shown). Overall, HLA allele frequencies were similar 
between males and females across all three class I loci (data not shown).
Table 3.1: HLA-A, -B, and -C allele frequencies in the Caio population
HLA-A alleles 
(n = 984)
Freq. HLA-B alleles 
(n = 812)
Freq. HLA-C alleles 
(n = 924)
Freq.
A*010101 0.051 B*0702 0.033 Cw*0102 0.043
A*0102 0.019 B*080101 0.108 Cw*0203 0.002
A*0201 0.066 B*130201 0.032 Cw*0210 0.095
A*0202 0.050 B*1401 0.003 Cw*0302 0.079
A*0205 0.008 8*140201 0.043 Cw*030301 0.013
A*030101 0.026 B*1503 0.127 Cw*0304 0.144
A*2301 0.173 B*1510 0.099 Cw*040101 0.154
A*260101 0.078 B*1516 0.011 Cw*050101 0.030
A*290201 0.017 B*1801 0.028 Cw*060201 0.048
A*3001 0.026 B*3501 0.095 Cw*0701 0.167
A*3002 0.071 B*3910 0.004 Cw*070201 0.030
A*310102 0.002 B*4001 0.001 Cw*0704 0.001
A*3201 0.011 B*4016 0.001 Cw*0802 0.042
A*3301 0.024 B*4102 0.007 Cw*0804 0.038
A*330301 0.186 B*4103 0.001 Cw*120301 0.008
A*340101 0.001 B*4201 0.009 Cw*140201 0.014
A*3402 0.021 B*4403 0.026 Cw*1502 0.004
A*3601 0.002 B*4410 0.001 Cw*1505 0.017
A*6601 0.013 B*4501 0.001 Cw*160101 0.035
A*6602 0.002 B*470101 0.001 Cw*1T 0.015
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A*6801 0.037 B*4901 0.067
A*680201 0.050 B*5001 0.010
A*7401 0.054 B*5101 0.016
A*8001 0.010 B*5201 0.015
B*530101 0.113
B*5601 0.007
B*5702 0.001
B*570301 0.015
B*5801 0.113
B*7801 0.001
B*7802 0.001
B*8201 0.009
n = total number of alleles for the locus of interest; a: alleles that could not be discriminated with 
exons 2 and 3 sequences (Cw*17 = Cw*1701/Cw*1702, and Cw*18 = Cw*1801/C w *1802). In bold 
are common HLA class I alleles with a population frequency > 9%.
HLA-A alleles and susceptibility to HIV-2 infection
Twenty four alleles were identified at the A locus in 492 individuals. The 
most frequent HLA-A allele was A*330301 (18.6%), followed by A*2301 (17.3%). 
Seven other alleles of this locus had their frequencies ranging from 5.0 to 7.8%  
(A*010101, A*0201, A*0202, A*260101, A*3002, A*680201, and >4*74) (Table 
3.1). A*7401 and A*7402 could not be fully discriminated with sequences accrued 
from exons 2 and 3 since their nucleotide and amino acid compositions are similar 
at these exons but differ in exon 1 by only one nucleotide at position 67 (codon 
23). A*7401 has an “A” at that position while A*7402 has a “T”, changing the 
amino acid at codon 23 from Arginine (R) in A*7401 to Tryptophan (W) in A*7402. 
We re-sequenced all A*74+ individuals to include exon 1. Analysis of their traces
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showed that they were all A*7401. The nine most frequent alleles with a 
population frequency of at least 5.0% made up 78.0% of all HLA-A cumulative 
frequencies in our study population. The most diverse group was HLA-A*02 with 
three different alleles {A*0201, A*0202, and A*0205). Their group cumulative 
frequency (12.4%) was shared almost equally between A*0201 (5.3%) and A*0202 
(5.0%).
We also determined the population genotype frequencies (GF) of all four­
digit HLA alleles found in the study population (Figure 3.1). A univariate analysis 
was performed to compare HLA-A genotype frequencies between cases (HIV-2 
infected) and controls (HIV antibody negative) (Table 3.2).
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In most instances, frequencies were similar between cases (n = 149) and controls (n 
= 309). However, the frequency of H LA-A*8001 , though a rare allele in this 
population (2.0% GF in the general population), was significantly higher in the 
infected group than controls (0.054 vs. 0.006, OR: 8.90 (1.86-42.53), p = 0.01). Eight 
out of ten (8/10) individuals carrying this allele were infected with HIV-2 and all of 
them were heterozygous for A*8001\ the other allele being either A*010101, 
A*260101, A*3001, A*3002, A*330301, or A*680201. This suggests that individuals 
with A*8001  might have an increased risk of acquiring HIV-2 compared to those 
without this allele.
Table 3.2: HLA-A genotypes and HIV-2 antibody status
Allele HIV-2 (n = 149) HIV-neg (n = 309) OR (95% Cl) p
A*01 0.121 (18) 0.146 (45) 0.80 (0 .44-1 .44) 0.45
A* 02 0.188 (28) 0.243 (75) 0.73 (0 .45-1 .18) 0.20
A*03 0.047 (7) 0.048 (15) 0.95 (0.38 - 2.40) 0.92
A*23 0.336 (50) 0.314 (97) 1.11 (0 .73-1 .68) 0.63
A*26 0.168 (25) 0.136(42) 1.28 (0 .75-2 .20) 0.37
A*29 0.013(2) 0.029 (9) 0.46 (0 .10-2 .15) 0.32
A*30 0.242 (36) 0.172 (53) 1.54 (0 .95-2 .48) 0.08
A*32 0.013(2) 0.023 (7) 0.59 (0 .12-2 .86) 0.51
A*33 0.383 (57) 0.392 (121) 0.96 (0 .64-1 .43) 0.84
A*34 0.047 (7) 0.039(12) 1.21 (0 .47-3 .15) 0.69
A*36 0.007(1) 0.003 (1) 2.11 (0.13-34.03) 0.60
A*66 0.020 (3) 0.036 (11) 0.55 (0.15- 1.99) 0.36
A*68 0.174 (26) 0.146 (45) 1.24 (0 .73-2 .10) 0.43
A*74 0.067(10)
A*80 0.054 (8)
0.120 (37) 
0.006 (2)
0 .53(0 .26-1 .10) 0.09
8.90(1 .86-42.53) 0.01
n = number of individuals, p: values after adjusting for gender and ethnicity
HLA-B alleles and HIV-2 acquisition
This predominantly Manjako population showed extensive diversity at the B 
locus with 32 different alleles out of the total 77 class I alleles detected (Table 3.1). 
The most common group of alleles (two-digit alleles) was HLA-B*15  with a cumulative 
frequency of 23.7%  distributed mostly between B*1503  (12.7% ) and B*1510  (9.9%). 
HLA-B*15  was also the group with the highest number of four-digit alleles (B*1503, 
B*1510, and B*1516) at the B locus. Six alleles were present in our samples at 
relatively high frequencies ranging from 9.5% to 12.7%. They include HLA-B*3501, - 
B*1510, -B*080101f -B*530101 , -B*5801, and -B*1503. These alleles together with 
B*140201  and B*4901 had a cumulative frequency of 76.5%  amongst all observed 
HLA-B frequencies in the study population.
A comparative analysis was done to see whether there was a difference in 
genotype frequencies between males (n = 131) and females (n = 275) and between 
HIV-2 infected participants (n = 143) and uninfected controls (n = 234). Individuals 
dually infected with HIV-1 and -2 (n = 29) were excluded from analyses because of 
their limited number and the potential for HIV-1 to confound our analyses. With the 
exception of HLA-B*080101, no significant difference in HLA-B  frequencies was 
observed between cases and controls nor between males and females. However, 
univariate analysis showed that the common HLA-B*080101  (10.8%  AF and 19.6%  
GF at the population level (Figure 3.1)), was more likely to be present in the HIV-2
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infected group than the control group (0.273 (n = 39) vs. 0.145 (n = 34), OR: 2.20  
(1.31-3.06), p = 0.003) (Table 3.3).
Table 3.3: HLA-B genotypes influence on HIV-2 acquisition
Allele HIV-2 (n = 143) HIV-neg (n = 234) OR (95% Cl) P
B*07 0.049 (7) 0.073 (17) 0.66 (0 .27-1 .63) 0.37
B*08 0.273 (39) 0.145 (34) 2.20 (1.31 -3.70) 0.003
B*13 0.056 (8) 0.060 (14) 0.93 (0.38 - 2.28) 0.88
B*14 0.098 (14) 0.081 (19) 1.23 (0 .60-2 .54) 0.57
B*15 0.385 (55) 0.449 (105) 0.77 (0 .50-1 .17) 0.22
B*18 0.063 (9) 0.043 (10) 1.51 (0 .60-3 .80) 0.39
B*35 0.140 (20) 0.214 (50) 0.60 (0 .34-1 .06) 0.08
B*39 0.014 (2) 0.004 (1) 3.30 (0.30 - 36.78) 0.33
B*41 0.014 (2) 0.013(3) 1.10(0 .18-6 .64) 0.92
B*42 0.028 (4) 0.004 (1) 6.73 (0.74 - 60.82) 0.09
B*44 0.056 (8) 0.051 (12) 1.09(0 .44-2 .75) 0.85
B*49 0.140 (20) 0.132 (31) 1.07 (0 .58-1 .95) 0.84
B*50 0.021 (3) 0.021 (5) 0.98 (0 .23-4 .16) 0.98
B*51 0.035 (5) 0.030 (7) 1 .17(0 .36-3 .76) 0.80
B*52 0.014 (2) 0.038 (9) 0.36 (0 .08-1 .67) 0.19
B*53 0.161 (23) 0.235 (55) 0 .62(0 .36-1 .07) 0.08
B*56 0.014 (2) 0.004 (1) 3.30 (0.30 - 36.78) 0.33
B*57 0.049 (7) 0.017(4) 2.95 (0.85-10.28) 0.09
B*58 0.224 (32) 0.192(45) 1.22 (0 .73-2 .03) 0.46
B*82 0.021 (3) 0.017(4) 1.23 (0 .27-5 .58) 0.79
n = number of individuals, p: values after adjusting for gender and ethnicity
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Almost all of these individuals in both the HIV-2 infected group (38/39) and the control 
group (30/34) were heterozygous for this allele. This indicates that HLA-B*080101  
could be directly or indirectly (if in strong LD with another locus) mediating the 
susceptibility effect and that individuals carrying this allele could be more susceptible 
to HIV-2 infection than those negative for B*080101  in this community.
W e then grouped all the HLA-B  alleles into two mutually exclusive groups as 
Bw4 or Bw6 based on their amino acid composition at positions 77-83. Those within 
the Bw4 group were further subdivided into Bw4-80l or Bw4-80T depending on 
whether the amino acid at position 80 was an isoleucine (I) or a threonine (T). It has 
been shown that HLA-B Bw4 alleles and in particular those with isoleucine at position 
80 (Bw4-80l) serve as ligands for some KIR molecules with 3 extracellular domains 
(KIR3D)184'186. However, Bw6 alleles predominated in our samples compared to Bw4 
alleles (58.9%  vs. 41.1%  respectively, p < 10'7). The majority of individuals (65.3% ) 
carried at least one copy of the Bw4 allele but only 17% of them were homozygous 
for Bw4 (Bw4/Bw4) while 34.7%  were homozygous for Bw6 alleles. This difference 
between homozygosity for Bw4 and Bw6 was significant (p < 10'7) within the cohort 
as a whole, and within groups (HIV-2 infected) and control (H IV negative).
Overall, there were more Bw4 alleles with isoleucine at position 80 than Bw4- 
80T in the entire cohort (57.8%  vs. 42.2% , p = 7.93 x 10'5). A  comparison of the 
proportion of individuals carrying at least one copy of Bw4-80l to those with Bw4-80T  
using the Bw6 homozygous as a reference group (Table 3.4) showed no difference 
between HIV-2 positive and HIV negative groups, suggesting that there is no 
influence of these groups of HLA-B  alleles on HIV-2 acquisition.
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Table 3.4: HLA-B Bw4 alleles and susceptibility to HIV-2 infection
Genotypes HIV-2 (n = 143) HIV-neg (n = 234) OR (95% Cl) P
Bw4/x 0.643 (92) 0.645(151) 0.99 (0 .64-1 .53) 0.97
Bw4-80l/x 0.378 (54) 0.440 (103) 0.85 (0.53- 1.38) 0.52
Bw4-80T/x 0.336 (48) 0.295 (69) 1 .15(0 .69-1 .91) 0.60
Bw6/Bw6 0.357 (51) 0.355 (83)
n = number of individuals, p: values after adjusting for gender and ethnicity
HLA-C alleles and susceptibility to HIV-2 infection in Caio
HLA-C locus had the lowest number of alleles (21) compared to A and B loci 
(24 and 32, respectively). Four hundred and sixty two samples were successfully 
assigned a HLA-C genotype. Those with one or more mismatches were excluded 
from analyses. The most common allele was Cw*0701 (16.7% ) followed by 
Cw*040101 (15.4% ) and Cw*0304 (14.4% ) (Table 3.1). The eight most common 
alleles (Cw*0802, Cw*0102, Cw*060201, Cw*0302, Cw*0210, Cw*0304, Cw*040101, 
and Cw*0701) had frequencies ranging from 4.2%  to 16.7%. A comparative analysis 
of HLA-C allele and genotype frequencies between HIV-2 infected (n = 147 
individuals) and uninfected (n = 283) revealed no difference between groups (Table 
3.5).
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Table 3.5: The effect of HLA-C genotypes on HIV-2 infection
Allele HIV-2 (n = 147) HIV-neg (n = 283) OR (95% Cl) P
Cw*01 0.088 (13) 0.074(21) 1.21 (0 .59-2 .50) 0.60
Cw*02 0.150 (22) 0.212(60) 0.66 (0 .38-1 .12) 0.12
Cw*03 0.401 (59) 0.438 (124) 0.86 (0 .57-1 .28) 0.45
Cw*04 0.293 (43) 0.300 (85) 0.96 (0 .62-1 .49) 0.87
Cw*05 0.082 (12) 0.042 (12) 2.02 (0 .88-4 .61) 0.10
Cw*06 0.075 (11) 0.095 (27) 0.75 (0.36- 1.57) 0.45
Cw*07 0.381 (56) 0.336 (95) 1.22 (0.81 -1.85) 0.35
Cw*08 0.136 (20) 0.155 (44) 0.85 (0 .48-1 .51) 0.59
Cw*12 0.014 (2) 0.018(5) 0.77 (0 .15-4 .04) 0.76
Cw*14 0.014 (2) 0.039(11) 0.34 (0 .07-1 .55) 0.16
Cw*15 0.054 (8) 0.039 (11) 1.45 (0 .57-3 .69) 0.44
Cw*16 0.054 (8) 0.074(21) 0.72 (0.31 -1 .67) 0.44
Cw*17 0.034 (5) 0.021 (6) 1.62 (0 .48-5 .39) 0.43
Cw*18 0.041 (6) 0.035(10) 1.16(0.41 -3.26) 0.78
n = number of individuals, p: values after adjusting for gender and ethnicity
W e next grouped all HLA-C  alleles into one of two mutually exclusive 
categories C1 or C2 based on their amino acid composition at position 80. If the 
amino acid at position 80 is asparagine, the allele is classified as group 1 (C1) 
whereas if lysine is at that position it is grouped as C2. This classification is important 
because certain killer immunoglobulin-like receptors on the surfaces of NK cells use 
HLA-C group 1 molecules while others use group 2 molecules as their ligands in 
order to modulate NK cell cytotoxic activities. W e then determined the distribution of
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C1 and C2 in Caio and tested for their potential effect on HIV-2 infection (Table 3.6). 
W e hypothesised that HIV-2 infection would be less likely in the group of individuals 
with functional activating KIR molecules (activating KIR + ligand) since they can 
readily detect non-self cells and more effectively activate NK cells to lyse the targets 
sooner than later post infection. It is known that the presence of one without the other 
leads to a null phenotype.
Table 3.6: The effect of HLA-C groups on HIV-2 infection
Genotypes HIV-2 (n = 147) HIV-neg (n = 283) P
C1/C1 0.338 (57) 0.392 (111) ns
C1/C2 0.463 (68) 0.438(124)
C2JC2 0.150 (22) 0.167 (48)
n: number of individuals, p: p-values at 5% level of significance
Overall, HLA-C group 1 was over-represented in our cohort (61.3%  vs. 38.7% , 
p < 10‘7 for C1 and C2, respectively). More than a third of the cohort (38.5% ) was 
homozygous for C1 (C1/C1) and only 16.0% were homozygous for C2 (C2/C2). 
Although C1/C1 was over-represented in both the HIV-2 infected and the uninfected 
groups separately, there was no significant difference in the various categories 
(C1/C1, C1/C2, and C2/C2) between the two groups (Table 3.6). This is an indication 
that individual HLA-C  alleles or groups of alleles did not influence susceptibility to 
HIV-2 infection in the study population.
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KIR genes and HIV-2 infection in the Caio population
DNA samples from the entire cohort were successfully typed for the presence 
or absence of 15 KIR genes including 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 
2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, and 2DP1. The technique (PCR- 
SSP) involved the use of two pairs of KIR gene-specific primers targeting conserved 
regions and annealing at 2 different exons of the same KIR gene in order to avoid 
false negative results, which could occur if there is a point mutation at one of the 
primer binding sites. All 14 functional KIR genes and the pseudogene 2DP1 were 
detected in our samples. As has been observed in other populations, most of the 
inhibitory KIR genes were present in almost all DNA samples (Table 3.7), with the 
exception of 2DL2 and 2DL5, which were each present at a frequency of about 50%. 
The ubiquitous 2DS4 gene was the only activating KIR gene that was found in nearly 
all samples (98.8% ). All other activating KIR gene frequencies were near 30%  on 
average.
A comparison of KIR gene frequencies between cases (H IV-2 infected) and 
controls (HIV negative) revealed that KIR2DS2 and the corresponding inhibitory gene 
KIR2DL2 (both of which are in strong LD with each other), were more likely to be 
present in the control groups than in cases (Table 3.8). The differences were 
statistically significant: OR = 0.67 (0.45-0.98), p = 0.04 for 2DS2 and O R = 0.63 (0.43- 
0.93), p = 0.02 for 2DL2. This finding indicates that individuals with KIR2DS2 and/or 
KIR2DL2 genes are more likely to be protected against H IV-2 acquisition in this 
predominantly Manjako community than those without any of these genes.
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Table 3.7 KIR gene frequency in the Caio population
Type Gene Number of individuals Frequency
2DL1 508 0.99
2DL2 287 0.56
2DL3 459 0.90
Inhibitory 2DL4 512 1.00
2DL5 246 0.48
3DL1 508 1.00
3DL2 513 1.00
3DL3 511 1.00
2DS1 101 0.20
2DS2 262 0.51
2DS3 139 0.27
Activating 2DS4 507 0.99
2DS5 131 0.26
3DS1 94 0.18
Pseudogene 2DP1 505 0.98
KIR molecules are primarily expressed on NK cell surfaces and some T-cells. 
They are key regulators of NK cell activities and are of two types: the inhibitory and 
the activating KIRs. NK cells survey other cells in order to detect abnormalities in 
levels of HLA class I expression on the target cell surface. Both the KIR molecule 
and its corresponding ligand (s) need to be present in the same individuals for the 
KIR to be functional. Table 3.9 shows some KIR and their known or putative ligands. 
The absence of one renders the other null.
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Table 3.8: KIR genes and susceptibility/resistance to HIV-2 infection
Genes HIV-2 (n = 150) HIV-neg (n = 328) OR (95% Cl) P
2DL1 0.980 (147) 0.994 (326) 0.31 (0.05- 1.85) 0.20
2DL3 0.860 (129) 0.909 (298) 0.62 (0 .34-1 .13) 0.12
2DL5 0.507 (76) 0.466 (153) 1 .17(0 .80-1 .72) 0.42
2DS1 0.227 (34) 0.189 (62) 1.25 (0 .78-2 .01) 0.35
2DS3 0.247(37) 0.277 (91) 0.85 (0 .55-1 .33) 0.48
2DS4 0.993 (149) 0.985 (323) 2.37 (0.27 - 20.47) 0.43
2DS5 0.293 (44) 0.238 (78) 1.34 (0 .87-2 .06) 0.19
2DP1 0.973 (146) 0.988 (324) 0.45 (0.11 -1 8 2 ) 0.26
2DS2 0.440 (66) 0.543 (178) 0.67 (0.45 - 0.98) 0.04
2DL2 0.480 (72) 0.595 (195) 0.63 (0.43 - 0.93) 0.02
3DS1 0.167(25) 0.204(67) 0.78 (0 .47-1 .29) 0.34
3DL1 0.987 (148) 0.991 (325) 0.70 (0.11 -4 .22) 0.69
n = number of individuals, p: values after adjusting for gender and ethnicity
To look at the effect of HLA-KIR compound genotypes on HIV-2 infection, we 
studied the group of individuals that have the corresponding ligands for their KIR  
molecules. Table 3.10 shows some of the HLA-KIR combinations found in our study 
population. A comparison of HLA-KIR compound genotype frequencies between 
HIV-2 infected and uninfected groups showed that individuals expressing K IR2DS2 or 
KIR2DL2 along with at least one copy of HLA-C group 1 were less likely to be HIV-2  
positive (OR: 0.63 (0.41-0.95), p = 0.03; and OR: 0.66 (0.44-0.99), p = 0.04, for 
KIR2DS2 and 2DL2, respectively).
95
Table 3.9: KIR and their corresponding ligands
KIR Ligands specificity HLA alleles
KIR2DL2,
KIR2DL3
(KIR2DS2)*
C1 77S - 80N
Cw1, Cw3, Cw7, Cw8, Cw12, 
Cw13, Cw14, CW16
KIR2DL1
(KIR2DS1)a
C2 77N - 80K
Cw2, Cw4, CW5, CW6, Cw15, 
Cw17, CW18
KIR3DL1
(KIR3DS1)a
Bw4
80I
B*1516, B*4901/03, B*51, B*52, 
B*53, B*57, B*58, B*59
KIR3DL1 80T
B*13, B*27, B*37, B*44, B*4902, 
B*5303/09
KIR2DL4 HLA-G
KIR3DL2
HLA-A3 
HLA-A11
2: The activating receptors KIR2DS1, KIR2DS2, and KIR3DS1 are very similar to their corresponding 
inhibitory counterparts in nucleotide and amino acid composition (>90% similarity) and are thought to 
be using similar ligands but with much weaker interaction for the activating receptors.
In brief, the protective effect described earlier with individual 2D S2  and 2DL2  genes 
was linked to functional KIR  genes i.e. KIR  genes present in the same individual 
together with their corresponding ligands. No difference was observed in individuals 
having KIR2DS2 or 2DL2 molecules without C1 and vice-versa.
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Table 3.10: The effect of KIR-HLA combinations on HIV-2 infection
Genotypes HIV-2 (n) HIV negative (n) OR (95% Cl) P
3DS1: BW4-80I/X 0.035 (5) 0.074(17) 0.48 (0.17-1.40) 0.18
Bw6/Bw6 0.352 (50) 0.355 (82)
3DS1: BW4-80I/X 0.035 (5) 0.074 (17) 0.46 (0.16-1.27) 0.13
Others 0.965 (137) 0.926 (214)
2DS2: C1/x 0.338 (49) 0.449 (124) 0.63 (0.41 - 0.95) 0.03
Others 0.662 (96) 0.551 (152)
2DL2: C1/x 0.386 (56) 0.489 (135) 0.66 (0.44 - 0.99) 0.04
Others 0.614 (89) 0.511 (141)
2DS1: C2Jx 0.138 (20) 0.120 (33) 1.18(0.65-2.13) 0.60
Others 0.862 (125) 0.880 (243)
2DL1: C1/x 0.834 (121) 0.826 (228) 1.06 (0.62-1.82) 0.83
Others 0.165 (24) 0.174(48)
n = number of individuals, p: values alter adjusting tor gender and ethnicity.
W e also compared the frequency of individual KIR  genes in Caio with those 
reported in other populations in Africa, Europe and Asia and to the best of our 
knowledge this is the first study examining KIR/HLA combinations in Guineans and 
Gambians. In 2005, Denis et al. reported KIR frequencies in 118 subjects from 
Senegal. In our study we found the frequency of all activating genes (except 
KIR2DS5) to be higher compared to data from the neighbouring Senegalese 
population (Table 3.11). The most striking difference was observed among carriers 
of KIR3DS1 (19% vs. 4 % respectively). Our future plan is to sequence KIR3DS1  
along with those genes that showed significant differences between cases and 
controls (KIR2DS2  and KIR2DL2) to confirm our present observations. The KIR3DS1
97
gene has previously been reported to be low in most African populations and some 
experts believe, based on sequences derived to date, that the KIR3DS1  gene is 
monomorphic. However, the statistics from the international KIR database indicates 
14 different allelic forms of this gene. Our observation (high frequency of KIR3DS1  
compared to other African populations), if confirmed by sequencing, will further 
strengthen our beliefs that this group of Manjako population from the Caio sector in 
north-western coast of Guinea Bissau is distinct. Moreover we may be able to identify 
genuine polymorphisms in the KIR3DS1 gene. Most if not all the inhibitory genes 
frequencies were similar to that reported by Denis and his group187.
In a more genetically distant South African population, most of the activating 
KIR  genes frequencies were higher compared to what we obtained in this study. 
KIR3DS1 was not reported which could either mean that the authors did not look for 
this gene or that the gene was completely absent. The frequencies of framework 
genes are consistent in most populations reported in Table 3.11.
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Discussion
One of the objectives of this study was to determine the type of HLA alleles 
and KIR  genes present in two well characterised West African cohorts: one in Caio, 
Guinea Bissau and the other in Fajara, The Gambia. Also we aimed to study the 
relationship between the presence or absence of these highly polymorphic genes with 
susceptibility or resistance to HIV-2 infection and disease progression assessed using 
markers of progression to AIDS such as decline in CD4+ T  cell count and increase in 
viral load over time.
HLA-A*8001 weakly associates with susceptibility to HIV-2 infection
W e detected 15 different A serological groups (two-digit alleles) and 24 HLA-A 
subtypes (four-digit alleles) (Figure 3.1) in Caio. Although, the allele and genotype 
frequencies did not differ between groups (HIV-2 infected and HIV negative controls), 
some of them differed considerably from those observed in neighbouring populations.
HLA-A*01 genotype frequency in this predominantly Manjako community 
(13.8% ) was comparable to that seen in the Fulani population from Burkina Faso 
(13.3% )188 and Fula and Mandinka in The Gambia189 (13.3%  and 13.2%, 
respectively), but differed from that reported in a Malian population (7 .3% )190.
HLA-A*02  is one of the most widely studied class I allele in different 
populations. W e found its genotype frequency in Caio to be 22.5%  (Table 3.1), which 
is slightly lower compared to other populations. Allsopp and colleagues reported that 
35.8%  of Wolof and 44.0%  of Serere in The Gambia are A 2  positive189. In Mali, Kalidi 
et al. reported A2  frequency to be 29.2% 190. A low A2  frequency has been described 
also in the Mossi tribe (3.7% ) in Burkina Faso188. In many Caucasoid and Oriental 
populations, the frequency of A2  varies between 25%  and 42%  average98. HLA-A*02
is one of the most polymorphic group of alleles at the A locus with currently 244  
closely related subtypes described in the Immunogenetic database94. In Caio, we 
found that A *02  was the most diverse group of allele at the A locus with 3 subtypes: 
A*0201, A *0202  and A*0205. The former being the most common as is customary in 
other populations worldwide but its allele frequency (6.6% ) was relatively low 
compared to most populations with high resolution typing data. For example, in 
Ugandans, A*0201  allele frequency was 18.4% 191 while it varied between 12.1%  and 
14.9% in different regions of the Cape Verdes Islands192.
In the present study, a rare allele HLA-A*8001 showed a weak association with 
HIV-2 acquisition. Individuals positive for HLA-A*8001 were more likely to be HIV-2 
infected than those without. Eighty percent of individuals with this genotype were 
HIV-2 infected (Table 3.2). This is an indication that despite being a rare allele in this 
population, HLA-A*8001 could be directly or indirectly mediating HIV-2 acquisition. 
To the best of our knowledge, this trend has not been reported before in HIV-2 and 
warrants further investigation in other well established HIV-2 cohorts. It is however in 
line with the suggestions from Trachtenberg and colleagues137 that rare HLA alleles 
may have a selective advantage over more frequent alleles in populations where HIV- 
1 rapidly adapts to the more frequent HLA alleles. If confirmed that A*8001  leads to 
increased susceptibility to HIV-2 infection in HIV-2 endemic areas, investigations into 
the mechanisms by which A*8001  affects susceptibility to HIV-2 may provide new  
insight into how HIV infects cells and may also inform future vaccine design to block 
HIV infection.
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HLA-B alleles associate with HIV-2 infection
Our data showed that B locus was the most diverse of all class I loci in Caio 
with 32 different alleles. W e demonstrated in this study for the first time that a strong 
association exists between HLA-B*080101  and susceptibility to HIV-2 infection in this 
sample of the W est African study populations. Individuals with this phenotype were 
two times more likely to be HIV-2 infected than those without. B*08  is a common 
allele in Caio, its AF (10.8% ) and GF (19.6% ) are relatively high compared to other 
W est African populations. It was almost absent in three ethnic groups in Burkina 
Faso188. Our data are in accordance with those of Andrien et al. from a study 
conducted in a population in Dakar Senegal (GF= 20.5% )193. In The Gambia, the 
phenotype frequency of B*08 varied from 13.3% to 23.9%  in different ethnic 
groups189. HLA-B*08 forms part of the 8.1 ancestral haplotype, which is carried by 
most Caucasians with the serological B8 type and has been associated with 
accelerated HIV-1 disease, susceptibility to insulin-dependent diabetes mellitus 
(IDDM), and systemic lupus erythematosus194 among others.
HLA-C  alleles did not affect HIV-2 infection
None of the individual HLA-C  alleles were associated with susceptibility or 
resistance to HIV-2 infection in Caio, even after grouping them into C1 and C2. 
However, the classification of C alleles into two mutually exclusive groups (C-group 1 
(C1) and C-group 2 (C2)) was important because certain HLA-C molecules have 
been shown to serve as ligands for KIR molecules and both the KIRs and their 
corresponding ligands need to be present in the same individual for the KIRs to 
become functional.
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Activating KIR frequencies are higher in Caio compared to neighbouring 
populations
In this study we used KIR specific primers (SSP) to investigate the presence or 
absence of 15 KIR  genes in an isolated community cohort of HIV-2 infected and 
uninfected individuals belonging mostly to the Manjako tribe in North-Western Guinea 
Bissau. W e found all 15 KIR  genes in this sample of W est African population at 
various frequencies. A  comparative analysis of the KIR  gene frequencies found in 
Caio with published data from neighbouring populations and elsewhere revealed that 
activating KIR  genes frequencies were significantly higher in Caio compared to the 
neighbouring populations e.g. Senegalese, while those of the inhibitory KIRs were 
generally similar. The frequencies of activating KIRs in Caio were similar to those in 
Southern Africa, Europe and Asia.
Literature search indicates that KIR3DS1  is rare in people of African ancestry 
and common in Caucasoid populations. Indeed, most published KIR data from Africa 
rarely include KIR3DS1  in their tables or analyses due its low frequency in those 
populations. Recent studies employing new molecular tools to detect KIR  genes 
have reported that KIR3DS1  frequencies vary greatly from one population to another 
even within geographically small areas. For examples, Single and colleagues have 
reported the frequency of 3DS1  in three major ethnic groups in Nigeria to be 12% in 
Yuroba, 6.3%  in Ibo, and 3.4%  in Hausa195, all within the same country. In Ivory 
Coast, Jennes et al. found 3DS1 frequency to be as high as 16% in a cohort of 
commercial sex workers in Abidjan196.
Genetic diversity is generally high in Africa and there is a wide range of ethnic 
groupings in Sub Saharan Africa. The reason for the differences observed between 
KIR  gene frequencies in Manjakos from Caio and the Senegalese is uncertain. One
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of the reasons why these two neighbouring populations have different KIR gene 
frequencies could be due to sample sizes. Denis et al. analysed KIR data generated 
from 90 Senegalese while we used 513 individuals in our analysis. One other reason 
could be the ethnic diversity. In Caio, more than 95% of the study participants were 
from a single tribe (Manjako) and anthropological studies have shown that they are 
sexually isolated from neighbouring populations. There are however, considerable 
inter-marriages between Manjakos and Europeans especially French and 
Portuguese. Thus it is possible that the high frequencies reflect admixture with 
populations with high frequencies of activating KIR genes. In Caio, almost every 
family sponsors at least one of their children to go to Europe for work or education. It 
may therefore not be surprising that the frequencies of activating KIRs in Caio are 
very similar to those of the French. For example KIR2DS2  frequency is 51%  in 
Manjakos and 51%  in French187 while it is 42%  in Senegalese187; that of 2D S5  is 26%  
in Caio and 27%  in French while it is 30%  in Senegalese and 62%  in South African197.
KIR-HLA compound genotypes in HIV-2 infected Guineans
The interaction between KIR and HLA molecules at the cellular level strictly 
governs the activity of natural killer (NK) cell in an individual, a very important step in 
the innate immune system. KIR molecules on the surface of NK cells continually 
interact with other cell surface molecules looking for their corresponding ligands, 
which are HLA class I molecules. The nature and degree of interaction between 
these molecules determines the type of signal to be sent to the NK cell. In the 
presence of the corresponding ligands for the inhibitory KIRs, an inhibitory signal is 
sent to the NK cell not to kill the target, which is recognised as a “s e lf  cell. But in the 
absence of the ligands for the inhibitory receptor, the signal sent to the NK cell will
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instead be a stimulatory one. This in turns activates NK cells to kill the target, which 
must have been recognised as a “non-self cell (e.g. a virally infected cell or a cell 
undergoing transformation to become a tumour). In Caio, we observed that most of 
the inhibitory KIR genes were present in almost every sample while the activating KIR 
genes were relatively low compared to their corresponding inhibitory counterparts.
But epidemiological evidence is accumulating from large population studies in 
Western cohorts indicating that KIR3DS1 in individuals carrying at least one copy of 
HLA-B Bw4-80l (one of the Bw4 serological group of alleles with Isoleucine at position 
80), is associated with rapid progression to AIDS following HIV-1 infection. Although, 
the frequency of KIR3DS1 was several folds higher in our study population compared 
to other African populations, it was not as high as in most Caucasoid populations. 
The reason we could not find any association between KIR3DS1 and HIV-2 disease 
in this community cohort could relate to several factors: (1) the fact that HIV-2 has a 
different course of disease presentation compared to that of HIV-1, (2) population 
genetic differences, and (3) the differential frequency of KIR3DS1 in the studied 
populations.
In this study however, we report some new associations between certain KIR 
genes and HIV-2 infection. W e discovered in the course of our analyses that the 
large majority of Caio individuals carrying the KIR2DS2 or KIR2DL2 genes in the 
presence of their corresponding ligands HLA-C group 1 alleles are more likely to be 
free from HIV-2 infection. This is an indication that these functional KIR genes in 
people with the compound genotype (KIR2DS2/C1 or KIR2DL2/C1) may be 
associated with protection from HIV-2 acquisition at least in this community. At this 
stage we are unable to distinguish which of these KIR2D genes is mediating the 
observed effect since both 2DS2 and 2DL2 segregate from the same locus. Plans
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are on the way to sequence these genes in order to describe this association in future 
publications. There were no data on KIR from an HIV-2 cohort prior to our work, 
which made it impossible to compare our findings with previous findings in the context 
of HIV-2 infection and/or disease. W e have replicated this study in a multi-ethnic 
cohort in Fajara, The Gambia and a comparative analysis of both data sets is 
presented in the concluding chapter (Chapter 7) of this thesis.
In summary, we found that individuals from this predominantly Manjako 
community in Caio with certain HLA genotypes including HLA-A*8001  or HLA- 
B*080101  were more likely to be at a greater risk of acquiring HIV-2 infection than 
those without any of these alleles. None of the HLA-C  alleles individually or 
collectively influenced susceptibility or resistance to HIV-2. However, those 
individuals expressing KIR2DL2 or KIR2DS2 molecule together with at least one copy 
of their corresponding ligands (C1) were protected against HIV-2 infection.
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C HA PTER  4 : THE EFFECT OF HLA CLASS I AND KIR 
GENE FREQUENCIES ON MARKERS OF DISEASE 
PROGRESSION
In this chapter we discussed the HLA and KIR data collected from Caio 
participants who were singly infected with HIV-2. A substantial proportion of this 
group had participated in the majority of studies conducted in the Caio field station 
over the years since the first serosurveys in 1989. This group of people also included 
a subset of 65 individuals who were infected before 1989, of whom 64 were still alive 
19 years later. The MRC unit in The Gambia has conducted three population 
serosurveys in Caio since the establishment of the field station.
The first serosurveys was conducted in 1989-90, in which 7.9%  of the adult 
population was infected with H IV-2181. The second survey was conducted in 1996-8  
and the third took place in 2007-8. Several other studies with specific research 
questions were conducted between the surveys. These studies focussed on gaining 
a better understanding of mechanisms driving HIV-2 infection into long-term non­
progression (LTNP) -  a phenomenon observed in the majority of HIV-2 infected 
individuals in West Africa. During these studies and surveys, different immunological 
and virological parameters were recorded including CD4+ T  cell counts (absolute and 
percentage), CD8+ T cell counts, CD38, p2m, neopterin, and HIV-2 viral load 
measurements. In the present study, the effects of individual classical HLA class I 
gene variants on HIV-2 outcomes were explored using internationally accepted 
markers of HIV disease progression (decline in CD4+ T  cell count and increase in HIV  
viral load over time).
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The effect of HLA-A gene variants on HIV-2 viral load
A total of 138 individuals had between two and four HIV-2 viral load 
measurements (median = 3) documented at various time points between 1991 and 
2007 and 135 of them also had a similar number of measurements of absolute and/or 
percent CD 4+ T  cell counts over the same period of time, in addition to their HLA-A  
data. The dates of seroconversion are unknown for most infected subjects.
To study the effect of allelic variations at the HLA-A locus on HIV-2 disease 
and rate of progression, we computed the mean square root (sqrt) of absolute CD 4+ T  
cell count measurements recorded in 1991, 1996, 2003 and 2006 for each person 
and compared the values between groups of individuals positive for a particular HLA- 
A allele versus those negative for the allele of interest (Table 4.1). The average 
mean sqrt CD4+ T  cell count for the entire cohort was 24.70. Similarly, we log- 
transformed HIV-2 viral load (VL) measurements collected over the same period of 
time, calculated their means, and compared them between groups. The average 
mean logioHIV-2 viral load was 3.10 for the entire cohort. These comparisons 
showed that none of the HLA-A variants had a significant influence on CD 4+ T  cell 
dynamics or the rate of HIV-2 replication (Table 4.1). There was however a trend that 
HIV-2 patients who had the A*7401  genotype might do better in controlling viral 
replication than those negative for this genotype since they had an overall low HIV-2  
VL (mean logi0HIV-2 VL = 2.41, p = 0.09).
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Table 4.1: The effect of HLA-A variants on mean square root of absolute CD4+ T cell 
count and mean log10HIV-2 viral load (VL)
A lle le M ean sq rt 
C D 4 (n = 135)
R SE P M ean log H IV -2  
V L  (n = 138)
R SE P
A*01+ 23.71 (16) 0.98 1.61 0.76 2.97 (16) 1.02 0.25 0.87
A*01- 24.23 (119) 2.92  (122)
A*02+ 25.20 (23) 1.05 1.32 0.39 2.98  (24) 1.02 0.20 0.80
A*02- 23.96 (112) 2.92 (114)
A*03+ 24.45 (7) 1.02 2.41 0.90 2 .7 4 (7 ) 0.93 0.38 0.61
A*03- 24.15 (128) 2 .94  (131)
A*23+ 23.38 (46) 0.95 0.93 0.30 2.91 (48) 0.99 0.14 0.89
A*23- 24.57 (89) 2.94 (90)
A*26+ 24.47 (23) 1.01 1.33 0.80 2.85 (24) 0.97 0.20 0.68
A*26- 24.11 (112) 2 .95  (114)
A*29+ 19.15 (1) 0.79 6.38 0.43 4.01 (1) 1.37 1.00 0.28
A*29- 24.21 (134) 2.92 (137)
A*30+ 23.18 (33) 0.95 1.10 0.31 3.12 (34) 1.09 0.17 0.19
A*30- 24.49 (102) 2 .87  (104)
A*32+ 29.22 (2) 1.19 4.47 0.26 3 .1 5 (2 ) 1.08 0.71 0.76
>4*32- 24 .09 (133) 2.93 (136)
A*33+ 24.90 (53) 1.05 0.87 0.28 2.90  (54) 0.98 0.14 0.78
>4*33- 23 .69 (82) 2.95 (84)
A*34+ 26.31 (7) 1.09 2.39 0.36 2.95 (7) 1.01 0.38 0.96
A*34- 24.05 (128) 2 .93  (131)
>4*36+ 15.05 (1) 0.62 6.31 0.15 2 .3 3 (1 ) 0.80 1.00 0.55
A*36- 24.24 (135) 2 .93  (137)
A*66+ 26.27 (3) 1.09 3.68 0.56 2.06  (3) 0.70 0.57 0.13
A*66- 24.12 (132) 2 .95  (135)
A*68+ 23.53 (24) 0.97 1.31 0.59 3.01 (24) 1.03 0.21 0.69
A*68- 24.31 (111) 2.91 (114)
A*74+ 24.77 (10) 1.03 2.02 0.76 2.41 (10) 0.81 0.31 0.09
A*74- 24.12 (125) 2 .97  (128)
A*80+ 23.30 (8) 0.96 2.25 0.69 3 .1 9 (8 ) 1.10 0.35 0.45
A*80- 24.22 (127) 2.91 (130)
n = number of individuals; +: individuals with the allele of interest; individuals without the allele of interest; R: ratio of 
with/without; p = uncorrected p-values, adjusted for age and gender and considered significant when £ 0 .05.
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HLA-B variants and markers of HIV disease progression
The number of HIV-2 infected individuals with both HLA-B data and serial VL 
measurements (median = 3) was 138 and 135 of these also had serial CD4  
measurements (two to four) collected over time as described above. The mean 
square root (sqrt) absolute CD4+ T cell counts was calculated as well as the mean 
log-ioHIV-2 VL. A  comparison of these means was done between groups of 
individuals with and without the HLA-B  variant of interest as shown in Table 4.2  
below. Individuals positive for both HIV-1 and HIV-2 (dually infected) were excluded 
from these analyses.
Table 4.2: The effects of HLA-B alleles on CD4+ T cell count and HIV-2 viral load 
measurements
A lle le Mean sq rt 
C D 4 (n = 135)
R SE P M ean logio HIV-2  
V L  (n = 138)
R SE P
B*07+ 22.38 (6) 0.91 2.54 0.42 2.78 (6) 0.95 0.40 0.73
B*07- 24.47 (129) 2.92 (132)
B*08+ 24.43 (37) 1.00 1.02 0.95 2.92 (37) 1.00 0.16 0.97
B*08- 24.36 (98) 2.91 (101)
B*13+ 2 2 .5 9 (8 ) 0.92 2.17 0.40 2 .88  (8) 0.99 0.34 0.92
B*13- 24.49 (127) 2.91 (130)
B*14+ 26 .72  (14) 1.11 1.65 0.14 2 .39  (14) 0.80 0.26 0.04
B*14- 24.11 (121) 2.97 (124)
B*15+ 22 .39  (52) 0.87 0.83 0.003 3.24 (53) 1.20 0.13 0.001
B*15- 25 .62  (83) 2 .70  (85)
B*18+ 22 .67  (9) 0.93 2.05 0.39 2.97 (9) 1.02 0.33 0.84
B*18- 24 .50  (126) 2.91 (129)
B*35+ 2 6 .1 9 (1 9 ) 1.09 1.41 0.17 2 .55  (19) 0.86 0.22 0.08
B*35- 24 .08  (116) 2 .9 7 (1 1 9 )
B*39+ 27.87 (1) 1.14 6.20 0.57 2.56  (1) 0.88 0.98 0.72
B*39- 24.35 (134) 2.91 (137)
B*41+ 19.38 (1) 0.79 6.16 0.42 3.77  (2) 1.30 0.69 0.21
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B*41- 24.42 134) 2.90 136)
B*42+ 20.38 4) 0.83 3.07 0.19 2.99 4) 1.03 0.49 0.88
B*42- 24.50 131) 2.91 134)
B*44+ 26.58 7) 1.10 2.33 0.33 2.16 8) 0.73 0.34 0.03
B*44- 24.26 128) 2.96 130)
B*45+ 25.26 1) 1.04 6.18 0.89 2.53 1) 0.87 0.98 0.70
B*45- 2 4 .37 134) 2.91 137)
B*47+ 31.18 1) 1.28 6.15 0.27 2.91 1) 1.00 0.98 1.00
B*47- 24.33 134) 2.91 137)
B*49+ 21.59 19) 0.87 1.40 0.03 3.28 20) 1.15 0.22 0.07
B*49- 24.83 116) 2.85 118)
B*50+ 28.54 3) 1.18 3.56 0.24 2.27 3) 0.78 0.56 0.25
B*50- 24.28 132) 2.92 135)
B*51+ 26.63 5) 1.10 2.75 0.41 2.38 5) 0.81 0.43 0.21
B*51- 24.29 130) 2.93 133)
B*52+ 23.33 2) 0.96 4.37 0.81 2.76 2) 0.95 0.69 0.83
B*52- 24.39 133) 2.91 136)
B*53+ 26.71 21) 1.12 1.33 0.06 2.68 23) 0.91 0.20 0.21
B*53- 23.95 114) 2.96 115)
B*56+ 19.55 2) 0.80 4.35 0.27 2.59 2) 0.89 0.69 0.64
B*56- 24.45 133) 2.92 136)
B*57+ 28.22 7) 1.17 2.30 0.09 3.43 7) 1.19 0.37 0.15
B*57- 24.17 128) 2.88 131)
B*58+ 25.16 31) 1.04 1.11 0.42 3.10 31) 1.09 0.17 0.21
B*58- 24.14 104) 2.85 107)
B*82+ 26.48 3) 1.09 3.55 0.55 1.86 3) 0.63 0.56 0.06
B*82- 24.33 132) 2.93 135)
n = number of individuals; +: individuals with the allele of interest; individuals without the allele of interest; R: ratio of 
with/without; p = uncorrected p-values adjusted for age and gender and considered significant when £  0 .05
The results revealed that HLA-B*15  was a strong predictor of HIV-2 disease 
progression assessed using well correlated markers of progression to AIDS (CD4+ T  
cell count and viral load). Individuals positive for HLA-B*15  had their overall mean 
sqrt CD4+ T cell counts significantly lower (22.39, SE: 0.83, p = 0.003,) and their 
overall mean logi0HIV-2 VL considerably higher (3.24, SE: 0.13, p = 0.001) compared
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to those without B*15  (mean sqrt CD4+ T  cell counts = 25.62, SE: 0.65; and mean 
logioHIV-2 VL = 2.70, SE: 0.10, respectively). Three different HLA-B*15  subtypes 
were present in the study population: B*1503, B*1510, and B*1516. B*1503
(AF=12.8% , and G F=24.6% ) and B*1510  (AF=9.9%, and G F=18.6% ) were the 
predominant subtypes at the population level. A  univariate analysis comparing CD4  
count and viral load among groups of infected individuals positive for individual B*15  
subtypes revealed that those participants expressing B*1503  had even lower CD4  
count (mean sqrt CD4+ T cell count = 21.51, SE: 1.5, p = 0.006) and higher HIV-2  
viral load (mean log-ioHIV-2 VL = 3.36, SE: 0.18, p = 0.006) compared to B*1503- 
negative individuals (mean sqrt CD4+ T  cell count = 24.85, SE: 0.55; and mean 
logioHIV-2 VL = 2.92, SE: 0.08) (Table 4.3). This effect was not seen with the other 
common B*15  allele (B*1510) neither was it seen with the minor B *1516  allele 
(AF=1.1%, and GF=2.2% ). This suggests that B*1503  accounts for the overall poor 
prognosis seen with HLA-B*15.
Table 4.3: Effects of HLA-B*15 subtypes on CD4 count and HIV-2 viral load
M ean sq rt 
C D 4 (n)
R SE P M ean log H IV-2  
V L  (n)
R SE P
B*15+ 22 .39  (52) 0.87 0.83 0.003 3.24 (53) 1.20 0 .13 0.001
B*15- 25 .62  (83) 2.70 (85)
B*1503+ 21.51 (27) 0.86 1.15 0.006 3.36 (28) 1.20 0.18 0.006
B*1503- 2 5 .1 0 (1 0 8 ) 2 .80  (110)
B*1510+ 24 .39  (25) 1.00 1.23 0.99 3.07 (25) 1.07 0 .19 0.36
B*1510- 24 .38  (110) 2 .87  (113)
B*1516+ 20 .89  (3) 0.85 3.57 0.32 2.96 (3) 1.02 0 .57 0.94
B*1516- 2 4 .4 6 (1 3 2 ) 2.91 (135)
n: number of H IV -2+ individuals with serial C D 4+ T  cell counts or viral load measurements; +: individuals with the allele of interest;
individuals without the allele of interest; R: ratio of with/without; p: uncorrected p-values adjusted for age and gender and 
considered significant when £  0.05; The total number of H IV -2 infected individuals analysed was 135.
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Some of the B alleles showed a marginal association with control of viral 
replication including HLA-B*14 and HLA-B*44. HIV-2 infected people with either of 
these genotypes had a significantly lower HIV-2 VL compared to those without any 
B*14  or B*44  in their genotypes (Table 4.2). On the other hand, HLA-B*49 
individuals who are infected with HIV-2, tended to have a lower CD4+ T-cell count and 
a trend towards higher viral load (Table 4.2), behaving almost like their 503- 
positive counterparts.
Furthermore, we checked the effect of HLA-B molecular grouping into Bw4, 
Bw6; Bw4-80l, and Bw4-80T, on CD 4+ T cell count and their impact on HIV-2 viral 
load measurements over time, but no significant difference was noted between 
groups (data not shown).
The effect of HLA-C alleles on HIV-2 disease
W e performed similar analyses as described above for HLA-A and -B using 
138 HIV-2 infected participants who had their HLA-C  genotype assigned and also had 
two to four time points measurements recorded for CD4+ T  cell count and HIV-2 VL  
(Table 4.4). HLA-Cw*02, which is in LD with HLA-B*15, showed similar trends as 
observed with B*15-positive individuals. HIV-2 infected people with Cw*02  genotype 
(carriers of at least one copy of Cw*02  alleles) had significantly lower C D 4+ T  cell 
count (mean sqrt CD4+ T  cell count = 21.26, SE: 1.39, p = 0.02). Cw*02 carriers also 
showed a trend towards having high HIV-2 VL (mean logioHIV-2 VL = 3.29, SE: 0.21, 
p = 0.10). Meanwhile their counterparts (HIV-2 infected individuals who were 
negative for Cw*02 allele) had a better preserved immune system (mean sqrt CD 4+ T  
cell count = 24.74, SE: 0.58; and mean logioHIV-2 VL = 2.90, SE: 0.09, respectively).
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Table 4.4: The effect of HLA-C on CD4 count and HIV-2 viral load
A lle le M ean sq rt 
C D 4 (n = 135)
R SE P M ean log10H IV -2 V L  
(n = 138)
R SE P
Cw*01+ 23 .04  (13) 0.95 1.76 0.48 3 .1 4 (1 3 ) 1.07 0.28 0.48
Cw*01- 24 .35  (122) 2.94 (125)
Cw*02+ 2 1 .2 6 (2 0 ) 0.86 1.39 0.02 3.29 (21) 1.13 0.21 0.10
Cw*02- 2 4 .7 4 (1 1 5 ) 2.90 (117)
Cw*03+ 24 .44  (56) 1.02 0.84 0.74 2 .83  (57) 0.93 0.13 0.19
Cw*03- 24 .07  (79) 3.05 (81)
Cw*04+ 24.91 (41) 1.04 0.98 0.40 2 .8 6 (4 1 ) 0.95 0.15 0.43
Cw*04- 23 .92  (94) 3.00 (97)
Cw*05+ 24.50 (12) 1.01 1.83 0.87 2 .90  (12) 0.98 0.29 0.83
Cw*05- 24.19 (123) 2 .96  (126)
Cw*06+ 26.02 (9) 1.08 2.13 0.38 2.56 (10) 0.86 0.32 0.19
Cw*06- 24.09 (126) 2.99 (128)
Cw*07+ 23.76 (49) 0.97 0.90 0.53 3 .1 9 (5 1 ) 1.13 0.14 0.04
Cw*07- 24.48 (86) 2.82 (87)
Cw*08+ 24 .70  (20) 1.02 1.41 0.71 2.67 (20) 0.89 0.22 0.16
Cw*08- 2 4 .1 4 (1 1 5 ) 3.01 (118)
Cw*12+ 2 8 .1 2 (1 ) 1.16 6.35 0.54 2.55 (1) 0.86 1.00 0.68
Cw*12- 2 4 .1 9 (1 3 4 ) 2.96 (137)
Cw*14+ 19.46 (1) 0.80 6.35 0.45 3.48 (1) 1.18 1.00 0.60
Cw*14- 24 .26  (134) 2.95 (137)
Cw*15+ 22.52 (6) 0.93 2.57 0.50 3.18 (7) 1.08 0.37 0.54
Cw*15- 24 .30  (129) 2 .95  (131)
Cw*16+ 28.47 (7) 1.19 2.36 0.07 2.32 (7) 0.78 0.37 0.08
Cw*16- 23 .99  (128) 2.99 (131)
Cw*17+ 20.22 (5) 0.83 2.80 0.15 2.96 (5) 1.00 0.44 0.99
Cw*17- 24 .38  (130) 2.96 (133)
Cw*18+ 24 .45  (6) 1.01 2.58 0.93 3.22 (6) 1.09 0.41 0.50
Cw*18- 24.21 (129) 2.95 (132)
n: number of H IV -2+ individuals with serial C D4 count or viral load measurements; +: individuals with the allele o f interest; 
individuals without the allele of interest; R: ratio of with/without; p: uncorrected p-values adjusted for age and gender and 
considered significant when £ 0.05
Two HLA-Cw*02  subtypes were present in our samples (Cw *0203  and
Cw*0210), the most frequent of which was Cw*0210  (AF=9.6%  and G F=18.7% ).
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Cw*0203  was rare in this population (AF=0.2%  and GF=0.4% ). A  comparative 
analysis revealed that individuals with HLA-Cw*0210  had a much lower CD4 count 
(mean sqrt CD4+ T  cell count = 20.64, SE: 1.53, p < 0.001) and a much higher HIV-2  
VL (mean logi0HIV-2 VL = 3.45, SE: 0.24, p < 0.001) compared to those without this 
genotype (mean sqrt CD4+ T cell count = 24.51, SE: 0.54 and mean logioHIV-2 VL = 
3.02, SE: 0.08, respectively). The other HLA-C  allele with a significant susceptibility 
effect on VL was Cw*07. There were 3 HLA-Cw*07  subtypes (Cw*0701 , Cw*070201, 
and Cw*0704), the most frequent being Cw*0701 (AF=16.7%  and GF=29.4% ). HIV-2  
infected individuals expressing Cw*0701 had higher HIV-2 viral load compared to 
those without this allele (mean logioHIV-2 VL = 3.34, SE: 0.15 vs. 2.97, SE: 0.09, p = 
0.03), but the CD4+ T  cell count did not differ between those positive for Cw*0701  and 
those negative for that allele. This effect was neither seen with individuals expressing 
Cw*070201 nor those with the Cw*0704  genotype.
W e then grouped individuals into two mutually exclusive groups: HLA-C group 
1 (C 1) or HLA-C group 2 (C2) based on the amino acid composition of their HLA-C  
alleles at position 80 as described above. A  comparative analysis was performed on 
overall CD4 count and viral load. No significant difference was found between groups 
indicating that these groups had no influence on CD 4+ T  cell count or H IV-2 VL in this 
community cohort.
The influence of KIR genes on markers of HIV-2 disease
All samples were successfully genotyped for the 15 KIR genes. A  substantial 
number of HIV-2 infected subjects (n = 142) had serial H IV-2 VL measurements and 
139 of these also had serial CD 4+ T  cell measurements over the same period of time
115
as described earlier. Their CD4 counts and HIV-2 viral loads were analysed as for 
HLA class I above. W e compared the mean sqrt CD4+ T  cell count as well as the 
mean logioHIV-2 VL between groups of individuals positive for a particular KIR gene 
versus others (individuals who are HIV-2 positive but are negative for the gene of 
interest). The analysis showed that none of the individual KIR  genes independently 
affected the course of HIV-2 disease once infection was established (Table 4.5). No 
significant difference was noted in the mean sqrt CD4+ T  cell count of people with a 
particular KIR  gene and those without. The mean log-ioHIV-2 VL was similar between 
individuals with a KIR  gene of interest and those without.
Table 4.5: The effect of KIR genes on CD4 count and HIV-2 viral load
G enes M ean sq rt C D4  
(n = 139)
R SE P M ean log H IV -2  
V L  (n = 142)
R SE P
2DL1+ 24.20 (136) 0.91 0.54 0.51 2.95 (139) 1.15 0.08 0.51
2DL1- 26.64 (3) 2.56 (3)
2DL2+ 23 .78  (65) 0.96 0.78 0.41 2.92 (65) 0.99 0.12 0.87
2DL2- 24.66 (74) 2.95 (77)
2DL3+ 24 .25  (120) 1.00 0.57 1.00 2.96 (123) 1.06 0.09 0.50
2DL3- 24 .24  (19) 2.79 (19)
2DL4+ 24 .25  (139) - - - 2.94 (142) - 0.08 -
2DL4- 0.00 (0) 0.00 (0)
2DL5+ 23.69 (68) 0.96 0.76 0.30 2.86 (69) 0.95 0.12 0.37
2DL5- 24.79 (71) 3.01 (73)
2DS1+ 25.42 (31) 1.06 1.12 0.24 2 .8 6 (3 1 ) 0.97 0.18 0.64
2DS1- 23.91 (108) 2.96 (111)
2DS2+ 23.63 (59) 0.96 0.81 0.32 2.96 (59) 1.01 0.13 0.78
2DS2- 24.70 (80) 2.92 (83)
2DS3+ 23.66 (32) 0.97 1.11 0.54 2.80 (33) 0.94 0.17 0.37
2DS3- 24.43 (107) 2.98 (109)
2DS4+ 24.29 (138) 1.31 0.53 0.37 2.94 (141) 1.51 0.08 0.32
2DS4- 18.60 (1) 1.95 (1)
2DS5+ 23 .98  (40) 0.98 0.99 0.75 2.94 (40) 1.00 0.16 0.95
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2DS5- 24 .36  (99) 2.93 (102)
3DL1+ 24 .29  (138) 1.31 0.53 0.37 2.94 (141) 1.51 0.08 0.32
3DL1- 18.60 (1) 1.95 (1)
3DL2+ 24 .25  (139) - 0.53 - 2 .94 (142) - 0.08 -
3DL2- 0.00 (0) 0.00 (0)
3DL3+ 24 .25  (139) - 0.53 - 2 .94 (142) - 0.08 -
3DL3- 0.00 (0) 0.00 (0)
3DS1+ 25 .70  (22) 1.07 1.33 0.24 2.70  (22) 0.91 0.21 0.22
3DS1- 23 .98  (117) 2.98 (120)
2DP1+ 2 4 .1 8 (1 3 5 ) 0.91 0.54 0.45 2.96 (138) 1.33 0.08 0.14
2DP1- 26 .57  (4) 2.22 (4)
n: number of H IV -2+ individuals; +: individuals with the allele of interest; individuals without the allele of interest; R: ratio of 
with/without; p: uncorrected p-values adjusted for age and gender and considered significant when £ 0.05.
Next, we grouped individuals based on whether or not they have a KIR  gene 
together with its corresponding ligand(s) since we know that KIR  is non-functional in 
the absence of the HLA class I gene(s) that encode for its ligand(s). W e performed 
similar comparative analyses as above between people with a particular KIR-HLA  
compound genotype and those without. CD4+ T cell count and HIV-2 VL  
measurements were similar between individuals with a compound genotype of 
interest and those lacking that genotype as illustrated in Table 4.6 below. This 
suggests that the compound genotypes under investigation do not influence disease 
progression assessed using CD4+ T  cell count and viral load measurements.
Table 4.6: The effect of KIR-HLA compound genotypes on HIV-2 disease
Genotypes Mean sqrt R SE p Mean log R SE p
_______________________ CD4 (n)___________________________ VL (n)____________________
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3DS1: Bw4-80l/x 27.88 (5) 1.17 2.91 0.20 3.07 (5) 1.07 0.43 0.67
Bw6/Bw6 23 .93  (47) 0.94 2.87 (47) 0.14
3DS1: Bw4-80l/x 27 .88  (5) 1.15 2.74 0.20 3.07 (5) 1.05 0.44 0.76
Others 24 .24  (130) 0.54 2.91 (133) 0.08
2DS2: C1/x 22.92 (43) 0.92 0.95 0.10 3.01 (43) 1.02 0.15 0.69
Others 24 .83  (92) 0.65 2.94 (95) 0.10
2DL2: C1/x 23 .07  (50) 0.93 0.89 0.10 2.95 (50) 1.00 0.14 0.92
Others 24 .90  (85) 0.68 2.96  (88) 0.11
2DS1: C2/x 24 .16  (18) 1.00 1.49 0.97 2.94 (18) 0.99 0.23 0.91
Others 24 .23  (117) 0.58 2 .9 6 (1 2 0 ) 0.09
2DL1: C2Jx 2 4 .1 5 (1 1 2 ) 0.98 0.60 0.76 2.97 (115) 1.02 0.09 0.83
Others 24 .59  (23) 1.32 2.92 (23) 0.21
n: number of H IV -2+ individuals; R: ratio of individuals with the gene of interest /  Others; p: uncorrected p-values adjusted for age  
and gender and considered significant when £ 0.05.
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Discussion
HLA and KIR  genes are located on separate chromosomes indicating that at 
meiosis both blocks of genes segregate independently into newly formed daughter 
cells. Differential susceptibility to progression to AIDS following HIV infection is well 
documented and understanding why some people progress rapidly to overt 
immunodeficiency shortly after infection with HIV-1 while others go on to become 
LTNPs (> 50%  of HIV-2 patients) is a major goal in the field of HIV research. It is 
however becoming progressively clearer that viral characteristics, individual 
behaviour, and several other factors related to the environment and genetics of the
■ 70 79 83host are key determinants of susceptibility to infection and disease progression
8 4 1 9 8
In this study, we aimed to investigate the relative contribution of two very 
important host genetic factors - HLA and KIR  genes - in HIV-2 disease in W est 
African populations. Killer cell immunoglobulin-like receptors are important regulators 
of NK cell activity and determine the outcome of the first encounter between immune 
cells and the viral particles, which succeeded in breaching the first layer of the body’s 
defence mechanisms and gain entrance into the body. Together with HLA alleles, 
KIR molecules determine the molecular targets of the cellular immune responses of a 
given host once infection is established. However, genetic polymorphisms in the 
MHC and KIR regions on chromosomes 6 and 19, respectively, which lead to 
variability in peptide-epitope binding, can effectively compromise the presentation of 
peptide-epitope complexes to T  cells thereby interfering with the appropriate host 
immune responses against specific pathogens.
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Ideally, genetic diversity at the HLA and KIR loci should provide protection 
against epidemic infections while the heterogeneity in immune response to a 
pathogen observed at the individual level ensures that escape mechanisms of an 
infectious agent are encountered and dealt with accordingly. This has clearly been 
demonstrated in several infectious diseases61 66 67 and is likely to be true also in HIV  
infection. A growing number of associations from independent epidemiological 
studies have been reported between HLA and KIR  genes and differential HIV-1 
disease progression but very little is known of their role in HIV-2 disease 
manifestations. Here we report our findings on the possible association between HLA 
and KIR  genes and HIV-2 disease using internationally accepted markers of disease 
progression in a group of individuals singly infected with HIV-2 in a community cohort 
in Caio, Guinea Bissau.
HLA-A genotypes did not influence HIV-2 disease progression
W e generated HLA class I and KIR genotype data from 151 individuals singly 
infected with HIV-2. A significant proportion of these individuals were long-term non- 
progressors that have been living with the virus for more than 19 years with no AIDS- 
related symptoms. This is an indication that the majority of HIV-2 infected individuals 
are controlling the virus better than their HIV-1 counterparts. Analysis of individual 
H M  alleles and KIR  genes comparing known indicators of HIV disease progression 
(CD4+ T cell count and HIV-2 viral load) between those with the allele or KIR  gene of 
interest and those without was also performed.
None of the 24 HLA-A alleles (four-digit alleles) and none of the 15 HLA-A 
group of alleles (two-digit alleles) was strongly associated with markers of disease 
progression in this sample of the W est African population. The exception, however,
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was a trend towards better control of HIV-2 viral replication observed with people 
having at least one copy of HLA-A*7401 in their genotypes. HIV-2 infected 
individuals with this genotype had an overall higher CD 4+ T  cell count than their 
counterparts who were negative for A*7401  (although the difference did not reach 
significant level) and their overall mean log-ioHIV-2 VL was also slightly lower 
compared to those without this genotype (p = 0.09). All A *740 '/-positive individuals in 
Caio (n = 11) were heterozygotes with a majority of them pairing with A*2301  (6 out of 
11). W e did not see any influence of the only >4*23 allele found in this population 
{A*2301) on CD4+ T  cell count or HIV-2 VL. However, in two cohorts of 241 HIV-1 
infected Caucasians, Kaslow and colleagues found that A*23 was associated with 
rapid progression to A ID S116. In another study, Chen and co-workers while working 
on a small paediatric cohort of 36 LTNP and 14 rapid progressors, showed that 
A*2301  also associates with rapid disease progression following HIV-1 infection199. 
The other alleles in these >4*7407-positive individuals included A*3303, A *6802  and 
A*2601. These other alleles individually did not influence the rate of C D 4+ T  cell 
decline or increase in HIV-2 viral load.
HLA-B alleles showed opposite effects with HIV-2 disease outcomes
W e analysed individual HLA-B  alleles as for HLA-A above, comparing CD 4+ T  
cell count and HIV-2 viral load in a group of HIV-2 patients positive for a particular 
HLA-B allele to those of the remainder (HIV-2 infected individuals negative for the 
allele of interest). Out of twenty two HLA-B groups of alleles (two-digit alleles), four of 
them showed significant differences between those possessing the allele of interest 
and those without. Two of these (HLA-B*15  and -B*49) were associated with bad
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prognosis (a sign for rapid disease progression) while the other two (HLA-B*14 and - 
B*44) were associated with protection against rapid progression to AIDS.
The most striking finding was that of HLA-B*15, which clearly showed that 
individuals with this genotype had an overall low CD4+ T  cell count (p = 0.003) and an 
overall high HIV-2 viral load (P = 0.001) compared to their HLA-B*15-negative 
counterparts. This effect was attributed to the common B*1503  subtype and not seen 
with the other two B*15  subtypes B*1510  and B*1516. The other B  allele that tended 
to behave like B*15  was B*49. HIV-2 infected individuals with this genotype had a 
significantly lower CD4+ T  cell count (p = 0.03) and a trend towards a high viral load 
(p = 0.07). This is in accordance with Kaslow findings that B*49  was associated with 
rapid disease progression in homosexual Caucasians infected with H IV -1116.
W e found B*14  and B*44  carriers in our study population to be associated with 
long-term non-progression and protection against disease progression. In two 
independent studies of mixed high risk groups of Caucasians, Magierowska and 
Hendel showed that B*14  was associated with non-progression134 20°. Our finding of 
8*74  being associated with non-progression also supports a more recent finding by 
Leligdowicz et al. who reported while working on the same Caio population that 8*74+  
individuals chronically infected with HIV-2 elicited a stronger, highly avid and 
polyfunctional cell mediated immune responses of higher magnitude and broader 
specificity to HIV-2 gag  peptides designed from p26 region of the HIV-2 proteome 
than people with other HLA-B alleles201. The association of HLA-B*44  with control of 
viremia in HIV-2 infected patients is an interesting observation. Flores-Villanueva et 
al. reported in 2001 a similar finding in a cohort of thirty-nine HIV-1 seropositive 
subjects with known date of seroconversion132. They found that a significant 
proportion of subjects with HLA-8*44 alleles were able to control viral replication and
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thus progressed more slowly to full blown AIDS. On our part we found that amongst 
HIV-2 infected individuals, the group of people with at least one copy of 8 *4 4  alleles 
(either B*4403  or B*4410) were better controllers of HIV-2 replication as their overall 
viral load was significantly lower compared to the group without any of the B*44  
alleles. Their overall CD 4+ T  cell count was however not different from that of the 
8*44-negative HIV-2 group.
A number of HLA-B  alleles have been associated with progression to AIDS  
following HIV-1 infection in different populations and “at risk” groups with opposite or 
conflicting findings. But the most consistent findings have been with B*27, B*57, and 
a subset of B*35  alleles known as 8*35-P x including B*3502, B*3503, and B*3504. 
Alleles of HLA-B*27  and -B *57  offer a protective effect against rapid progression to 
AIDS in HIV-1 infected subjects. In Caio, 8 *2 7  was completely absent while 8 *5 7  
was rare (AF = 1.6% in the general population). On the other hand, HLA alleles that 
have been categorised as 8*35-P x have been consistently associated with rapid 
progression to AIDS. By definition, 8*35-Px group of alleles comprises those 8 *3 5  
alleles that can accommodate peptides with proline (P) at position 2 and any other 
amino acid apart from tyrosine (Y) at position 9. In Caio, all the 8*35-positive 
individuals were B*3501, which is not a member of the 8*35-P x complex and we did 
not see any significant difference comparing their CD4+ T  cell count and HIV-2 viral 
load to those of 8*35-negative HIV-2-positive subjects. This implies that most of the 
alleles found associated with HIV-1 disease by other investigators did not show 
similar effects in HIV-2 disease. This might be due to a number of factors ranging 
from the viral factors to environmental and/or population diversity. Most of the HIV-1 
association studies have been conducted in Caucasian cohorts with known dates of 
seroconversion. Our study subjects were blacks from a seroprevalent cohort.
HLA-C and KIR-HLA compound genotypes and HIV-2 outcomes
W e carried out similar analysis as described above for each of the HLA-C  
alleles detected in the study population. Two out of fourteen HLA-C  groups of alleles 
(two-digit alleles) were associated with HIV-2 disease. HLA-Cw*02, which is in strong 
LD with HLA-B*15  was associated with low CD4+ T  cell count but not significantly so 
with HIV-2 viral load. HIV-2 infected individuals who carried any of the Cw*02  alleles 
(Cw*0203  and Cw*0210) had a significantly low CD4+ T  cell count compared to those 
without the Cw*02 genotype but their overall HIV-2 viral load, although high, was not 
statistically different from that obtained from Cw*02-negative HIV-2 infected 
counterparts. However, further analyses discriminating between Cw*02  subtypes 
revealed clearly that HLA-Cw*0210  was strongly associated with bad prognosis. 
Individuals who were HIV-2 positive and carrying at least one copy of Cw*0210  were 
more likely to progress with the disease faster than those negative for that allele. 
Their CD4+ T  cell count was much lower (p < 0.001) and their HIV-2 log™ VL much 
higher (p < 0.001) compared to others (HIV-2 positive HLA-Cw *0210-negative). This 
effect was not seen with the other Cw*02 allele (HLA-Cw*0203). The second HLA-C  
allele, which was found to associate with HIV-2 disease in this predominantly 
Manjako population was HLA-Cw*07. The group of individuals positive for Cw *07  had 
an overall higher HIV-2 viral load than those negative for Cw*07, indicating that 
Cw*07  could be associated with rapid disease progression. This demonstrates that 
this group of individuals might not be able to control viral replication even though their 
CD4+ T cell count was similar to that of the Cw*07-negative group. All other HLA-C  
alleles did not affect the CD4+ T cell count and HIV-2 viral load dynamics. Grouping 
all HLA-C  alleles into C1 and C2 did not change the nature of the association.
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Certain HLA-B and -C molecules are used as ligands by some KIR molecules. 
The interaction between a KIR and its corresponding ligand(s) determines the type of 
signal to be delivered to the NK cell harbouring that particular KIR on its cell surface. 
An epistatic interaction has been described between KIR3DS1-HLA-Bw4-80I and 
HIV-1 disease169. In the present study, we also grouped individuals based on 
whether or not they have a KIR and its corresponding ligand and studied the effect of 
the identified compound genotypes on the rate of CD4+ T  cell count decline and 
increase in HIV-2 viral load. W e observed that none of the KIR-HLA combinations 
was associated with HIV-2 disease.
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CHAPTER 5 : KIR GENE PROFILES AND HLA CLASS I 
HAPLOTYPES IN CAIO, GUINEA BISSAU
In order to determine the relative contribution of individual KIR  gene profiles in 
HIV-2 acquisition and/or disease progression, we reconstructed the KIR  gene profile 
of each study participant in the order in which the KIR genes are arranged on 
chromosome 19. W e subsequently grouped them into the conventionally accepted 
KIR  profiles A ” and “B” and then analysed the profile pool stratified by HIV status. 
Similarly, we carried out HLA class I haplotypes reconstruction using Arlequin 
v3.11202 and estimated the frequencies of two- and three-locus haplotypes in our 
study population.
The categorisation of KIR genes into profiles A ” or “B” depends on the number 
of activating and inhibitory KIR  genes present in an individual without taking into 
consideration whether they appear on only one or both haplotypes. Haplotype A  
comprises mainly genes coding for inhibitory receptors (KIR2DL and KIR3DL) - in the 
absence of KIR2DL2  - with or without KIR2DS4, which is expressed by almost every 
NK cell. Haplotype B is a mixture of genes encoding both activating (KIR2DS and 
KIR3DS) and inhibitory KIR molecules. KIR  gene profile A  (two copies of the A  
haplotypes) lacks all activating KIR  genes except 2DS4  and also lacks the inhibitory 
gene 2DL2. KIR  gene profile B, has a variable number of activating and inhibitory 
KIR  genes; when a B profile is present, it is difficult to determine whether the KIR  
haplotypes present are BB or AB except the genes are sequenced and their 
nucleotides composition analysed. A substantial number of genes on A haplotypes 
are highly polymorphic, as are a smaller subset of genes on B haplotypes. The
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majority of B haplotypes exhibit extensive variation in gene content and are said to be 
polygenic in nature.
KIR gene profiles in Caio
A KIR  gene profile represents a combination of inhibitory, activating, as well as 
pseudogenes that are present on at least one haplotype in a given individual. They 
are classified into two groups (A and B) depending on the number and type of 
individual haplotypes making the profile. KIR profile A  comprises two copies of A  
haplotypes while profile B can either be AB or BB haplotypes. Analysis of our KIR  
gene pool revealed 75 different profiles (2 A and 73 B profiles) with 26 of them being 
present in at least 1% of the study population (Table 5.1). The most frequent KIR  
gene profile was one composed of two A haplotypes (A1), which was present in 32%  
of our samples. A1 was slightly, but not significantly over-represented in the infected 
group (Figure 5.1) (38% vs. 29% , p = 0.062). The second “A” haplotype (A2) was 
seen in only one sample and was very similar to A1 except that it lacked 2DL3.
Of the 73 B profiles, B1 was the most common; 12% in the general population, 
10% in the HIV-2 infected group, and 12% in the control group. B2 was the second 
most common B haplotype: 7% in the general population, 4%  and 9%  in the HIV-2  
infected and HIV negative groups, respectively. None of the differences in KIR  gene 
profile frequencies between cases and controls reached significant level. One of the 
B profiles closely resembled A 1, the only difference being the presence of KIR2DL2  
(B73 profile).
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Univariate analyses were performed to see if any of the KIR  profiles detected 
in this study could influence HIV-2 acquisition or predict progression to AIDS, but 
none of them impacted on susceptibility/resistance to HIV-2 as their frequencies were 
similar between infected and uninfected groups. There was also no significant 
association with disease progression assessed using markers of HIV disease 
progression (absolute CD4+ T  cell count and HIV-2 viral load). KIR profile 
frequencies were very similar between cases and controls and also between males 
and females.
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Figure 5.1: Most frequent KIR gene profiles found in Caio
HLA class I haplotypes in the Caio population
The test for Hardy-Weinberg (H-W ) equilibrium was performed with Arlequin 
v3.11. Using a Fisher’s Exact test, at the intra-population level, all three loci were in 
equilibrium (p-values = 0.18517, 0.25241, and 0.10134 for HLA-A, -B, and -C loci, 
respectively). Table 5.2 shows the frequency of two-locus HLA class I haplotypes 
detected in the Caio community. Haplotypes with frequencies less than one percent 
are not shown in this table. HLA B*1503-Cw *0210  was the most frequent two-locus 
haplotype with a frequency of 9.8%  in the general population. Seven other 
haplotypes had frequencies above 5% and together made up 48.3%  of all B-C 
haplotypes. Only two A-B haplotypes (A*330301-B*1510  and A*2301-B*1503), and 
two A-C haplotypes (A*330301-Cw *0304  and A*2301-Cw *0210) had frequencies 
greater than or equal to 5%. Analysis of the three-locus HLA class I data showed that 
HLA-A*330301-B*1510-Cw*0304  (6.2% ) and A*2301-B*1503-Cw *0210  (5.3% ) were 
by far the most frequent three-locus haplotypes in our study population. Other three- 
locus haplotypes with more than 1% population frequency are shown below in Tab le  
5.3. Haplotype frequencies were not statistically different comparing males and 
females and were similar between cases and controls in this community.
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Table 5.3: Common HLA class I three-locus haplotypes in Caio
Haplotype Frequency*
A *330301-B*1510-Cw*0304 0.062
A *2301-B*1503-Cw*0210 0.053
A*2301-B*4901-Cw*0701 0.030
A*260101-B*080101-Cw*0304 0.030
A*010101-B*080101-Cw*0102 0.025
A*260101-B*5801-Cw*0701 0.024
A *7400-B *530101-Cw*040101 0.024
A *330301-B*130201-Cw*0804 0.021
A *2301-B*5801-Cw*0302 0.018
A *330301-B*5801-Cw*0302 0.018
A *6801-B*1503-Cw*0210 0.018
A *3002-B*1801 -Cw*050101 0.017
A*010101-B*530101-Cw*040101 0.014
A *2301-B*350101-Cw*040101 0.014
A *3002-B *350101-Cw*040101 0.014
A*7400-B*140201-Cw*0802 0.012
A*0201-B*5201-Cw*160101 0.011
A *3002-B*1503-Cw*040101 0.011
A *330301-B *350101-Cw*040101 0.011
A*0102-B*4901-Cw*0701 0.010
A *0201-B*350101-Cw*040101 0.010
A*0202-B*4901-Cw*0701 0.010
A*680201-B *530101-Cw*040101 0.010
#: haplotypes with frequencies > 0.01
Discussion:
In humans, the KIR  gene complex is located within a region that undergoes 
rapid expansion and contraction over time, resulting in extensive variability in gene 
contents across many haplotypes. The extreme polymorphism at the KIR loci is 
thought to be beneficial since they provide protection against a wide range of 
pathogens and diseases. Two KIR haplotypes have been defined to regroup and 
harmonise the huge amount of haplotypic data continually being generated by various 
investigators. Certain KIR  genes have consistently been found on virtually all 
haplotypes and have been called “framework genes” while others have been reported 
on only a few haplotypes163. The so called framework genes include KIR2DL4, 3DL2, 
3DL3, and 3DP1.
KIR gene profile “A” predominates in the Caio population
KIR  gene profile frequencies in Caio were determined by direct counting after 
we individually assigned a profile to each and every one of the study participants. As 
is usual in populations worldwide, B profiles were highly diversified on the basis of 
gene content with 73 distinct B profiles (B1-B73) while A profiles were very much 
conserved with only two A profiles being present (A1 and A2). The only difference 
between the two A profiles was the absence of the inhibitory gene KIR2DL3  in profile 
A2. In contrast to Caucasoid populations, KIR  gene profile A1 was by far the 
commonest in this Manjako population with 163 (32% ) subjects carrying this profile 
comprising six inhibitory KIR  genes: 3DL3, 2DL3, 2DL1, 2DL4, 3DL1, and 3DL2  in 
addition to the single activating gene 2DS4, and the pseudogene 2DP1. In most 
populations worldwide, the frequencies of A and B profiles are evenly distributed. 
The second most common profile was a B profile (B1), present in 12% of the study
population. The difference in gene content between A1 and B1 profiles was the 
presence of two genes encoding the activating receptors 2DS2 and 2DS3, two others 
encoding the inhibitory receptors 2DL2 and 2DL5, and the absence of the gene 
encoding 3DL3 in profile B1. Thirty-seven individuals (7% ) had all 15 KIR  genes in a 
B profile named B2. Overall, twenty-six (26) KIR  gene profiles (25 B and 1 A, 
respectively) were present in at least 1% of the study population.
KIR profiles and HLA class I haplotypes did not influence HIV-2 infection 
or disease
In an attempt to understand the relative contribution of the KIR  gene profiles on 
HIV-2 acquisition, we stratified our analysis of KIR  gene profile pool by HIV status and 
compared the frequencies of individual gene profiles between HIV-2 infected and 
uninfected control groups. W e observed that the frequency of A1 was slightly higher 
in the infected group than in controls but the difference was not statistically significant. 
As expected, some of the B profiles were slightly over-represented in controls while 
others were more frequent in cases. Overall, none of the KIR  gene profiles found in 
this community cohort significantly influenced susceptibility or resistance to HIV-2  
infection.
Similarly, we looked at the potential role of KIR  gene profiles in the course of 
HIV-2 disease using universal markers of HIV disease progression. W e compared 
the CD4+ T  cell count and viral load data between groups of individuals whom are 
carriers of a KIR  gene profile of interest and those negative for that profile. For all 
profiles, we observed no significant influence on CD 4+ T  cell dynamics after 
comparing the overall CD4+ T  cell count between individuals with a profile of interest 
to those without. Similarly, none of the KIR  gene profiles could influence viral
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replication since no significant difference was found comparing viral load 
measurements between groups with any of the KIR  gene profile and those without the 
profile of interest. This is an indication that none of the KIR  gene profiles detected in 
this predominantly Manjako population can influence disease progression following 
HIV-2 infection.
Similarly, we determined the two- and three-loci HLA class I haplotypes in this 
population and carried out similar analyses as for the KIR  gene profiles above. None 
of the two-loci and none of the three-loci haplotypes were associated with HIV-2  
acquisition. There was also no indication of them influencing disease progression 
after HIV-2 infection has been established.
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C HAPTER 6 :  HLA CLASS I AND KIR GENE
FREQUENCIES AND HIV-2 ANTIBODY STATUS IN FAJARA, 
THE GAMBIA
This chapter describes the frequencies of classical HLA class I genes (HLA-A, 
-B and -C )  as well as those of 15 KIR  genes in 600 adults Gambians living in and 
around the Greater Banjul area and attending the MRC Genito-Urinary Medicine 
(GUM ) clinics in Fajara. The relationship between HLA alleles and HIV-2 status 
defined by antibody levels was examined. Analysis of KIR  genes profiles in relation 
to susceptibility or resistance to HIV-2 infection was performed. The effect of HLA- 
KIR  combinations on HIV-2 acquisition was also explored.
HLA alleles and genotype frequencies in Fajara, The 
Gambia
A total of 600 samples collected from consented adult Gambians were typed 
for HLA class I and 15 KIR  genes. HLA typing was done by SBT using the BigDye 
Terminator v3.1 (Applied Biosystems, USA) while KIR typing was done by the PCR- 
SSP method. Analysis of HLA sequences was done with “Assign 400” software 
(Conexio Genomic, Western Australia) and verified both manually and with other 
conventional sequence analysis software such as “Sequence Analysis v5.2” (Applied 
Biosystems, USA), and CLC Main Workbench v5 (CLC BIO A/S, Aarhus C, 
Denmark). A few samples could not be assigned a genotype because their sequence 
traces did not precisely match known HLA consensus sequences, which are available 
in the public HLA and immunogenetics databases94. A  deviation from a known 
consensus sequence by at least one nucleotide was considered to be a mismatch 
and the result labelled indeterminate. Such samples were repeated and if the
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mismatch persisted after two repeats, the samples were classified as indeterminate. 
W e suspect that these are most likely new HLA class I alleles that are yet to be 
described in other populations and therefore have not made it yet to the public 
databases. Due to limitation of funds, we could not further characterise these 
supposedly new alleles in the present study. Our HLA data analysis therefore was 
based on 589 HLA-A, 583 HLA-B, and 595 HLA-C genotypes.
Table 6.1 summarises the allele frequencies of classical HLA class I (A, B, and 
C) loci (4- to 6-digit alleles) found in the Fajara clinical cohort. Individual allele 
frequencies were calculated as a proportion of the total number of alleles determined 
for the locus of interest. The genotype frequency of a particular allele was estimated 
as the proportion of individuals positive for the allele of interest compared to the total 
number of individuals with a genotype result assigned for that locus. Overall, 28 HLA- 
A, 50 HLA-B  and 23 HLA-C  alleles (>4-digits) were detected in this sample of the 
Gambian population. Figure 6.1 shows the frequency of two-digit HLA class I results. 
The number of individuals with two copies of the same allele (homozygosity) was 
highest at the C locus: A-A = 5.60%  (n=33); B-B = 2.92%  (n=17); and C-C = 9.41%  
(n=56). Individuals homozygous at two loci were rare - only 2 individuals were 
homozygotes A-B (0.35% ) and 2 others homozygotes B-C (0.35% ), while just a single 
person was homozygote A-C (0.17% ). No three-locus homozygosity was seen in our 
samples (Table 6.2).
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Table 6.1: HLA-A, -B, and -C allele frequencies in the Fajara population
HLA-A
Alleles
Frequency
(n=1178)
HLA-B
Alleles
Frequency
(n=1166)
HLA-C
Alleles
Frequency
(n=1190)
A*010101 0.048 56) B*070201 0.047 55) Cw*0102 0.021 25)
A*0102 0.017 20) B*070501 0.011 13) Cw*0201 0.001 1)
A*0103 0.001 1) B*080101 0.087 102) Cw*020202 0.021 25)
A*0105 0.001 1) B*1301 0.001 1) Cw*0210 0.096 114)
A*020101 0.080 94) B*130201 0.004 5) Cw*0302 0.061 72)
A*0202 0.045 53) B*1401 0.001 1) Cw*030301 0.010 12)
A*0205 0.015 18) B*140201 0.029 34) Cw*0304 0.097 116)
A*030101 0.037 44) B*1403 0.001 1) Cw*040101 0.187 222)
A*2301 0.171 201) B*1503 0.096 112) Cw*0403 0.001 1)
A*240201 0.013 15) B*1510 0.032 37) Cw*050101 0.022 26)
A*260101 0.056 66) B*1516 0.015 17) Cw*060201 0.064 76)
A*290101 0.002 2) B*1518 0.001 1) Cw*0701 0.109 130)
A*290201 0.017 20) B*1801 0.021 25) Cw*070201 0.030 36)
A*3001 0.065 76) B*2703 0.010 12) Cw*0802 0.034 40)
A*3002 0.069 81) B*2705 0.005 6) Cw*0804 0.008 9)
A*3004 0.003 3) B*3501 0.130 151) Cw*120301 0.010 12)
A*310102 0.006 6) B*350801 0.001 1) Cw*140201 0.014 17)
A*3201 0.022 26) B*3510 0.001 1) Cw*1403 0.002 2)
A*3301 0.062 73) B*370101 0.007 8) Cw*150201 0.001 1)
A*330301 0.074 87) B*3901 0.002 2) Cw*1505 0.023 27)
A*3402 0.036 42) B*3910 0.013 15) Cw*160101 0.121 144)
A*3601 0.002 2) BM00201 0.005 6) Cw*17a 0.056 67)
A*6601 0.013 15) B*4016 0.001 1) Cw*18a 0.013 15)
A*6603 0.003 3) B*4102 0.010 12)
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A*6801 0.041 (48) B*4103 0.002 (2)
A*680201 0.058 (68) B*4201 0.018(21)
A*7401 0.036 (42) B*4202 0.022 (26)
A*8001 0.013(15) B*440201 0.001 (1)
B*4403 0.015(18)
B*4410 0.004 (5)
B*45a 0.021 (25)
BM70101 0.001 (1)
B*4901 0.039 (46)
B*5001 0.017(20)
B*5002 0.001 (1)
B*5101 0.023 (27)
B*5104 0.001 (1)
B*5109 0.002 (2)
B*5201 0.016(19)
B*530101 0.119(139)
B*5501 0.002 (2)
B*5601 0.008 (9)
B*5605 0.001 (1)
B*5702 0.005 (6)
B*570301 0.006 (7)
B*5704 0.001 (1)
B*5801 0.076 (89)
B*7801 0.055 (64)
B*780202 0.001 (1)
B*8201 0.011 (13)
n: total number of alleles for the locus of interest;a: alleles that could not be discriminated with exons 2 
and 3 sequences (B*45 = B*4501/07, Cw*17 = Cw*1701/Cw*1702/Cw*1703, and Cw*18 = 
Cw*1801/Cw*1802).
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Table 6.2: Zygosity at HLA-A, -B, and -C loci
Locus Percent
homozygous (n)
Percent
heterozygous (n)
A (n=589) 5.60 (33) 94.40 (556)
B (n=583) 2.92 (17) 97.08 (566)
C (n=595) 9.41 (56) 90.59 (539)
A-B (n=564) 0.35(2) 99.65 (562)
A-C (n=578) 0.17(1) 99.83 (577)
B-C (n=572) 0.35 (2) 99.65 (570)
A-B-C (n=556) 0(0) 100.00 (556)
n: number of genotypes
HLA-A alleles and susceptibility to HIV-2 infection in Fajara
Twenty eight different HLA-A alleles (4- to 6-digits) were detected from 589  
individuals (Table 6.1). The most frequent HLA-A allele was A*2301  (17.1% ) 
followed by A*020101  (8.0% ) and A*330301  (7.4%). Five other A  alleles were also 
relatively frequent with frequencies ranging from 5.6% to 6.9%  (A*260101 , A*3001, 
A*3002, A*3301, and A*680201). The eight most frequent alleles at the A locus with 
at least 5% allele frequency at the population level made up 63.5%  of all HLA-A  
frequencies in this sample of the Gambian population. W e re-sequenced all samples 
containing A*74 (n = 40) to include exon 1 since we were unable to discriminate 
between A*7401  and A*7402, which have similar nucleotide compositions at exons 2 
and 3. The analysis showed that they were all A*7401 with the amino acid in codon 
23 being R (Arginine). The most diverse group of alleles (2-digits) was HLA-A*01
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with four different subtypes: A*010101, A*0102, A*0103, and A*0105. Their overall 
population frequency was 6.7% , with A*010101  (4.8% ) predominating.
Univariate analysis was performed to compare HLA-A genotype frequencies 
between 189 HIV-2 infected and 250 uninfected controls (Table 6.3). Comparisons 
between cases and controls were adjusted for gender, ethnicity and age at date of 
sample collection. In all instances, genotype frequencies were similar between cases 
and controls.
Table 6.3: HLA-A and susceptibility to HIV-2 infection
HLA-A
Alleles
HIV-2 
(n = 189)
HIV negative 
(n = 250)
OR
(95% Cl) P*
A*01 0.106 (20) 0.120 (30) 0.86 (0.43-1.70) 0.663
A*02 0.243 (46) 0.260 (65) 0.84 (0.51-1.39) 0.503
A*03 0.079 (15) 0.072 (18) 1.19(0.54-2.62) 0.662
A*23 0.360 (68) 0.304 (76) 1.27 (0.81-2.01) 0.303
A*24 0.021 (4) 0.024 (6) 1.11 (0.26-4.76) 0.893
A*26 0.138 (26) 0.096 (24) 1,59 (0.81-3.13) 0.180
A*29 0.016(3) 0.032 (8) 0.78 (0.19-3.26) 0.738
A*30 0.222 (42) 0.284 (71) 0.67 (0.40-1.11) 0.117
A*31 0.010(2) 0.012(3) 2.05 (0.31-13.50) 0.455
A*32 0.063(12) 0.032 (8) 2.13(0.76-6.00) 0.152
A*33 0.217(41) 0.276 (69) 0.67 (0.40-1.11) 0.119
A*34 0.058(11) 0.080 (20) 1.02 (0.43-2.39) 0.968
A*36 0.005 (1) 0.004 (1) 1.36 (0.05-37.75) 0.858
A*66 0.048 (9) 0.024 (6) 1.85 (0.54-6.29) 0.325
A*68 0.169 (32) 0.176 (44) 0.96 (0.55-1.70) 0.901
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A*74 0.095(18) 0.060(15)
A*80 0.026 (5) 0.024 (6)
1.41 (0.64-3.12) 0.397
0.66(0.15-2.89) 0.580
(p: p values adjusted for gender, ethnicity and age but not for multiple comparisons
HLA-B alleles and HIV-2 acquisition in Fajara
The B locus was the most diverse in this population with 32 different 
serologically defined groups (2-digit alleles) and 50 alleles (4- to 6-digits) detected in 
583 adults (Table 6.1). The most frequent allele at the B locus was B*3501 
(AF=12.6% , G F=23.7% ), closely followed by B*530101  (AF=11.8% , G F=21.9% ) and 
B*1503  (AF=9.9%, GF=18.8% ). Other frequent alleles include B*080101, B*5801, 
and B*7801 with allele frequencies ranging from 5.4%  to 8.9% . Only six alleles at the 
B locus had an allele frequency above 5% that cumulated to 56.3%  of all B alleles. 
The most common and diverse group of alleles was HLA-B*15  with four subtypes 
(B*1503, B*1510, B*1516, and B*1518) and a cumulative allele frequency of 14.7%  
while their combined genotype frequency was 28.4% . B*1503  represented 67%  of all 
B*15  subtypes. The second most diverse group of alleles was HLA-B*35  (AF=12.8% , 
GF=24.1% ). Three B*35  subtypes were found in our samples: B*3501, B*350801, 
and B*3510. The predominant subtype was B*3501  representing 98.6%  of all B*35  
subtypes.
A comparative analysis was done to explore differences between HIV-2  
infected (n = 203) and uninfected control subjects (n = 247). Of note, individuals 
infected with HIV-1 or dually infected with both HIV-1 and HIV-2 were excluded from 
this study. In a multivariate model adjusting for gender, ethnicity, and age, we found 
that two HLA-B alleles (B*14 and B*57) were associated with protection against HIV-2
acquisition (Table 6.4). Individuals positive for HLA-B*14 were less likely to be HIV-2
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infected (OR = 0.31, 95%  Cl: 0.11-0.90, p = 0.031). Similarly, the number of 
individuals with at least one copy of HLA-B*57  in their genotypes was more in the 
uninfected group than in the HIV-2 infected group (OR = 0.13, 95%  Cl: 0.02-0.80, p = 
0.029).
Table 6.4: HLA-B alleles and susceptibility to HIV-2 infection 
HLA-B HIV-2 HIV negative OR "
Alleles (n = 203) (n = 247) (95% Cl) p*
B*07 0.128 (26) 0.089 (22) 1.36 (0.69-2.66) 0.370
B*08 0.177 (36) 0.158 (39) 1.21 (0.68-2.14) 0.518
B*14 0.034 (7) 0.077 (19) 0.31 (0.11-0.90) 0.031
B*15 0.300 (61) 0.279 (69) 1.22 (0.76-1.94) 0.409
B*18 0.069 (14) 0.036 (9) 1.54 (0.56-4.23) 0.398
B*27 0.030 (6) 0.032 (8) 1.20 (0.35-4.15) 0.777
B*35 0.271 (55) 0.215(53) 1.42 (0.86-2.34) 0.165
B*37 0.010(2) 0.020 (5) 0.79(0.14-4.60) 0.796
B*39 0.020 (4) 0.032 (8) 0.27 (0.07-1.08) 0.065
B*41 0.025 (5) 0.028 (7) 0.73 (0.21-2.60) 0.631
B*42 0.089 (18) 0.077(19) 1.05 (0.49-2.26) 0.900
B*44 0.030 (6) 0.049 (12) 0.81 (0.28-2.32) 0.691
B*45 0.049 (10) 0.049 (12) 1.19(0.45-3.16) 0.731
B*49 0.059 (12) 0.073(18) 0.83 (0.35-1.98) 0.676
B*50 0.025 (5) 0.036 (9) 0.89 (0.26-3.03) 0.855
B*51 0.059 (12) 0.046 (12) 1.21 (0.46-3.18) 0.692
B*52 0.030 (6) 0.028 (7) 1.11 (0.29-4.15) 0.881
B*53 0.212(43) 0.206 (51) 0.93 (0.56-1.56) 0.790
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B*56 0.025 (5) 0.016 (4) 2.14 (0.47-9.67) 0.323
B*57 0.010(2) 0.040 (10) 0.13(0.02-0.80) 0.028
B*58 0.118(24) 0.121 (30) 1.20 (0.62-2.32) 0.594
B*78 0.084(17) 0.130 (32) 0.60 (0.30-1.20) 0.148
B*82 0.020 (4) 0.032 (8) 0.81 (0.22-3.04) 0.756
*: p values adjusted for gender, ethnicity and age at the time of sample collection; in bold are alleles 
with significantly different frequencies in cases and controls
W e next grouped all B alleles into the two mutually exclusive categories Bw4 
and Bw6 based on their amino acid composition at positions 77-83. The Bw4 group 
was further subdivided into Bw4-80l and Bw4-80T depending on whether the amino 
acid at position 80 was an isoleucine (I) or a threonine (T). HLA-B Bw4-80l alleles 
serve as ligands for KIR3DL1 and possibly KIR3DS1 molecules although the latter is 
yet to be proven experimentally184'186. Our analysis showed that none of these 
categories (Bw4, Bw4-80l, and Bw4-80T) could significantly influence susceptibility or 
resistance to HIV-2 (Table 6.5).
Table 6.5: The effect of Bw4-80l and Bw4-80T on HIV-2 infection
Alleles
HIV-2 
(n = 203)
HIV negative 
(n = 247)
OR
(95% Cl)
*
P
Bw4+ 0.537(109) 0.580 (143) 0.88 (0.57-1.35) 0.550
Bw6/Bw6 0.463 (94) 0.421 (104)
Bw4-80l+ 0.473 (96) 0.502 (124) 0.89 (0.57-1.39) 0.610
Bw6/Bw6 0.463 (94) 0.421 (104)
Bw4-80T+ 0.084 (17) 0.113(28) 0.82 (0.39-1.73) 0.596
Bw6/Bw6 0.463 (94) 0.421 (104)
*: p values adjusted for gender, ethnicity and age
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HLA-C and susceptibility to HIV-2 infection in Fajara
A total of 23 HLA-C  alleles (4- to 6-digits) were found in 595 adult Gambians 
that participated in this study. Compared to A and B loci, this locus had the lowest 
number of alleles. The number of people with potentially new alleles (one or more 
mismatches) was also small (n = 5). They were all excluded from analyses and we 
plan to re-sequence them at a later date in order to characterise them better. The 
most frequent HLA-C  allele was Cw*040101  (AF=18.7% , G F=33.6% ) followed by 
Cw*160101  (AF=12.1% , G F=22.0% ) and Cw*0701 (AF=10.9% , G F=20.8% ) (Table  
6.1). Five other alleles had their allele frequencies ranging from 5.6%  to 9.7%  
including Cw*0210, Cw*0302, Cw*0304, Cw*060201, and Cw*1700.
Comparative analyses of HLA-C  allele and genotype frequencies between 
HIV-2 infected (n = 203) and uninfected (n = 266) (Table 6.6) and between males (n = 
131) and females (n = 457) was performed. Frequencies were similar between 
groups in a multivariate model adjusting for gender, ethnicity and age.
W e also grouped all HLA-C  alleles into one of two mutually exclusive 
categories C1 (group 1), if the amino acid at position 80 is asparagine or C2 (group 
2), if it is lysine. W e then analysed the distribution of these categories to see if they 
had any influence on HIV-2 acquisition. None of the categories had any influence on 
HIV-2 infection since frequencies of C1 and C2 were similar between groups. 
Individuals with these genotypes: C1/C1, C1/C2, and C2/C2 were also equally 
distributed between the infected and the uninfected groups.
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Table 6.6: HLA-C and susceptibility to HIV-2 infection
HLA-C
Alleles
HIV-2 
(n = 203)
HIV negative 
(n =266)
OR
(95% Cl) P*
Cw*01 0.059 (12) 0.034 (9) 2.31 (0.84-6.36) 0.106
Cw*02 0.232 (47) 0.241 (64) 1.00 (0.61-1.64) 0.993
Cw*03 0.261 (53) 0.301 (80) 0.81 (0.51-1.29) 0.382
Cw*04 0.360 (73) 0.320 (85) 1.15(0.74-1.78) 0.536
Cw*05 0.064 (13) 0.038(10) 1.40 (0.53-3.73) 0.496
Cw*06 0.094(19) 0.120 (32) 0.99 (0.51-1.91) 0.967
Cw*07 0.296 (60) 0.233 (62) 1.48 (0.92-2.39) 0.104
Cw*08 0.059 (12) 0.090 (24) 0.46 (0.20-1.08) 0.075
Cw*12 0.010(2) 0.026 (7) 0.17(0.03-1.03) 0.054
Cw*14 0.030 (6) 0.038 (10) 1.12(0.37-3.44) 0.842
Cw*15 0.034 (7) 0.049 (13) 0.44 (0.15-1.28) 0.132
Cw*16 0.227 (46) 0.222 (59) 1.11 (0.68-1.84) 0.671
Cw*17 0.128 (26) 0.105 (28) 1.01 (0.53-1.92) 0.983
Cw*18 0.020 (4) 0.038 (10) 0.33 (0.09-1.21) 0.094
*: p-values adjusted for gender, ethnicity and age, significant if p £ 0.05
HLA class I haplotypes in Fajara
Each HLA locus was checked for Hardy-Weinberg (H-W ) equilibrium using 
Arlequin software202. All three loci were in equilibrium (p values: 0.12752, 0.33722, 
and 0.16409 for HLA-A, -B, and -C loci, respectively). Table 6.7 and Table 6.8 show 
the two- and three-locus HLA class I haplotype frequencies in Fajara (excluding those 
haplotypes with frequencies less than 1% in the general population).
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The total number of possible A-B haplotypes was 504. Of these, only 17 had a 
population frequency greater than or equal to one. A*2301-B*3501  was the most 
frequent A-B haplotype with a frequency of 3.3%  followed by A*2301-B*1503  (2.2%). 
The estimated number of possible A-C haplotypes was 351, of which 27 had a 
frequency of 1% or higher. A*2301-Cw*0401  was the most frequent A-C haplotype 
(3.3%). Similarly, only 25 out of 390 estimated B-C haplotypes were relatively 
frequent and seven of these had frequencies ranging from 3.9%  to 9.4%  (Table 6.7). 
The most frequent was B*3501-Cw*0401  (9.4% ) followed by B *1503-Cw *0210 (8.8% ) 
and B*5301-Cw*0401  (7.5%).
Table 6.7: Two-locus HLA class I haplotypes in Fajara
A-B Freq* A-C Freq* B-C Freq*
A*2301 B*3501 0.033 A*2301 Cw*0401 0.033 B*3501 Cw*0401 0.094
A*2301 B*1503 0.022 A*2301 Cw*0701 0.027 B*1503 Cw*0210 0.088
A*3301 B*7801 0.019
CMooCO*< Cw*0401 0.023 B*5301 Cw*0401 0.075
A*2301 B*5301 0.018 A*0202 Cw*0401 0.022 B*0801 Cw*0304 0.061
A*0201 B*1503 0.018 A*2301 Cw*0210 0.022 B*7801 Cw*1601 0.050
A*2301 B*4901 0.017 A*3301 Cw*1601 0.020 B*5801
CMoCOo•Xo 0.045
A*0101 B*0801 0.016 A*3001 Cw*1700 0.020 B*4901 Cw*0701 0.039
CMoCMo*< B*3501 0.015 A*3002 Cw*0701 0.016 B*5301 Cw*0602 0.034
A*2601 B*0801 0.015
CMoCOCO*< Cw*0401 0.016 B*1510
oCOoXo 0.029
A*2301 B*0801 0.015 A*0201 Cw*0210 0.016 B*1402
CMOCOoX£O 0.028
A*6802 B*5301 0.014 A*2301
oCOo■X£O 0.016 B*5801 Cw*0701 0.027
A*3002 B*3501 0.013 A*2301 Cw*1601 0.015 B*4202 Cw*1700 0.020
COoCOCO*< B*3501 0.011 A*3303 Cw*0304 0.015 B*5101 Cw*1601 0.019
A*2301 B*0702 0.011 A*2601 Cw*0304 0.015 B*4500 Cw*1601 0.018
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A*0301 B*5301 0.011 A*2301
CNoCOo*£o 0.015 B*1801 O :» * o cn o 0.018
A*0101 B*5301 0.010 A*2301
CMOCOo*o 0.015 B*4201 Cw*1700 0.017
A*2301 B*5801 0.010 A*0201 Cw*1601 0.014 B*5001 Cw*0602 0.017
A*3301 Cw*0304 0.013 B*0702 Cw*1505 0.017
A*0101 Cw*0401 0.013 B*0702 Cw*0702 0.016
A*0301 Cw*0401 0.013 B*5201 Cw*1601 0.016
A*3303 Cw*0210 0.012 B*3501 Cw*0701 0.015
A*3001 Cw*0304 0.012 B*1516 Cw*1402 0.013
A*3002 Cw*1601 0.011 B*8201 Cw*0302 0.012
A*0201 Cw*0401 0.010 B*0801 Cw*0102 0.010
A*3402 Cw*0401 0.010 B*4102 Cw*1700 0.010
A*2301 Cw*0702 0.010
A*3303 Cw*0401 0.010
*: Only haplotypes with at least 1% population frequency are listed, Hap: haplotype, Freq: frequency
Analysis of the three-locus HLA class I haplotype data showed that HLA- 
A *2301-B *3501-C w *0401 (2.9% ) and A*2301-B*1503-Cw *0210 (2.3% ) were the most 
frequent three-locus haplotypes in our samples (Table 6.8). Only 13 out of 1311 
estimated three-locus haplotypes were relatively frequent with frequencies ranging 
from 1.0% to 2.9%.
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Table 6.8: Three-locus HLA haplotypes in the Fajara cohort
A-B-C Freq*
A*2301 B*3501 Cw*0401 0.029
A*2301 B*1503 Cw*0210 0.023
A*3301 B*7801 Cw*1601 0.020
A*2301 B*4901 Cw*0701 0.018
A*0202 B*3501 Cw*0401 0.013
A*0201 B*1503 Cw*0210 0.013
A*2601 B*0801 Cw*0304 0.013
A*3002 B*3501 Cw*0401 0.013
A*2301 B*5801 Cw*0302 0.013
CMoCOCO*< B*5301 Cw*0401 0.013
A*2301 B*5301 Cw*0602 0.012
A*2301 B*5301 Cw*0401 0.010
A*3303 B*1503 Cw*0210 0.010
A 0 /
KIR genes/profiles and HIV-2 infection in Fajara
All 600 samples were successfully typed for 15 KIR genes by PCR-SSP as 
described in Chapter 2. W e used two pairs of KIR gene-specific primers to target 
conserved regions. These primers annealed to 2 different exons of the same KIR 
gene to reduce the chances of missing the presence of the gene if there happened to 
be a point mutation at one of the primer binding sites. All 14 KIR genes and the 
pseudogene 2DP1 were detected in our samples. Framework genes (KIR3DL3, 
3DL2 and 2DL4) were present in almost every sample. Most of the inhibitory genes, 
with the exceptions of 2DL2 and 2DL5, had frequencies ranging from 86.7%  to 
100.0% (Figure 6.2). KIR2DL2 and KIR2DL5 genes were present in less than half of 
the study population. Apart from the ubiquitous 2DS4 gene that was present in 596  
out of 600 samples, other activating KIR gene frequencies ranged between 6.7%  to 
37.7%  with most of them (4/5) being well below 30%.
In a multivariate model comparing KIR frequencies between HIV-2 infected 
cases (n=215) and HIV antibody negative controls (n=272) controlling for sex, ethnic 
groups and age, none of the KIR genes showed a particularly strong association with 
susceptibility or resistance to HIV-2 infection (Table 6.9). However, KIR2DL4 showed 
a borderline significant difference between cases and controls (p = 0.03) where 
KIR2DL4 was common among HIV antibody negative (56.4% ) compared to HIV-2  
infected individuals (43.6% ). KIR gene distribution was similar between males 
(n=132) and females (n=468).
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Inhibitory genes Activating genes
Figure 6.2 KIR gene frequencies in the Fajara clinical cohort
A KIR gene without its ligand has a null phenotype. To study the effect of KIR- 
HLA combinations on HIV-2 infection in a clinical cohort in Fajara, we grouped 
individuals based on whether the ligand(s) for their KIR genes were present in the 
same individual. A comparative analysis of KIR-HLA compound genotypes between 
HIV-2 infected and uninfected groups showed that none of the compound genotypes 
had a significant influence on HIV-2 acquisition (Table 6.10) in this multi-ethnic 
population. The analysis was again adjusted for gender, ethnic grouping and age at 
recruitment.
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Table 6.9: KIR gene frequencies in cases and controls
Genes
HIV-2
(n=215)
HIV negative 
(n=272)
OR
(95% Cl) P*
Inhibitory 2DL1 0.972 (209) 0.985 (268) 0.35 (0.08-1.43) 0.144
2DL2 0.428 (92) 0.482 (131) 0.97 (0.64-1.46) 0.871
2DL3 0.902 (194) 0.849 (231) 1.44 (0.78-2.69) 0.247
2DL4 0.963 (207) 0.985 (268) 0.23 (0.06-0.84) 0.026
2DL5 0.460 (99) 0.452 (123) 1.18(0.78-1.78) 0.423
3DL2 0.977 (210) 0.989 (269) 0.46(0.10-2.18) 0.329
Activating 2DS1 0.112(24) 0.085 (23) 1.27 (0.65-2.51) 0.487
2DS2 0.358 (77) 0.364 (99) 1.09(0.71-1.66) 0.698
2DS3 0.219(47) 0.265 (72) 0.84 (0.52-1.35) 0.468
2DS4 0.986 (212) 0.996(271) 0.32 (0.02-4.31) 0.392
2DS5 0.256 (55) 0.254 (69) 1.13(0.71-1.78) 0.615
3DS1 0.060 (13) 0.085 (23) 0.69 (0.31-1.52) 0.356
Pseudo 2DP1 0.986 (212) 0.982 (267) 1.01 (0.21-4.77) 0.991
*: P values adjusted for gender, ethnicity, and age at sample collection
The number of activating and inhibitory KIR genes present in an individual 
constitutes his/her KIR profile, which in turn comprises a number of haplotypes. 
There are two basic types of KIR haplotypes: the “A” haplotypes comprising mainly 
inhibitory KIR genes (but without 2DL2) and no activating KIR other than 2DS4. The 
“B” haplotype on the other hand is a combination of both activating and inhibitory 
KIRs.
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The analysis of all KIR  gene profiles obtained from this Gambian population 
showed the presence of 91 different profiles: two profiles A  (A1 and A2) and 89 B 
profiles. Profile A1 was by far the most frequent (38.2% ), followed by B1 (8.5% ) and 
B2 (6.2% ). A2 profile, detected in 5 out of 600 samples, was very similar to A1 
except for the absence of KIR2DL3. In addition to B1 and B2, twelve other B profiles 
were present in at least 1% of the study population (Table 6.11). A  comparative 
analysis of some of the common KIR  gene profiles in the HIV-2 infected and control 
groups showed that none of the profiles was significantly associated with HIV-2  
infection (Figure 6.3).
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Figure 6.3 Most common KIR gene profiles in cases and controls
Discussion
In this part of the study, we determined and analysed HLA and KIR genetic 
polymorphisms in the Fajara clinical cohort for two important reasons: (1) to describe 
the genomic variations at the HLA class I and KIR loci in this other sample of West 
African populations and (2) to examine whether variation at these selected loci is 
associated with susceptibility to HIV-2. W e also aimed to study the relationship 
between KIR-HLA compound genotypes and HIV-2 infection.
HLA class I alleles/haplotypes do not influence HIV-2 infection in Fajara
A total of 17 HLA-A serological groups (2-digit alleles) and 28 HLA-A subtypes 
(4- to 6-digit alleles) were detected in Fajara. HLA-A alleles and genotype 
frequencies were similar between cases and controls. Comparing our data with other 
published frequencies from the sub region, we found that HLA-A*02  allele and 
genotype frequencies in Fajara (AF=13.2% , G F=23.9% ) were lower compared to 
other populations. For example, in the Bakola Pygmies in Cameroon, A *02  genotype 
frequency was 50% while it was 37%  in the Mbenzele population in Central Africa 
Republic203. Our HLA-A allele frequencies findings were similar to those reported by 
Allsopp and colleagues189 who serologically determined the frequencies of classical 
HLA class I in different tribes in the Gambia in the early 1990’s.
Analysis of HLA-B data generated from this HIV-2 clinical cohort in Fajara 
revealed, as is the case in most of the world populations, that B locus was the most 
diversified of all class I loci. W e found 50 distinct B alleles with four to six digits that 
can be grouped in 28 different serological groups. Two alleles (B*14  and B*57) were  
more frequent in the control group than in the HIV-2 infected group, suggesting that
these groups of alleles could be associated with protection against HIV-2 acquisition.
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Although the p values remained significant after adjusting for gender, ethnicity and 
age at recruitment, the number of subjects positive for any of these alleles was small 
(26 for B*14  and 12 for B*57, respectively) and the results should be interpreted 
cautiously. Both B*14  and B*57  had three subtypes each but with the exception of 
B*140201  (AF=3.0% , GF=5.9% ), all the other subtypes were rare (allele frequencies 
below 1%). In general, authors of most published HLA data from Sub Saharan Africa 
have detected very low allele and genotype frequencies for B*14  and B*57. For 
example, Modiano et al. found in random samples collected from three ethnic groups 
in Burkina Faso, that the allele frequency of B*14  was 0.0%  in Rimaibe, 0.9%  in 
Mossi, and 3.0%  in Fulani while that of B*57 was 4.7%  in Mossi and 0.0%  in Fulani 
and Rimaibe, respectively. If the protective effect observed in this Gambian cohort is 
real, it would support the proposition made by Trachtenberg et al. that rare HLA 
alleles more often offer protection against HIV infection and/or outcomes than 
common alleles in populations where HIV viruses have adapted to the more frequent 
alleles137.
In this cohort, we detected 14 HLA-C  group of alleles (2-digits) comprising 23  
distinct alleles (4- to 6-digits). W e repeated similar analyses as for HLA-A  and -B  
above to determine the influence of individual HLA-C  alleles on HIV-2 infection. None 
of the C alleles or genotypes was associated with susceptibility or resistance to HIV-2  
infection. Similarly, none of the C1, C2, C1/C1, C1/C2, or C2/C2 categories could 
influence susceptibility or resistance to HIV-2 in this sample of W est African 
population.
In order to determine the influence of HLA class I haplotype on HIV-2 infection, 
we reconstructed and estimated the frequency of all possible HLA class I haplotypes 
using Arlequin software. Comparing the two-locus and three-locus HLA class I
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haplotypes between HIV-2 infected and uninfected groups, we observed that none of 
the differences in haplotype frequencies between the two groups reached significant 
level (p > 0.05).
Potential new KIR2DL2 alleles detected in Fajara samples
W e detected all 15 KIR  genes in our Fajara samples. Knowing that genetic 
diversity is high in African populations, we anticipated that there could be some new  
polymorphisms not yet described in the literature in some of our samples. W e then 
opted to use two pairs of primers annealing to two different exons of the same gene 
to detect the presence of each KIR  gene. This was an attempt to minimise the 
likelihood of assigning false negative results to samples with new KIR2DL2  alleles 
containing some point mutation(s) at the primer binding sites. Rightly so, we 
observed that for some of our samples (about 10%), there was a specific band on 
lane 4 but none in lane 3 and this was consistent after several repeats (see 
Appendix 12 for a sample of the gel scoring sheet). Lanes 3 and 4 contained a pair 
of primers each, designed to amplify two segments of KIR2DL2 : one in exon 4 at 
position 419 to 591 (a segment of 173 bp) and the other in exon 5 at position 813 to 
963 (a segment of 151 bp). Ideally, in the presence of known KIR2DL2, there should 
be a specific band in both lanes 3 and 4 simultaneously.
The pattern described above indicated that there could be new KIR2DL2  
alleles in our study population that have not yet been described or published in public 
databases since these primers were designed for conserved regions using all traces 
available in public databases. W e repeated the typing 2 to 3 times to confirm the 
pattern and designed a new set of primers to amplify and sequence some of the
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samples for the region encompassing the primer binding sites in exons 4 and 5 of 
K IR 2 D L 2 .
Bi directional sequencing was performed and the resultant traces analysed 
using Mutation Surveyor software version 3.1 (SoftGenetics, USA). The analysis 
revealed that there were two point mutations at both primer binding sites preventing 
primers from annealing properly thereby resulting in no amplification in lane 3. Due to 
limited financial resources, we could not further characterise the suspected new 
alleles. However plans are in place to fully sequence these samples for KIR2DL2  
genes. W e also plan to deposit the resultant traces in public databases for the benefit 
of the scientific community.
KIR frequencies in Fajara are similar to other West African populations
Comparing our data to the little available data in Sub Saharan Africa and 
particularly West Africa, we observed that the frequencies of most of the KIR  genes 
detected in these Gambian samples were in agreement with data from Senegal187, 
Ghana193, and Nigeria195. Of note, however, was the particularly low frequency of 
activating KIR  genes in most of these populations. Single et al. recently showed that 
the frequencies of two activating KIR  genes (KIR2DS1  and KIR3DS1) were very low 
in West and East Africa and that the phenotypic frequencies of these two genes 
increased with increasing geographical distance from East Africa eventually peaking 
in the Oceania and Americas195.
In a multivariate analysis comparing the frequency of individual KIR  genes 
between cases and controls, adjusting for age, sex and ethnicity, we observed that 
only KIR2DL4  was weakly associated with protection against H IV-2 infection. All 
other individual KIR  gene frequencies were similar between both groups. Similarly,
164
the frequencies of “functional” KIR  genes (those KIR  genes that were present with 
their corresponding ligands in the same individuals) were similar between cases and 
controls.
NK cell activity is fundamental in humans and activating receptors are needed 
to activate NK cells to carry out their cytolytic activities in response to immune 
stimulation by a “non-self. The consistent low frequency of activating KIR  genes in 
most African population raises important questions: (1) Are there new activating KIR 
genes in Africans that can not be detected with our current typing techniques? (2) Are 
there alternative pathways to activate NK cells in the absence of activating KIR 
molecules? To date, ligands for most activating KIRs are yet to be discovered. 
Further research needs to be conducted to address some of these pertinent 
questions.
W e detected 91 distinct KIR  gene profiles in Fajara samples with the most 
common being the same A1 profile that predominated in Caio. However, none of 
these profiles was found to influence HIV-2 infection.
In brief, we analysed 600 samples from adults Gambians in Fajara for HLA-A , 
HLA-B, HLA-C, and KIR  genes. W e detected 28 HLA-A, 50 HLA-B, and 23 HLA-C  
alleles (4- to 6-digits). Apart from the high heterogeneity at the B locus, two HLA-B  
alleles {B*14, B*57) showed weak protection against HIV-2 acquisition (p=0.031 and 
p=0.029, respectively). None of the HLA class I haplotypes was associated with 
susceptibility or resistance to HIV-2 infection in this Gambian population. All 15 KIR  
genes were detected in our samples but none of these showed a particularly strong 
association with susceptibility or resistance to HIV-2 infection. HLA-KIR compound 
genotypes also did not affect risk of HIV-2 acquisition.
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KIR profile A1 was the most frequent of the 91 profiles detected in this sample 
of the Gambian population. The frequencies of all the KIR  gene profiles were similar 
between cases and controls and therefore did not significantly influence HIV-2  
infection.
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CHAPTER 7 : CONCLUSIONS
In nearly three decades since the first identification of the new human 
retrovirus causing an unusual and debilitating disease with profound immune 
suppression, AIDS remains the most devastating disease of our time. It is the leading 
cause of death among hospitalised adults in developing world4. The burden of AIDS  
on most African populations is huge. The rate of new infection is highest in Sub 
Saharan Africa4 and prevalence continues to increase alongside improved survival 
following the introduction and successful implementation of antiretroviral programmes 
in many countries South of Sahara in the last ten years or so. In this part of the 
world, most hospital wards are still full of emaciated men and women infected with the 
virus. More than 50 million Africans have been directly or indirectly affected by the 
scourge of HIV/AIDS. The demographic impact of AIDS pandemic is complex and 
not yet fully understood. Sub Saharan Africa remains the epicentre of the pandemic 
where both HIV-1 and HIV-2 co-exist with many other infectious diseases such as 
malaria, gastroenteritis, pneumonia and tuberculosis.
The HIV epidemic in West Africa is caused by two closely related retroviruses 
HIV-1 and HIV-2. The latter, which is the focus of this thesis, was first reported to 
have infected healthy Senegalese prostitutes in 198515 and was isolated the following 
year from two West African patients with AIDS: one from the Cape Verdes Islands 
and the other from Guinea Bissau3. It is structurally very similar to HIV-1 and shares 
between 30 to 60%  homology at nucleotide level. Although they both target same cell 
populations for destruction, their rate of infection and the resultant pathogenesis are
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quite different. Slow CD4+ T  cell decline, slower progression to full-blown AIDS and 
higher numbers of long-term non-progressors (LTNP) are some of the characteristics 
of HIV-2. However, at the later stage of the disease, HIV-2 infected patients 
eventually develop immunodeficiency with low CD4+ T  cell count, high HIV-2 viral 
load and a clinical feature similar to that observed in their HIV-1 infected counterparts 
at the same stage of disease204.
The reason(s) behind the attenuated course of HIV-2 infection and disease 
progression in a substantial proportion of HIV-2 infected individuals are yet to be 
uncovered. Immunogenetic factors are likely to be key determinants of whether or 
not an infected person rapidly develops clinically overt immunodeficiency or becomes 
a LTNP. Epidemiological evidence is accumulating, indicating a range of distinct viral 
and host genetics and possibly some environmental factors that contribute to the 
observed differences. Among these are molecules of the M HC and KIR regions that 
are the most important antiviral innate and adaptive immune response regulators.
A lot is now known about the pathogenesis of HIV infection but not much is 
known about correlate of protective immunity observed in most patients. The factors 
that influence the interindividual variability with regards to susceptibility to HIV  
infection and progression to AIDS are not well understood. Host immunogenetic 
factors such and HLA and more recently KIR  genes, which are extraordinarily 
polymorphic, have been repeatedly investigated in many large and well established 
cohorts around the world since the isolation of HIV-1 in 1981. A  good number of 
these genes and alleles as well as compound genotypes have been implicated in the 
control of HIV-1. Independent epidemiological studies have demonstrated the effect 
of HLA-B*35-Px subsets, notably B*3502, B*3503, and B*3504, with rapid 
progression to AIDS following HIV-1 infection69 134; while HLA-B*27, and -B*57, as
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well as KIR3DS1+Bw4-80I have been associated with long-term survival. However, 
very little is known about the role of the above mentioned genes/alleles in HIV-2 
infection and disease progression.
The main goal of this study was to determine the type of HLA alleles and KIR  
genes present in two well characterised W est African cohorts: one in Caio, Guinea 
Bissau (a country with one of the highest prevalence of HIV-2 infection in the world) 
and the other in Fajara, The Gambia (a country with one of the lowest prevalence of 
HIV infection in general). Our second major objective was to relate the presence or 
absence of these highly polymorphic genes with susceptibility or resistance to HIV-2  
infection and disease progression assessed using known markers of progression to 
AIDS such as decline in CD4+ T  cell count and increase in viral load over time.
To the best of our knowledge, there is no information about HLA-linked genetic 
control of HIV susceptibility in these populations (Caio and Fajara). In general, within 
the African continent, there is a paucity of information on the importance of HLA and 
KIR  genes in the susceptibility to infectious diseases including HIV. This is partly due 
to the difficulties in clearly identifying “at risk” populations for longitudinal studies 
since the frequency and degree of exposure to HIV is difficult to measure more so in 
an African context. The fact that there is limited amount of HLA and KIR genotyping 
information on African cohorts and the heterogeneity in the typing techniques used in 
generating the few currently available data, makes it difficult for us to compare our 
data with others in the sub region. W e only have to rely on studies reporting HLA  
genotype distribution in HIV-positive and HIV negative individuals in a single risk 
group across the continent and elsewhere in the western world.
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The exact time of seroconversion is unknown for the infected group and the 
extend of exposure of those considered HIV negative at the time of testing can not be 
defined in this study. This is a general phenomenon in most African cohorts.
This study provides and describes frequencies of MHC class I HLA-A , -B  and - 
C and KIR  genes in a predominantly Manjako community in Caio, Guinea Bissau and 
in a multi-ethnic Gambian cohort in Fajara, The Gambia. Comparisons of allele and 
genotype frequencies were made between these populations and their neighbouring 
populations in W est Africa including Senegal, Mali, Cameroon and other more distant 
populations in East and South Africa. HLA class I alleles with higher frequencies in 
the Caio community were as follows: A*3303, and A*2301  for HLA-A; B*1503, 
B*5301, B*5801, B*0801, B*1510, and B*3501 for HLA-B ; and Cw*0701, Cw*0401, 
Cw*0304, and Cw*0210  for HLA-C. In the Fajara cohort the most common alleles 
(frequency of 9% and above) included: A*2301 for HLA-A; B*5301, B*3501, and  
B*1503  for HLA-B; and Cw*0401, Cw*1601, Cw*0701, Cw*0304, and Cw*0210  for 
HLA-C. Both populations are separated by a distance of more than 600 Km on the 
W est coast of Africa and yet share many common HLA types albeit at different 
frequencies.
HLA-A frequencies in Caio and Fajara
W e found the genotype frequency of HLA-A*33 to be significantly higher in 
Caio compared to Fajara (38.8% vs. 24.7% , p < 1x1 O'6). A *33  is a common African 
allele existing in all ethnic groups with an average frequency of about 5%  in blacks98. 
Amerindian and Oriental populations share similar frequencies at the population level 
(about 5% ) while it is less frequent in Caucasians. The lowest population frequency 
of A *33 was recorded from Australian Aboriginals (0.5% )98. In African populations as
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well as African Americans, the frequency of A *33  varies greatly ranging between 0.0  
and 16.0%. For example, in West African pygmy populations e.g. Mbenzel and 
Bakolas, A *33  was reported to be 0.08%  and 0.18% , respectively203; it is 2.8%  in 
Ethiopians, 3.1%  in Botswana, and 13.3% in Fulani population in Burkina Faso.
HLA-A*33 is a split of the serologically defined A19 group of alleles205 at the 
HLA-A locus. Currently there are 29 subtypes of A*33  described in the IMGT/HLA  
database94 making it the second most polymorphic of the A19 splits after A*30. In 
both the Caio and Fajara subjects studied, we only identified two A*33 subtypes: 
A*3301  and A*330301. The latter was by far the most frequent subtype in Caio, 
where its frequency was seven fold higher than that of A*3301. In Fajara, however, 
both subtypes were equally distributed.
Spinola and colleagues recently reported HLA-A*33  frequency among males 
from four different ethnic groups (Balanta, Fula, Bijagos, and Papel) within Guinea 
Bissau206 and found the highest frequency to be in the Bijagos ethnic group (10.7% ). 
A literature search of published data from Sub Saharan Africa indicates that the Caio 
population exhibit the highest frequency of A*33, notably A *330301 . The reason(s) 
for this high frequency of HLA-A*33 in Caio can only be speculative. Data from a 
neighbouring Senegalese population reported a frequency of 12.9% in a group of 
female commercial sex workers (CSW )115. It is however difficult to compare our A *33  
genotype frequency to those mentioned above since each of these studies derived 
their frequency from only a handful of people of a single gender (23 Bijagos males in 
the case of Spinola et al. and 62 female CSW  in the case of Diouf et al.).
In The Gambia, Allsop et al. serologically analysed the frequency of classical 
HLA class I antigens in various ethnic groups189 and reported that reactivity to A33  
antigen was as high as 36.0%  in Serere (n = 25), 24.4%  in Jola (n = 123), 23.3%  in
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Fula (n = 90), and 24.4%  in Manjago (n = 41). In our study, although using a different 
typing technique and a larger sample size (n = 600), we found the overall frequency 
of A *33  to be 24.7%  in our Gambian cohort. It is worth noting that we studied a multi­
ethnic group in Fajara comprising Mandinka (46.5% ), Jola (13.6% ), Fula (13.4% ), 
Wolof (10.6% ), Manjako (3.7%), Serer (3.7%), Serahuli (2.6% ), Aku (0.6% ), and other 
minority ethnic groups classified together as “Other” (5.5%).
Analysis of HLA-A types stratified by ethnicity showed that HLA-A*33  
frequency was highest in Manjako (35.3% ). In a predominantly Manjako community 
in Caio, we saw a similar trend that A *33  frequency was high (38.8% ). This is an 
indication that people of the Manjako tribe may overall exhibit a high frequency of 
HLA-A*33  independent of their geographical location since these two Manjako 
populations (Caio and Fajara) are quite far apart from each other and yet have similar 
A*33  genotype frequencies (38.8%  vs. 35.3% , respectively, p = 0.768). This supports 
previous observations that Manjakos are truly a unique set of people with their unique 
values207 and now distinct immunogenetic factors that distinguish them from their 
neighbouring West African populations.
All Manjako subjects from the Fajara cohort carried the A*330301  subtype as 
opposed to all other ethnic groups in which the frequencies of A*330301  and A*3301  
were similar. For example, the Wolof ethnic group in The Gambia also had high 
genotype frequency of A*33  (34.0%  overall) but the frequency of A*330301  was not 
significantly different from that of A*3301  amongst the Wolof people (52.9%  vs. 
47.1% , respectively, p = 0.791).
Another report by Cao et al, showed high heterogeneity of HLA-A*33  
frequency in different populations191 across South, East, Central and W est Africa:
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Zulu (0.5% ), Kenyan Nandi (0.4%), Kenyan Luo (2.3%), Zambians (1.2%), Ugandans 
(4.6%), Cameroonians (2.8% ), and Malians (11.2% ).
The genotype frequency for HLA-A*74  was also high in Caio when compared 
to Fajara but with a borderline statistical significance (10.6%  vs. 7.1% , respectively, p 
= 0.045). A*74  is another split of A19 serological group of alleles. It is generally 
considered to be an African allele. Its frequency varies among studied populations in 
Sub Saharan Africa: 0.2%  in Zimbabwe Harare Shona (n = 230)193, 6.5%  in Zulu (n = 
51), 5.0%  in Cameroonians (n = 47 )191, 6.6%  in Mossi in Burkina Faso (n = 53 )188, 
and 19.6% in male Bijagos in Guinea Bissau (n = 23)206. A *74  is less polymorphic 
compared to other members of the A19 splits with only 14 alleles described to date94.
The sequences of exons 2 and 3 of all of our samples that were positive for 
A *74 were analysed using “Assign 400” - a specialised software from Conexio 
Genomics, Western Australia and they suggested that the genotypes of these 
individuals could either be A*7401  or A*7402. Both of these alleles have identical 
nucleotide composition in those exons that we investigated. It is known that A*7401  
differ from A*7402  by a single point mutation in exon 1 at nucleotide position 67 
(codon 23) where the former has an “A” and the latter a T  in that position208. This 
single non-synonymous mutation results in an amino acid change from Arginine (R) to 
Tryptophan (W) or vice versa at codon 23 of A*74 protein depending on which of 
these two alleles existed first.
In an attempt to distinguish between these two alleles, we amplified a segment 
comprising exon 1 from all A*74-positive samples and re-sequenced them. Analysis 
of the traces showed that the amino acid at codon 23 was R, indicating therefore that 
the A*74  allele in both Caio and Fajara was A*7401.
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HLA-A*24 allele was completely absent in Caio but present in 2.6%  of our 
Gambian subjects (p = 0.0003) mainly from the Mandinka and Fula tribes. It is one of 
the most polymorphic alleles at the A locus with 118 subtypes currently described in 
the public database94 and it is not a common allele of Africans98. The average 
population frequency of HLA-A*24 in Africans is 3.1%, ranging from 0.5%  to 6.2% . It 
is therefore not surprising that A*24  was absent in the predominantly Manjako 
community in Caio, Guinea Bissau and in many other tribes in our Gambian cohort. It 
is worth mentioning that this allele was also absent in Manjako of Gambian origin that 
we studied. Australian Aboriginals harbour the highest frequency of A*24  in the world 
(48.6% , ranging from 32.0%  to 65.7% )98.
The only other HLA-A allele that we found to be present in Gambians at 
significantly higher phenotype frequency than in Guineans was A *30  (25.6%  vs. 
19.6%, respectively, p = 0.031). This allele is commonly found in Africans with 
frequencies ranging from 9.3%  to 31.6%  (average 14.8% )98. A *30  is also a split from 
the A19 serological lineage. It is considered the most polymorphic of all the A19  
splits with 32 known subtypes. In our samples we found three of the 32 subtypes: 
A*3001, A*3002, and A*3004. The most frequent subtype in Caio was A *3002  
(14.5% ) and none had the A *3004  genotype, which was also rare among the Fajara 
subjects (0.6% ). All the three subtypes were present in Fajara but the overall A *30 
genotype frequency (25.6% ) was equally distributed between individual carrying 
either A*3001  or A *3002  (12.6%  and 13.0%, respectively).
In studying the effect of HLA-A variation on risk of HIV-2 acquisition we found 
one of the 24 HLA-A alleles (HLA-A*8001) to be weakly associated with increased 
risk of HIV-2 infection. This association was only seen in the Caio community cohort 
and not in the Fajara clinical cohort. The fact that we did not see this w eak effect in
174
Fajara might be due to the multi ethnic nature of the cohort, since in Caio we had 
almost an homogenous population (>95%  Manjako).
HLA-B frequencies in Caio and Fajara
HLA-B locus was the most diversified of all class I loci in our study populations: 
50 and 32 alleles (4- to 6-digits) detected in Fajara and Caio, respectively. Four of 
them were present at significantly higher allele and genotype frequencies in Caio 
compared to Fajara: HLA-B*13, -B*15, -B*49, and -B*58. On the other hand, six 
others alleles had significantly higher allele and genotype frequencies in Fajara than 
Caio including HLA-B*07, -B*35 , -B*39, -B*42, -B*45, and -B*78. W e also found that 
three of the 50 B alleles in Fajara were absent in Caio samples: HLA-B*27, -B*37, 
and -B*55.
HLA-B*13  was relatively rare in Fajara compared to Caio (1.0%  vs.6.4%, p = 
2.6x1 O'6). It was detected in only 6 out of 583 Fajara samples that were successfully 
assigned a B genotype. B*13  frequency in Caio was comparable to the average 
frequency found in Oriental populations98 where it predominates. Shen and 
colleagues reported a frequency of 11.1% in a subset of Han population209 from Xi’an 
in China. Other studies on the same Han populations from the Northern210 and 
Southern211 parts of China found that B*13  frequencies ranged from 9.0%  to 11.2%. 
In contrast, apart from this high frequency observed in the Manjako population in 
Caio, most populations in Sub Saharan Africa exhibit low frequencies of B*13  ranging 
from 0.0%  to about 3.0%. For example, in a study carried out on 52 individuals from 
the Zulu191 population in South Africa, HLA-B*13  frequency was 1.5%, in Cameroon it 
was 2.7% , while in Ugandans212 it was 2.0% . In another study in Burkina Faso, none
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of the subjects from the three tribes studied (Fulani (n = 49), Mossi (n = 53), and 
Rimaibe (n = 47)) carried the B*13 allele188.
Of the 32 subtypes of HLA-B*13  described in the immunogenetics database, 
we detected only two: B*1301  and B*130201. The former was very rare and seen 
only in one Fajara sample and the latter, B*130201  was quite common in both 
populations.
A number of studies have implicated HLA-B*13 with susceptibility to type II 
psoriasis vulgaris213, Chronic Myelogenous Leukemia (CLM )214, and the control of 
HIV-1 clade C viral replication215 21B. Many epidemiological studies continue to show 
that specific HLA-B  alleles (such as B*13, B*14, B*15, B*27, B*35, B*53, 8*57, and 
B*58) collectively exert a strong impact on HIV-1 infection and disease progression. 
For example, in individuals infected with clade C HIV-1 virus in Zambia, HLA-B*13  
was associated with successful viral control216. In our samples, the phenotypic 
distribution of HLA-B*13 between individuals infected with HIV-2 virus and controls 
(HIV negative individuals) was similar in both Caio and Fajara.
HLA-B*15  was the most frequently encountered allele in both Caio and Fajara. 
Comparative analysis of HLA-B*15  phenotype frequency between these cohorts 
showed a statistically significant difference (41.4%  vs. 26.8% , respectively, p = 
1.4x1 O'6). The phenotypic distribution of HLA-B*15  varies from one African population 
to another. In W est African Pygmies, B*15  allele frequency was 8.5%  in the 
Mbenzele tribe (n = 36) and 20.0%  in the Bakolas ethnic group (n = 50)203; in a cohort 
of HIV-1 positive and negative individuals217 in Botswana (n = 161) it was reported as 
2.6%; in Burkina Faso, B*15  genotype frequencies ranged between 6.6%  (Mossi) and 
17.0% (Rimaibe)188. In neighbouring Senegal it was 22.3%  in Dakar population (n = 
112); and in the Twana group in South Africa it was 26.8%  (n = 41 )193.
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HLA-B*15  is one of the most polymorphic alleles in humans. There are 
currently 181 subtypes in the Immunogenetics database. Of these, we detected three 
in Caio: B*1503, B*1510, and B*1516; and four in Fajara B*1503, B*1510, B*1516, 
and B*1518. The latter was very rare and present only in a single Fajara sample. 
The most common subtype was B*1503  followed by B*1510  in both cohorts. None of 
the four B*15  subtypes was associated with susceptibility to HIV-2 infection. Their 
allele and genotype frequencies were similar between cases (HIV-2 infected) and 
control (HIV negative) individuals.
In Caio, where the majority of HIV-2 infected individuals had laboratory data 
available on CD 4+ T  cells count and HIV-2 VL measurements overtime, we found a 
strong association between HLA-B*15 and disease progression assessed using 
universal markers of HIV disease progression such as CD4+ T  cell count and viral 
load. This association was entirely attributed to B*1503  since the other common B*15  
allele B*1510  frequency was similar between groups with or without the allele. 
Individuals positive for B*1503  had a considerably higher HIV-2 VL and lower 
absolute CD 4+ T  cell count compared to those negative for B*1503. This was not a 
haplotype effect since none of the HLA class I haplotypes carrying the B *1503  allele 
was seen to be mediating a similar effect. The haplotype frequencies were similar 
between infected and uninfected groups in both cohorts. W e hypothesised that this 
association was ethnic-specific, even though we could not see a similar trend in the 
few Manjakos in our multi-ethnic Fajara cohort probably because of the small sample 
size (n=18). Is B*1503  a surrogate marker for another gene or group of genes that 
could be the actual mediator(s) of the observed effect? This possibility can only be 
excluded after further investigations into the functional role of HLA-B*1503  in HIV  
infection. Part of these analyses concerning the association between HLA-B*1503
and markers of disease progression (CD4+ T cell count and HIV-2 VL in the Caio 
cohort has been written and submitted for publication in a peer review journal (Journal 
of Immunology) and is currently under review (see Appendix 15 for a copy of the 
submitted manuscript)
The other B  allele that was present in Caio at a significantly high frequency 
than in Fajara was HLA-B*49  (12.8%  vs. 7.2%, respectively, p = 0.003). B*49  has 
previously been reported as a common allele in blacks and Caucasians98. Our 
frequencies were higher compared to those reported in cohorts in Zambia216 (2.4% ), 
Botswana217 (0.3%), Uganda212 (5.4%), Senegal193 (7.1%); and significantly lower 
compared to that found in Ethiopians (31.4% ) from a low resolution typing218. HLA- 
B*49  was found to be associated with rapid progression to AIDS following HIV-1 
infection with subtype B virus116. The region of the human MHC encompassing HLA- 
B*49 is one of the least polymorphic within B locus with only six subtypes described in 
the immunogenetics database. Only one of these was found in our study populations 
(B*4901) in line with most African studies that employed high resolution (4- to 6-digits) 
HLA typing techniques.
HLA-B*58  was over-represented in the Caio community (21.2%  vs. 13.9%, p = 
0.002, Caio and Fajara genotype frequencies, respectively). This group of alleles has 
been reported to have the highest population frequency in blacks98. There are 23  
alleles of B*58  officially published to date94. In this study, we found only one of the 
subtypes - B*5801. This is in line with observations made from recent studies in W est 
Africa where B*5801 was the only B*58  allele found at relatively high frequency 
among 65 male Guineans192, 138 Malians191, and 149 individuals from 3 ethnic 
groups in Burkina Faso188. The over-representation of HLA-B*5801  has been 
associated with protection against rapid progression to AIDS following HIV-1 infection
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in Western populations and in East African cohorts219 22°. Since the date of 
seroconversion was unknown for most of our study participants, we could not 
determine the exact effect of these genes/alleles on the rate of disease progression 
with high precision. W e, however, used available information on markers of disease 
progression to assess the potential effect of HLA alleles detected in the study 
population on HIV-2 disease. There was no trend to indicate that any of the markers 
of disease progression (CD4+ T  cell count and HIV-2 VL) was influenced in any 
direction by HLA-B*5801 .
W e also observed that the phenotypic distribution of HLA-B*78  was hugely 
imbalanced between the two populations with a relatively high frequency in Fajara 
compared to Caio (10.8%  vs. 0.5% , respectively, p <1x10'7). The dramatic low 
frequency seen in the Caio population is in agreement with what is known of other 
black populations where the average B*78  allele frequency has been reported to be
0.6%, ranging from 0.0% to 5.2% in Sub Saharan Africa. Conversely, the high 
frequency observed in the Fajara population both at the allelic and phenotypic levels 
is similar to that reported in a Senegalese population in Dakar193 (7.6%  allele 
frequency and 16.1% phenotype frequency). B*78  is generally rare in most 
populations world wide and has not been detected in many Caucasoid populations or 
Australian Aboriginals98.
B*78  is an oligomorphic group of alleles with only a few alleles described in the 
Immunogenetics database -  seven alleles. W e found one B*78  subtype in our Caio 
samples (B*7801) and two in Fajara: B*7801  and B*780201. The latter was seen in 
only 1 out the 583 Fajara samples. W e hypothesise that B*7801 is most likely a W est 
African allele predominant in the Senegambia area of W est Africa, which comprises 
the republic of Senegal and The Gambia. B*7801 allele frequency increases as you
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move from Cameroon towards the tip of W est Africa. It is 0.6%  in the Beti ethnic 
group in Cameroon221, 1.1% in Rimaibe in Burkina Faso188, 2.3%  in Guinea Bissau192, 
2.3%  in Ivory Coast222, and 6.9% in the Bandiagara tribe in Mali191.
HLA-C frequencies in Caio and Fajara
The C locus had the lowest number of alleles (4- to 6-digits) in both cohorts: 21 
in Caio and 23 in Fajara, respectively. None of these HLA-C  alleles were individually 
or collectively (C1, C2) associated with susceptibility or resistance to HIV-2 infection 
in both cohorts. However, some of the KIR/HLA  compound genotypes showed weak  
associations with protection against HIV-2 acquisition; in particular KIR2DL2  and 
KIR2DS2  when present with their corresponding/putative ligand -  HLA-C group 1 
were seen at significantly higher frequency in the uninfected group than in those 
infected with HIV-2. W e also reported in this study using the Caio population that 
individuals positive for Cw*02 had low CD4+ T cell count with a trend towards higher 
HIV-2 viral load than those without this genotype. Further analysis attributed this bad 
prognostic effect entirely to Cw*0210, which is in strong LD with HLA-B*1503  (as 
demonstrated by the high frequency of B*1503-Cw *0210  haplotype in this sample of 
the Manjako population from the Caio sector). HIV-2 infected individuals with the 
Cw*0210  genotype had a much lower CD4+ T  cell count and a much higher HIV-2 VL  
than previously observed with the overall Cw*02-positive group. This effect was not 
seen with the other Cw*02  allele (Cw*0203). W e also observed in Caio that HLA- 
Cw*07  was weakly associated with high HIV-2 viral load but not CD4 count.
KIR genes and profiles in Caio and Fajara
Inhibitory KIR  gene frequencies were similar between Caio and Fajara as is 
the case in other W est African populations. But the frequencies of some of the
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activating KIR were significantly higher in Caio than elsewhere in W est Africa but 
more similar to those found in Europe particularly France. Anthropological findings 
have shown that the Manjako communities are more open (sexually) to Europeans, 
usually from Portugal and France, than they are to their closest neighbours in W est 
Africa. Interestingly, KIR3DS1, which has been shown to be rare or absent in people 
of African ancestry, was present in Caio at a significant frequency. It is reasonable to 
think therefore, that the KIR3DS1  gene may have been introduced in Caio from 
Europe, especially Portugal since Guinea Bissau is a former Portuguese colony.
KIR3DS1 frequency in Fajara was comparable to those reported in other 
populations in Sub Saharan Africa. At least three epidemiological studies have 
demonstrated that KIR3DS1  is associated with protection against rapid progression to 
AIDS following HIV-1 infection, particularly when the infected individuals have its 
putative ligand HLA-B Bw4-80l169. W e did not see that effect in any of our HIV-2  
cohorts. Most of the beneficial or deleterious effects seen in HIV-1 cohorts were not 
seen in this HIV-2 study. Does this suggest different mechanisms of protective 
immunity between the two virus strains, or is it because the two viruses have different 
properties? Are our observations related to population diversity? Or the study 
designs? It is worth noting that we used two prevalent cohorts for our study and the 
exact dates of seroconversion are unknown for the infected groups, but this is likely to 
apply to any other HIV-2 cohort.
Summary
In the present study, we determined and analysed the frequencies of classical 
HLA class I and KIR  genes in 1113 consented adults (513 from a remote community 
cohort in Caio, Guinea Bissau, and 600 from an urban clinical setting in Fajara, The
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Gambia). W e detected 24 HLA-A, 32 HLA-B  and 21 HLA-C  alleles (4- to 6-digits) in 
Caio while in Fajara we found 28 HLA-A, 50 HLA-B  and 23 HLA-C  alleles (4- to 6- 
digits).
Individuals from the predominantly Manjako community in Caio who were 
positive for HLA-A*8001 or HLA-B*080101 were at higher risk of acquiring HIV-2 
infection than those without any of these alleles while those expressing either 
KIR2DL2 or KIR2DS2 molecules together with at least one copy of their 
corresponding ligands (C1) were protected against HIV-2 infection. In Fajara, two 
HLA-B  alleles (B*14, B*57) showed weak protection against HIV-2 acquisition 
(p=0.031 and p=0.029, respectively).
In the community cohort in Caio Guinea Bissau, HIV-2 infected individuals 
carrying the B*1503  (but not B*1510) allele had significantly higher HIV-2 viral loads 
and lower CD4 counts compared to those without this allele, suggesting that this 
allele is associated with poor control of viral replication and more rapid disease 
progression. The mechanisms of action of B*1503  in mediating this susceptibility 
effect is yet to be elucidated.
None of the HLA class I haplotypes and/or KIR gene profiles was associated 
with neither susceptibility/resistance to HIV-2 infection nor disease progression 
assessed using universal markers of H IV progression (CD4+ T  cell count and viral 
load) in both of these W est African cohorts. KIR profile A1 was the most frequent 
profiles but its frequency was similar between cases and controls.
W e observed a few differences in allele and genotype frequencies between the 
two study populations. One of the reasons that could help in explaining these 
differences could be in population diversity. Although both cohorts are located in the 
coast of West Africa, one is an isolated rural community cohort with the majority of the
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participants (>95% ) belonging to a single ethnic group (Manjako). The other (Fajara 
cohort) is located in an urban area with participants drawn from more than eight 
different ethnic groups. Epidemiological evidences have demonstrated that the Caio 
population is sexually isolated from neighbouring populations and more open to 
Europeans particular those from Portugal and France.
Although, the date HIV-2 entered into each of the W est African populations is 
not well known, it seems unlikely that HIV-2 has been around long enough to impose 
some form of selection pressure on those who survive the infection. If selection 
pressure can be used to explain the observed differences, it is likely pressure from 
other retroviruses closely related to HIV-2 such as HTLV-1 and HTLV-2, which are 
common in older women of Guinea Bissau origin223224.
Strengths and weaknesses
Studies described in this thesis are among the very few conducted in Sub 
Saharan Africa employing state-of-the-art molecular techniques such as SBT and 
PCR-SSP typing methods to detect the presence and describe the frequency of 
genes from highly polymorphic regions of the human genome -  M HC and LRC  
regions.
This is the first time that HLA class I, KIR and KIR-HLA compound genotypes 
are studied in great details in a sizable number of HIV-2 infected individuals in W est 
Africa. This will no doubt form the basis for more advanced immunological studies in 
these and other HIV-2 cohorts to understand better why HIV-2 is well controlled and 
less aggressive to the human host than H IV-1.
These studies also confirm that there is high diversity in African populations 
even in a geographically small region. One lesson learned from this work is that
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genetic studies carried out in specific ethnic groups may be more informative than 
those that study a more heterogeneous population. W e have shown in a 
predominantly homogenous population (>95%  Manjako) that people with HLA-B*1503 
genotype when infected with HIV-2 are more likely to progress to AIDS defining 
illnesses faster than those without this genotype. Secondly, HLA alleles that were 
associated with susceptibility to or protection against HIV-2 in Caio (albeit weakly) did 
not show any effect in a multi-ethnic Fajara cohort.
An inherent weakness of this study is the lack of knowledge on the date of 
seroconversion of HIV-2 infected subjects. The infected subjects in Caio were mostly 
recruited during serosurveys. The length of time between the serosurveys was quite 
long to see any trend in data collected between different time points. In Fajara, the 
ethnicity data was not available for the majority of those infected with HIV-2, and we 
were therefore unable to use the available CD4 count and HIV-2 viral load data to 
predict disease progression in that cohort.
Although a sample size of 1113 individuals can be considered large compared 
to previous studies, it is still a small sample size with a weak power to detect small 
but clinically significant differences between groups. W e therefore recommend a 
merging and consolidation of all HIV-2 cohorts around the globe to form a consortium 
for future immunogenetics studies.
There is paucity of data generated using SBT on HLA and KIR genes in the 
West African sub region and we had no choice but to compare our data with those 
available in the literature and public databases irrespective of the techniques used in 
generating the data.
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Future work
As mentioned earlier, data generated from this study will form the basis for 
more advanced functional work in the future. Some of the areas that we are keen on 
investigating include the following:
1. The role of HLA-B*1503  in the immune response to HIV-2.
In this study, we plan to use a series of in vitro immunological techniques to 
understand the immunological basis of HLA-B*1503  association with rapid disease 
progression in HIV-2 infected individuals. This will be done in two phases: (a) first, 
we will investigate the functional and phenotypic properties (cell surface markers 
that can help in their identification) of HLA-B*1503-restricted HIV-2 specific C D 8+ 
T cells to see if they generate a particular profile of soluble factors that promote 
HIV-2 replication in vitro; (b) second, through binding and affinity assays we will 
determine which of the KIR molecule(s) use HLA-B*1503 as their ligand and then 
investigate the nature of KIR interactions with HLA-B*1503 in modulating NK cell 
cytolytic activities. KIR-ligand interaction results in transduction of either an 
activating or an inhibitory signal to the NK cell. The overall balance of both signals 
is very important in determining what the action of NK cell will be on the target cell. 
If the activating signal predominates over the inhibitory one, the NK cell is 
stimulated to carry out its cytolytic function, but if the opposite is the case, the NK 
cell function will be inhibited.
2. Determination of new KIR  and HLA class I alleles in two W est African 
populations
Here we plan to carry out full length sequencing of those KIR genes that 
showed unusual patterns with PCR-SSP techniques. W e shall concentrate on 
those KIR genes that consistently showed a specific band on one but not the other
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of the two primer pairs that were designed to detect the presence of the gene by 
annealing to two highly conserved regions of the gene. W e shall design new 
primers to amplify the region encompassing both primer pairs, sequence that 
region and analyse it for the presence of mutation(s) at the primer binding sites. If 
mutations are detected that have not yet been described in public databases, we 
shall then design more primers to sequence the entire gene.
For the HLA class I genes, we plan to re-sequence all the samples that we 
could not amplify during the course of this project and those that we excluded from 
analysis because they had one or more mismatches compared to alleles already 
described in HLA and Immunogenetics databases.
W e also plan to deposit complete sequence traces of all new KIR  and HLA 
alleles in public databases to benefit the scientific community.
3. Paper write up and publication
W e have submitted one paper titled “The influence of HLA class I and HLA-KIR  
compound genotypes on HIV-2 infection and markers of disease progression in a 
Manjako community in W est Africa”, which is currently under review for publication 
in the Journal of Immunology (see Appendix 15). Two more manuscripts are 
being drafted to describe the genetic variants in HLA class I and KIR  genes in 
both Caio and Fajara populations.
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APPENDIX
APPENDIX 1
MRC Clinical Cohort Study OPDNO:| |___ |___ |___ | / 1___ |___ |___ |____|
Participant Information and Consent Sheet for Adults 
(to be read after the patient has been post-test counselled)
AIDS is caused by a small germ, called HIV. Some people become ill within a few  
years of becoming infected, others may stay healthy for 10 or more years. Currently 
there is no cure for HIV infection. There are expensive drugs that can slow down the 
disease - unfortunately these are not routinely available in The Gambia due to their 
high costs.
The MRC has been studying HIV infections for many years. W e are investigating the 
body's defences against this infection. W e do this by using a small amount of blood in 
tests in the laboratory, which reveal whether the defence system is strong or weak, 
and over time, whether it is maintaining its strength or is losing power. Because the 
immune system is a complicated system, there are many different tests than can be 
done. Also the amount and type of virus in the blood can be measured. New tests are 
developed every year. W e hope that these various studies will lead to the 
development of a vaccine in the long run. A  good vaccine would prevent infection with 
HIV, or prevent the development of disease, including AIDS.
W e invite you to enrol in our ongoing studies. W e offer you clinical check-ups every 
three months (or more often as necessary), and medication as needed, both free of 
charge. Your travel fees to and from the clinic will be paid back to you. W e will ask 
you twice a year (but sometimes up to 4 to 6 times per year) to provide a blood 
sample of about 15 mis (3 teaspoons). This blood sample is used to test the condition 
of your immune system (CD4 count), the strength of your blood (Hb), or to help us 
detect additional illnesses, which may be treatable. The doctor will give you the 
results of these blood tests at your next visit. W hat remains of the blood sample will 
be either directly used in research tests, or stored in deep-freezers, for later use in 
scientific tests. Some of these later tests could help to understand why some people 
might be more susceptible to infection or disease than others. Part of the reason 
could be that some people are born with a better ability to fight infection than others; 
such differences are called genetic. Taking this amount of blood is completely safe, 
and will not make you sick.
In case you haven’t come to the clinic for more than three months, a field worker will 
visit you at home to check whether you are well, and to invite you again to the clinic. 
The study and investigations have been approved by the Gambia Government/MRC  
Joint Ethical Committee. This study is meant to go on for many years, and no ending 
date is currently foreseen. Participation in this study is voluntary. If you agree to join 
the study, but change your mind later, and want to withdraw from the study, you may 
do so at any time.
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The doctors and scientists of the study will have access to information about you and 
your condition, but apart from these people no one else will. Your files are locked 
away in a safe place and no outsider will have access.
You are not obliged to provide blood samples, and you are completely free to decline 
this every time when it is asked; this will not affect the usual care you get from the 
MRC clinicians. If you do not understand this information, or you have any other 
concerns on this study, you can discuss this with Dr. Stephen Allen.
Do you have any questions?
Do you agree to enter the study?
I, .................................................................................. (clinician/counsellor) have explained to
the patient the above in a language familiar to the patient.
Signature:..............................................................  D a te .........................................................
I, ..........................................................................  have read /  been explained the above
information about the MRC's clinical cohort study and I understand the information. I 
agree to participate in the study. I understand that I can withdraw from the study at 
any time, without needing to give reasons, and without this affecting the care I receive 
at the MRC.
Signature /  thumbprint:................................................................
Date................................................................
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APPENDIX 2
CONFIDENTIAL MRC G ENITO -URINARY CLINIC
SOCIAL HISTORY FORM MALE (NSH2m)
version 27th September 2000
PARTI KEY INFORMATION
1 OPDNO
i i i i i / 
i i i i i
2 Sex Male = 1 
Female =2
3 Last Name
4 First Name
5 Date of interview (DD / MM / YYYY)
I I I  /  I I I  / 
I I. I I I
6 What is your age? (years)
I I I
7 Is an exact birth date available? Yes = 1 
No = 2 » 9
8 If yes, what is the exact birth date? 
(D D /M M /Y Y Y Y )
N.A.=88
I I |/| I |/| I I I 
J
9 Do you agree to participate in this 
study?
Yes = 1 
No = 2 >part V
If patient does not want to participate in the study, OR the patient 
is less than 15 years of age, stop the interview here, and go to part V.
PART II PERSONAL DETAILS
11 W hat is your nationality? Gambian = 1 
Senegalese = 2 
Other = 3
» 1 3
» 1 3
12 Please specify your 
nationality.
N.A. = 88
13 W hat is your ethnic group? Mandinka=01
Manjago=07
Fula=02
Aku=08
Jola=03
Other=09
W olof=04
Serahuli=05
Serer=06
14 W hat is your religion? Muslim = 1 
Christian = 2 
Other = 3
15 W hat is your permanent 
area of residence?
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16 In which Division is this Greater Banjul = 01 URD =
address? 06
W D = 02 Outside Gambia = 07
LRD = 03 Not applicable = 88
NBD = 04 Unknown = 99
MID = CRD = 05
17 Is this address a rural or Rural = 1 Urban = 2 Unknown
an urban area? = 9
N.A.
= 8
18 What is your marital status? Single = 1 
Married = 2 
Divorced = 3 
Widowed = 4
»  31
19 How many spouses have you had in your 
life?
N.A. = 88 
I I I
20 How many spouses did you divorce? N.A. = 88
I I I
21 How many spouses of yours have died? N.A. = 88 
I I I
22 MARRIED MEN ONLY: How many 
spouses do you have at present?
N.A. = 88
I I I
PART III OCCUPATION, EDUCATION, TRAVEL
31 W hat is your occupation?
32 Have you had any Koranic 
education?
Yes = 1 
No = 2 »  34
33 How many years did you 
complete? N.A. = 88
I I I
34 Have you had any primary 
education?
Yes = 1 
No = 2 »  38
35 How many years did you 
complete? N.A. = 88
I I I
36 Have you had any secondary 
education?
Yes = 1 
No = 2 
N.A. = 8
»  38  
»  38
37 How many years did you 
complete? N.A. = 88 
I I I
38 Lanauaae Skills: Verv well A  bit Not at all
Can you read an English 
newspaper?
Can you speak English?
1 2 3 
1 2 3 
1 2 3
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Can you write English?
Can you read a French 
newspaper?
Can you speak French?
Can you write French?
1 2 3 
1 2 3 
1 2 3
39 Have you travelled outside The Yes = 1
Gambia during the last 10 years? No = 2
40 Have you stayed outside The Yes = 1
Gambia for longer than one week No = 2 »  51
at one time in the last 10 years? N.A. = 8 »  51
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OPDNO: |___|___|___|___| / 1___|___|___|___|
41. Indicate for all locations outside The Gambia where you stayed for longer than 
one week at a time, during the last 10 years:
Country/City Gode Year of last 
stay
How long did 
you stay?
Code
A
B
C
D
E
F
G
H
I
I
PART IV HEALTH & SEXUAL HISTORY
51 Have you ever had a blood transfusion? Yes = 1 
No = 2 
Unknown = 9
»  53  
»  53
52 When was the blood transfusion? 
(state year of last blood transfusion)
N.A.=8888
I I I I I
53 Have you been circumcised? Yes = 1 
No = 2 
Unknown = 9
»  56  
»  56
54 Where were you circumcised? Bush = 1 
Hospital/HG = 2 
Other = 3 
N.A. = 8
55 How old were you when you were 
circumcised? (age in completed years)
N.A. = 88
I I I
56 Have you ever had sexual intercourse? Yes = 1 
No = 2
Unknown = 9
»
part V  
»
part V
57 How old were you when you had your first 
sexual intercourse? (age in years)
N.A. = 88
I I I
58 How many different sexual partners have you 
had in your whole life?
N.A. = 88
I I I
59 Have you ever seen a condom? Yes = 1
No = 2 »  62
N.A. = 8 »  62
60 Have you ever used a condom? Yes = 1
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No = 2 
N.A. = 8 
Unknown = 9
»  62 
»  62 
»  62
61 How often did you use condoms while having 
sexual intercourse during the last 12 months?
Always = 1 
Mostly = 2 
Sometimes = 3 
Rarely = 4 
Never = 5 
N.A. = 8 
Unknown =9
62 Have you ever had a sexually transmitted 
disease?
Yes = 1 
No = 2 
N.A. = 8 
Unknown = 9
63 Have you ever had sexual intercourse in 
exchange for presents or money?
Yes = 1 
No = 2
Not applicable = 8 
Unknown = 9
64 Have you ever had sex with a prostitute? Yes = 1 
No = 2
Not applicable = 8 
Unknown = 9
65 Have you ever had sexual intercourse with 
another man?
Yes = 1 
No = 2
Not applicable = 8 
Unknown = 9
PART V INTERVIEW DETAILS (do not ask these questions to patient)
Other details:
Language of interview:.................................................................
Name of field worker:..............................................  Signature:
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APPENDIX 3
CONFIDENTIAL MRC G ENITO -URINARY CLINIC
SOCIAL HISTORY FORM FEMALE (NSH2f)
version 27th September 2000
PARTI KEY INFORMATION
1 OPDNO
I I I I I /
2 Sex Male = 1 
Female =2
3 Last Name
4 First Name
5 Date of interview (DD /  MM / 
YYYY) I I I  /  I I I  / 
I I
6 W hat is your age? (years)
I I I
7 Is an exact birth date available? Yes = 1 
No = 2 »
9
8 If yes, what is the exact birth 
date?
( D D / M M / Y Y Y Y )
N.A.=88
I I I/I I I/I I I I
9 Do you agree to participate in this 
study?
Yes = 1 
No = 2 >pa
rtV
If patient does not want to participate in the study, OR the patient 
is less than 15 years of age, stop the interview here, and go to part V.
PART II PERSONAL DETAILS
11 What is your nationality? Gambian = 1 
Senegalese = 2 
Other = 3
»  13 
»  13
12 Please specify your 
nationality.
N.A. = 88
13 What is your ethnic group? Mandinka=01
Manjago=07
Fula=02
Aku=08
Jola=03
Other=09
W olof=04
Serahuli=05
Serer=06
14 W hat is your religion? Muslim = 1
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Christian = 2 
Other = 3
15 W hat is your permanent 
area of residence?
16 In which Division is this 
address?
Greater Banjul = 01 URD = 
06
W D = 02 Outside Gambia = 07 
LRD = 03 Not applicable = 88 
NBD = 04 Unknown = 99 
MID = CRD = 05
17 Is this address a rural or 
an urban area?
Rural = 1 Urban = 2 Unknown 
= 9
N.A.
= 8
18 W hat is your marital status? Single = 1 
Married = 2 
Divorced = 3 
Widowed = 4
»  31
19 How many spouses have you had in your 
life?
N.A. = 88
I I I
20 How many spouses did you divorce? N.A. = 88
I L _ I
21 How many spouses of yours have died? N.A. = 88
I I I
23 MARRIED W O M EN ONLY: How many 
spouses does your husband have at 
present (including yourself)?
N.A. = 88
I I I
24 MARRIED W OM EN ONLY:
W hat is your rank among the wives?
N.A. = 88
I I I
PART III OCCUPATION, EDUCATION, TRAVEL
31 W hat is your occupation?
32 Have you had any Koranic 
education?
Yes = 1 
No = 2 »  34
33 How many years did you 
complete? N.A. = 88
I I I
34 Have you had any primary 
education?
Yes = 1 
No = 2 »  38
35 How many years did you 
complete? N.A. = 88
I I I
36 Have you had any secondary 
education?
Yes = 1 
No = 2 
N.A. = 8
»  38 
»  38
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37 How many years did you 
complete? N.A. = 88
I I I
38 Lanauaae Skills: Verv well A  bit Not at all
Can you read an English 
newspaper?
Can you speak English?
Can you write English?
Can you read a French 
newspaper?
Can you speak French?
Can you write French?
1 2 3 
1 2 3 
1 2 3
1 2 3 
1 2 3 
1 2 3
39 Have you travelled outside The 
Gambia during the last 10 years?
Yes = 1 
No = 2
40 Have you stayed outside The 
Gambia for longer than one week  
at one time in the last 10 years?
Yes = 1 
No = 2 
N.A. = 8
»  42  
»  42
210
OPDNO: |___|___|___|___| / 1___|___|___|___|
41. Indicate for all locations outside The Gambia where you stayed for longer than
one week at a time, during the Iasi 10 years:
Country/City Code Year of last 
stay
How long did you 
stay?
Code
A
B
C
D
E
F
G
H
1
J
42 MARRIED W OM EN ONLY:
W hat is your husband's occupation?
N.A. = 88
43 MARRIED W OM EN ONLY:
Has your husband travelled or lived 
outside The Gambia during the last 
10 years?
Yes = 1 
No = 2 
N.A. = 8 
Unknown = 9
»  51 
»  51
44 MARRIED W OM EN ONLY:
Has your husband stayed outside 
The Gambia for longer than one week 
at one time, during the last 10 years?
Yes = 1 
No = 2 
N.A. = 8 
Unknown = 9
»  51 
»  51 
»  51
45. MARRIED W OM EN ONLY: Indicate for all locations outside The Gambia where
your husband stayed for longer than one week at a time during the last 10 /ears:
Country/City Code Year of last 
stay
How long did he 
stay?
Code
A
B
C
D
E
PART IV HEALTH & SEXUAL HISTORY
51 Have you ever had a blood transfusion? Yes = 1 
No = 2 
Unknown = 9
»  53 
»  53
52 When was the blood transfusion? 
(state year of last blood transfusion)
N.A. = 8888
I I I I I
53 Have you been circumcised? Yes = 1 
No = 2 
Unknown = 9
»  56 
»  56
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54 Where were you circumcised? Bush = 1 
Hospital/HC = 2 
Other = 3 
N.A. = 8
55 How old were you when you were 
circumcised? (age in completed years)
N.A. = 88  
I I I
56 Have you ever had sexual intercourse? Yes = 1 
No = 2 
Unknown = 9
» p a r t
V
» p a r t
V
57 How old were you when you had your first 
sexual intercourse? (age in years)
N.A. = 88
I I I
58 How many different sexual partners have you 
had in your whole life?
N.A. = 88 
I I I
59 Have you ever seen a condom? Yes = 1 
No = 2 
N.A. = 8
»  62 
»  62
60 Have you ever used a condom? Yes = 1 
No = 2 
N.A. = 8 
Unknown = 9
»  62 
»  62 
»  62
61 How often did you use condoms while having 
sexual intercourse during the last 12 months?
Always = 1 Never = 5 
Mostly = 2 N.A. = 8 
Sometimes = 3 Unknown =9 
Rarely = 4
62 Have you ever had a sexually transmitted 
disease?
Yes = 1 
No = 2 
N.A. = 8 
Unknown = 9
63 Have you ever had sexual intercourse in 
exchange for presents or money?
Yes = 1 
No = 2
Not applicable = 8 
Unknown = 9
PART V INTERVIEW DETAILS (do not ask these questions to patient)
Other details:.........................................................................................................................
Language of interview:......................................................................................................
66. Is this patient a "professional"? Yes = 1  No = 2 Unknown=9 |___ |
Name of field worker:....................................Signature:..............................  |___ |___
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A P PEN D IX  4
MRC Study SCC048 OPDNO:|___ |___ |___ |___ |/|___ |___ |___ |___ |
Project title: Human leukocyte antigen (HLA) and killer immunoglobulin-like 
receptor (KIR) in HIV-2 infection: a key component to HIV vaccine design and 
its evaluation in Africa 
Participant Information sheet
AIDS is caused by a small germ, called HIV. Some people become ill within a few  
years of becoming infected, others may stay healthy for 0 or more years. Currently 
there is no cure for HIV infection. However, there are expensive drugs that can slow 
down the disease and these are now available in The Gambia.
The MRC has been studying HIV infections for many years. W e are investigating the 
body's defences against this infection. W e do this by using a small amount of blood in 
tests in the laboratory, which reveal whether the defence system is strong or weak, 
and over time, whether it is maintaining its strength or is losing power. Because the 
immune system is a complicated system, there are many different tests that can be 
done. New tests are developed every year. W e hope that these various studies will 
lead to the development of a vaccine in the long run. A  good vaccine would prevent 
infection with HIV, or prevent the development of disease, including AIDS.
W e invite you to enrol in one of our studies, which is designed to research on why 
some people might be more susceptible to HIV-2 infection than others and why some 
infected individuals progress faster with the disease than others. Part of the reason 
could be that some people are born with a better ability to fight infection than others; 
such differences are called genetics. The blood sample you are about to give for your 
HIV screening will help us to determine your HIV status and if negative, what remains 
of the blood sample will be used for this study and future genetic studies that could 
help in understanding why some people might be more susceptible to infection or are 
at risk of progressing faster than others once infected. W e will offer you the usual 
M RC clinical care when you are ill and provide you with medication as needed, both 
free of charge. Taking this amount of blood, which is less than teaspoon is completely 
safe, and will not make you sick.
The study and investigations have been approved by the Gambia Government/MRC  
Joint Ethical Committee. Participation in this study is voluntary. If you agree to join the 
study, but change your mind later, and want to withdraw from the study, you are free 
to do so at any time.
The doctors and scientists of the study will have access to information about you and 
your condition, but apart from these people no one else will. Your files are locked 
away in a safe place and no outsider will have access.
You are not obliged to provide the blood sample, and you are completely free to 
decline this every time when it is asked; this will not affect the usual care you get from 
the MRC clinicians. If you do not understand this information, or you have any other 
concerns on this study, you can discuss this with Mr. Louis Marie Yindom.
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Do you have any questions?......................
S ignature:............................................................. thumbprint:
Date  ...................................................
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A P PEN D IX  5
MRC Study SCC1048 OPDNO:|___ |___ |____|___ |/ 1__ |___ |___ |___ |
Project title: Human leukocyte antigen (HLA) and killer immunoglobulin-like 
receptor (KIR) in HIV-2 infection: a key component to HIV vaccine design and 
its evaluation in Africa
Consent Form
Do you agree to enter the study? .......................
I...............................................................  (clinician/counsellor) have read and
explained the information as is in the “Participant Information Sheet” of this study to 
this participant in a language familiar to him/her.
Signature:...................................................  D a te .................................. ......................
I,   have read/been explained the information
from the “Participant Information Sheet” of the above mentioned study and I 
understand the information. I agree to participate in the study. I understand that I can 
withdraw from the study at any time, without needing to give reasons, and without this 
affecting the usual care I receive at the MRC.
Signature:............................................... thumbprint:
Date................................................................
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APPENDIX 6
Medical Research Council Laboratories and Proiecto de Saude Bandim
Invitation to the Caio Case Control cohort 
Subject Information Sheet
You have been given this sheet because you are invited to participate in the 
Caio Cohort. Please take time to read the following information. Please ask if 
there is anything that is not clear or if you would like to know more. Thank you 
for your time.
The Caio Field Station
The Bandim Health Project has been situated in Caio since 1989. The project 
provides health care linked to research and works closely with the Medical Research 
Council in The Gambia. A small group of fieldworkers, nurses, laboratory technicians, 
and doctors work at the project. They provide different services: continuous census, 
follow-up of children and pregnant women, accessibility to a doctor, transport for 
medical evacuation to Canchungo, malaria tests. In the past, we have been involved 
in different studies, for example Stepping Stones, Mother and Child Study, Case- 
Control Studies, Trachoma Study. The information we collect in these studies helps 
us to improve health care in general and specifically in Caio.
The Caio Case Control Cohort
W e would like to invite you to the Caio Case Control cohort. This cohort is a 
group of about 600 adult people of which some are HIV positive and some are HIV  
negative. W e have followed these people in our clinic and they have participated in 
different studies. All people in the Cohort receive a Green Card with their name, ID 
and photo. With this card, the person can come to visit the project and receive free 
medical care, medication and specialized treatment at referral hospitals if necessary. 
Last year and this year, a study was done in all the adults in Caio to see how many 
people are now infected with HIV. Unfortunately, many new people have become 
infected with HIV and we want to offer health care to these people.We are inviting 
both HIV positiveand HIV negative people. When you are part of the cohort, you 
might be asked to participates future scientific studies. Participation in these studies 
will be completelyvoluntary. Not participatingwill not affect receiving a green card or 
free access to free healt care.
The reason that a fieldworker is reading this information sheet to you is because we  
would like you to become a member of the cohort. The project's field workers do not 
know your status. You decide if you want to know your HIV result or not. If you would 
like to know your status, you can ask one of our conselors to counsel you abou your 
result.
If you want to participate, we would like you to sign a Consent Form, to know 
that you have understood all the information. After signing we will invite you to come 
visit the Project. There you will be registered and you will receive your personal 
Green Card. Then you will be seen by Dr. Carlos da Costa who will examine you and 
prescribe medication if necessary. He will ask you for a 5ml of blood donation, some 
of which will be used for your personal care and some for storage for future studies. 
The Field station doctor can ask you to donate 5ml of blood in de future for your
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clinical follow-up. Agin, a portion of the follow-up samples would be stored for future 
research. These bood samples are very valuable and could help improve our 
knowledge of VIH.the aim of this knowledge is to contribute to beter care for people 
infected with HIV. You are free to participate or not and this will not affect your Green 
Card and your free access to health care.
HIV
The Human Immunodeficiency Virus (HIV) is a virus that can cause AIDS, a 
deadly disease for which there is presently no cure. The virus can pass to someone 
who is not infected through sexual intercourse with an infected person, by direct 
contact with blood from an infected person, and from infected mothers during 
childbirth and breastfeeding. People can protect themselves against HIV using 
condoms during sexual intercourse, by avoiding direct contact with blood of other 
people, or using unsterilized razor blades or needles that have been used by others.
The most common virus causing AIDS is HIV-1, but a HIV-2, a similar virus, is 
more common in Caio than HIV-1. HIV-2 can cause AIDS as well, but not in all 
people. In addition, some people are exposed to HIV-1 and/or HIV-2 but don’t get 
infected with the virus and some people who are infected but do not develop AIDS for 
a very long time. No one knows why some people are naturally protected from 
disease or why HIV-1 and HIV-2 are so different.
The Guinean Government is offering drug treatment for people that have an 
advanced stage of HIV disease. These drugs cannot completely cure AIDS but can 
offer a productive and an almost normal life. These drugs are now also available in 
Caio and people are being treated with them by the Project’s physician.
Contact for further details: Tim Vincent, Carlos da Costa, Carla van Tienen, 
Aleksandra Leligdowicz, Thushan de Silva
Medical Research Council Laboratories and Proiecto de Saude Bandim
Caio Case Control cohort 
Consent Form
I have read the Information Sheet/The Information Sheet has been read to me.
I have understood the Information Sheet and I have had an opportunity to ask 
questions and have them answered.
I understand what participation in the Caio Case Control cohort means for me.
I understand that both HIV positive and HIV negative people are members of the Caio 
Cohort.
I understand that I receive a Green Card, with which I have access to free medical 
care and medication if I get sick.
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I understand that I have certain rights as a member of the Caio Cohort, as stated in 
the “Caio Cohort: Rights” (see Annex)
I give consent to participate in the Caio Cohort
Signature or index finger print of participant:
This form has been read by/l have read the above to:
(name of participant) in the language that he/she understands.
I believe that he/she understood what I have explained and that he/she has freely 
agreed to take part in the study.
Name of counsellor:______ __________________
Signature of counsellor:___________________________ _
Name of witness: _________________________
Signature of witness: ____________________________
Date: | | | / 1 | | /  l _ | _ l _ l _ l
For further information contact:
Carlos da Costa, Tim Vincent, Sarah Rowland-Jones, Carla Van Tienen, Aleksandra
Leligdowicz, Thushan de Silva
Address:
Prof Sarah Rowland-Jones 
MRC Laboratories, Fajara 
Atlantic Road, PO Box 273  
The Gambia, West Africa 
Tel: +220 449 6188 (the Gambia)
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APPEN D IX  7
MRC Study SCC1048
Project title: Human leukocyte antigen (HLA) and killer immunoglobulin-like 
receptor (KIR) in HIV-2 infection: a key component to HIV vaccine design and 
its evaluation in Africa
SPECIMEN REQUEST FORM
Hospital number:
Last N am e:--------------------------------------------------------------------
First N am e:--------------------------------------------------------------------
S e x :----------------------------------------------- A g e :-------------Years
Date of sample collection:---------------------------------------------
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APPENDIX 8
S0PL1 - Salting-out technique 
DAY ONE
Sample recording
Record the sample details (out patient department (OPD) number and the lab
number) on the record sheet
Label a 50 ml falcon tube for each sample
LYSING OF RBCs
Carefully transfer the sample into the labelled falcon tube 
Vortex vigorously (60-90 seconds)
Add TE 20-5 pH 8.0 buffer up to the 40 ml mark 
Mix by inverting the tube several times 
Allow to stand on ice for 15 minutes 
Centrifuge at 3500 rpm for 15 minutes
Carefully remove the supernatant (with 25 ml pipette) without disturbing the white cell 
pellet
Vortex vigorously (60-90 seconds)
Add more TE 20-5 pH 8.0 buffer up to 40 ml mark 
Vortex to mix (20 seconds)
Centrifuge at 3500 rpm for 15 minutes
Repeat washing (from step 10) until the white cell pellet is clean (appearing pinkish or 
white). NB: if the pellet is still not clean after 5 wash, add 20 ml sterile distilled water 
+ 20 ml TE 20-5 pH 8.0 for an additional wash.
LYSING OF WBCs
After the final wash, vortex vigorously (90-120 seconds) or until no clump is seen in 
the tube
Add 2 ml of TE 20-5 pH 8.0 buffer
Add 100 pi of 20%  SDS (final concentration = 1%)
Mix gently by inverting the tube several times
PROTEIN DIGESTION
Remove the proteinase-K (10 mg/ml solution) from the freezer only when ready to 
use and allow to thaw (preferably on ice)
Add 20 pi of proteinase K (10 mg/ml solution)
Return the proteinase-K immediately into the freezer
Gently invert the tube several times to mix
Place in a shaking water bath at 42°C
Incubate overnight and/or until no pellet is seen in the tube
DAY TWO
Remove samples from the water bath and allow to cool to room temperature 
Add 2.5 ml of 7.5 M ammonium acetate solution
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Mix gently by inverting the tube several times and place on ice.
Add 10 ml of ice cold absolute ethanol into each tube
Invert the tube several times to precipitate the DNA-ammonium salt complex out of 
the solution. A  whitish thread will be seen floating in the solution and immediately 
settles to the bottom of the tube upon standing
If the yield is not satisfactory, keep the tubes in -2 0 °C  freezer for 1-2 hours (optional 
step)
Centrifuge at 5000 rpm for 30 minutes
Remove the supernatant without disturbing the DNA pellet at the bottom of the tube 
Drain the remaining solution from the pellet by inverting the tube over a dry absorbent 
tissue briefly
Add 4 ml of sterile TE 20-5-NaCI 0.2M pH 8.0 
Vortex briefly (5-10 seconds)
Re-dissolve the DNA in a shaking water bath at 42°C until fully dissolved 
Remove from the water bath and allow to cool on ice
Re-precipitate the DNA in 8 ml of ice cold ethanol (the cooler the ethanol the better) 
Centrifuge at 5000 rpm for 30 minutes
Remove the supernatant carefully without disturbing the pellet and gently invert the 
tube over a dry absorbent tissue while watching your pellet making sure it doesn’t 
float out of the container during the draining process
Allow to air dry until no fluid is seen by the sides of the tube, then turn tubes upright 
for complete evaporation of ethanol.
Add 150 pi of TE 20-1 buffer in each tube and adjust the volume for bigger pellet 
Incubate in a water bath at 58°C overnight to re-dissolve. NB: do not shake.
Label a 1.5 ml eppendorf tube as follows: by the side -  study, lab number and date; 
on the lid -  lab number.
Remove tubes with DNA from the water bath, spin briefly at 1000 rpm and transfer 
the DNA into labelled Eppendorf vials.
Quantify the DNA using the Nanodrop instrument and store at +4 °C for immediate 
use or -20 °C for future use
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APPENDIX 9
List of KIR primers (SCC1048)
PRIMER Primer Sequence Number Synthesis Purification
Name of bases scale Method
K1 5'- gTT ggT CAg ATg TCA TgT TTg AA 23 0.2 pM HPLC & desalted
K2 5'- ggT CCC TgC CAg gTC TTg Cg 20 0.2 gM HPLC & desalted
K3 5'- Tgg ACC AAg AgT CTg CAg gA 20 0.2 gM HPLC & desalted
K4 5'- TgT TgT CTC CCT AgA AgA Cg 20 0.2 gM HPLC & desalted
K5 5'- CTg gCC CAC CCA ggT Cg 17 0.2 gM HPLC & desalted
K6 5'- ggA CCg ATg gAg AAg TTg gCT 21 0.2 gM HPLC & desalted
K7 5'- gAg ggg gAg gCC CAT gAA T 19 0.2 gM HPLC & desalted
K8 5'- TCg AgT TTg ACC ACT CgT AT 20 0.2 gM HPLC & desalted
K9 5'- CTT CAT CgC Tgg TgC Tg 17 0.2 gM HPLC & desalted
K10 5 - Agg CTC TTg gTC CAT TAC AA 20 0.2 gM HPLC & desalted
K11 5'- TCC TTC ATC gCT ggT gCT g 19 0.2 gM HPLC & desalted
K12 5'- ggC Agg AgA CAA CTT Tgg ATC A 22 0.2 gM HPLC & desalted
K13 5'- CAg gAC AAg CCC TTC TgC 18 0.2 gM HPLC & desalted
K14 5'- CTg ggT gCC gAC CAC T 16 0.2 gM HPLC & desalted
K15 5'- ACC TTC gCT TAC AgC CCg 18 0.2 gM HPLC & desalted
K16 5'- CCT CAC CTg TgA CAg AAA CAg 21 0.2 gM HPLC & desalted
K17 5'- TTC TgC ACA gAg Agg ggA AgT A 22 0.2 gM HPLC & desalted
K18 5'- ggg TCA CTg ggA gCT gAC AA 20 0.2 gM HPLC & desalted
K19 5'- Cgg gCC CCA Cgg TTT 15 0.2 gM HPLC & desalted
K20 5'- ggT CAC TCg AgT TTg ACC ACT CA 23 0.2 gM HPLC & desalted
K21 5'- Tgg CCC ACC CAg gTC g 16 0.2 gM HPLC & desalted
K22 5 - TgA AAA CTg ATA ggg ggA gTg Agg 24 0.2 gM HPLC & desalted
K23 5'- CTA TgA CAT gTA CCA TCT ATC CAC 24 0.2 gM HPLC & desalted
K24 5'- AAg CAg Tgg gTC ACT TgA C 19 0.2 gM HPLC & desalted
K25 5’- CTg gCC CTC CCA ggT CA 17 0.2 gM HPLC & desalted
K26 5'- TCT gTA ggT TCC TgC AAg gAC Ag 23 0.2 gM HPLC & desalted
K27 5'- gTT CAg gCA ggA gAg AAT 18 0.2 gM HPLC & desalted
K28 5'- gTT TgA CCA CTC gTA ggg AgC 21 0.2 gM HPLC & desalted
K29 5'- TgA Tgg ggT CTC CAA ggg 18 0.2 gM HPLC & desalted
K30 5'- TCC AgA ggg TCA CTg ggC 18 0.2 gM HPLC & desalted
K31 5'- CTT CTC CAT CAg TCg CAT gAA 21 0.2 gM HPLC & desalted
K32 5'- CTT CTC CAT CAg TCg CAT gAg 21 0.2 gM HPLC & desalted
K33 5'- AgA ggg TCA CTg ggA gCT gAC 21 0.2 gM HPLC & desalted
K34 5'- CgC TgT ggT gCC TCg A 16 0.2 gM HPLC & desalted
K35 5'- ggT gTg AAC CCC gAC ATg 18 0.2 gM HPLC & desalted
K36 5'- CCC Tgg TgA AAT CAg gAg AgA g 22 0.2 gM HPLC & desalted
K37 5'- TgT Agg TCC CTg CAA ggg CAA 21 0.2 gM HPLC & desalted
K38 5'- CAA ACC CTT CCT gTC TgC CC 20 0.2 gM HPLC & desalted
K39 5'- gTg CCg ACC ACC CAg TgA 18 0.2 gM HPLC & desalted
K40 5'- CCC ATg AAC gTA ggC TCC g 19 0.2 gM HPLC & desalted
K41 j 5'- CAC ACg CAg ggC Agg g 16 0.2 gM HPLC & desalted
K42 5'- AgC CTg CAg ggA ACA gAA g 19 0.2 gM HPLC & desalted
K43 5'- gCC TgA CTg Tgg TgC TCg 18 0.2 gM HPLC & desalted
K44 5'- CCT ggT gAA ATC Agg AgA gAg 21 0.2 gM HPLC & desalted
K45 5'- gTC CCT gCA Agg gCA C 16 0.2 gM HPLC & desalted
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K50 5- gCg CTg Tgg TgC CTC g 16 0.2 gM HPLC & desalted
K51 5'- gAC CAC TCA ATg ggg gAg C 19 0.2 gM HPLC & desalted
K52 5'- TgC AgC TCC Agg AgC TCA 18 0.2 gM HPLC & desalted
K53 5'- ggg TCT gAC CAC TCA TAg ggT 21 0.2 gM HPLC & desalted
K54 5'- gTC TgC CTg gCC CAg CT 17 0.2 gM HPLC & desalted
K55 5'- gTg TgA ACC CCg ACA TCT gTA C 22 0.2 gM HPLC & desalted
K56 5'- CCA TCg gTC CCA TgA Tgg 18 0.2 gM HPLC & desalted
K57 5'- CAC Tgg gAg CTg ACA ACT gAT g 22 0.2 gM HPLC & desalted
K58 5'- ACA gAg Agg ggA CgT TTA ACC 21 0.2 gM HPLC & desalted
K59 5’- ATg TCC AgA ggg TCA CTg gg 20 0.2 gM HPLC & desalted
K60 5'- gTC Agg ACA AgC CCT TCC TC 20 0.2 gM HPLC & desalted
K61 5 - gAg TgT ggg TgT gAA CTg CA 20 0.2 gM HPLC & desalted
K62 5'- TTC TgC ACA gAg Agg ggA TCA 21 0.2 gM HPLC & desalted
K63 5'- gAg CCg ACA ACT CAT Agg gTA 21 0.2 gM HPLC & desalted
C1 5'- TgC CAA gTg gAg CAC CCA A 19 0.2 gM HPLC & desalted
C2 5'- gCA TCT TgC TCT gTg CAg AT 20 0.2 gM HPLC & desalted
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APPEN D IX  10
Primer mix worksheet for KIR typing by PCR-SSP (SCC1048)
Lane Primer mix F. primer VoI(mI) R. primer VoI(mI) C1+C2 Water
1 KM1 K1 50 K2 50 50 850
2 KM2 K3 50 K4 50 50 850
3 KM3 K5 50 K6 50 50 850
4 KM4 K7 50 K8 50 50 850
5 KM5 K9 50 K10 50 50 850
6 KM6 K11 50 K12 50 50 850
7 KM7 K13 50 K14 50 50 850
8 KM8 K15 50 K16 50 50 850
9 KM9 K17 50 K18 50 50 850
10 KM10 K19 50 K20 50 50 850
11 KM11 K21 50 K22 50 50 850
12 KM 12 K23 50 K24 50 50 850
13 KM13 K25 50 K26 50 50 850
14 KM14 K27 50 K28 50 50 850
15 KM15 K29 50 K30 50 50 850
16 KM16 K58 50 K59 50 50 850
17 KM17 K34 50 K35 50 50 850
18 KM18 K36 50 K37 50 50 850
19 KM19 K38 50 K39 50 50 850
20 KM20 K40 50 K41 50 50 850
21 KM21 K42 50 K43 50 50 850
22 KM22 K44 50 K45 50 50 850
23 KM23 K60 50 K61 50 50 850
24 KM24 K62 50 K63 50 50 850
25 KM25 K50 50 K51 50 50 850
26 KM26 K52 50 K53 50 50 850
27 KM27 K54 50 K55 50 50 850
28 KM28 K56 50 K57 50 50 850
29 KM29 K31 50 K32+K33 100 50 800
30 C C1 50 C2 50 900
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A P PEN D IX  11
S0PL2: KIR Typing protocol by PCR-SSP (SCC1048)
Master mix
|j|/plate(12 samples)
D/water 1370.33
10X buffer 214.50
MgCI2 (50m M) 64.35
dNTPs (25m M) 17.16
Taq polymerase 10.725
Add 129 pi of this master mix into an 0.5 ml eppendorf tube containing 3 pi of DNA  
(50 ng/pl)
Add primer mixes into 30 wells of the thermowell plate using a multichannel pipette 
Primer mix 1 pl/well
Dispense 4 pi of the mega mix into wells containing the primer mix 
Total volume should be 5 pi.
Seal the plate, centrifuge briefly (1000 rpm for 1 minutes)
Load the plate into the PTC-200 thermal cycler (MJ Research, USA)
Run the program labeled “KIR”
Amplification condition
1 cycle 94 °C 3:00
5 cycles 94 °C 0:15 65 °C 0:15 72 °C 0:30
21 cycles 94 °C 0:15 60 °C 0:15 72 °C 0:30
5 cycles 94 °C 0:15 55 °C 1:00 72 °C 2:00
1 cycle 72 °C 7:00
Prepare a 3% agarose gel as bellow and allow to solidify
Agarose gel preparation
Agarose powder 12 g
0 .5 .  TBE buffer 400 ml
1. Mix and heat in a microwave at full power for 4.5 minutes
2. Allow to cool rapidly in water
3. Add 8 pi of Ethidium bromide (10gm/ml)
4. Mix and pour onto a casting tray with sealed edges
5. Put the combs in place and allow to set.
Gel electrophoresis
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Add 2.5 pi of loading buffer into each well containing the PCR products and load 7 pi 
of the mixture into the corresponding well of the agarose gel. Connect the gel tank to 
the power pack and run at 220 V  for 30 minutes.
Gel Photography
Cut the gel to size and place on the UV light box.
Position the Kodak Digital Gel Documentation Camera in place and take the gel 
picture.
Save the gel picture in the designated location in the computer.
Copy and paste each sample picture onto the word document template for 
subsequent interpretation.
Gel Interpretation
Adjust the gel picture to match the lanes on the template.
Score one (1) if the specific band is present and zero (0) if it is absent. Note: The 
specific band is the second band after the control band and any band in lane 6 should 
be the specific band (no control introduced here).
Save the word document with the corresponding sample IDs.
Data entry
Enter the results into Microsoft Access data base designed for this project and pass 
the gels to the data office for second entry.
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Sample of KIR gel interpretation sheet
Cohort FAJARA
Study EDCTP
ID Number xxxx
DNA Number YYYYY
Date Xx/xx/2006
Control Specific
Lanes
1 2 3 4 5 6 7 8
Gene Result Lane Size
2DL1 1 7 146
1 2 330
2DL2 0 3 173
0 4 151
2DL3 1 5 550
1 6 800
2DL4 1 7 254
1 8 288
2DS2 0 9 175
0 70 240
2DS3 0 f f 242
0 12 190
2DS4 1 13 204
0 14 197/219
2DS5 0 15 126
0 16 178
3DL1 1 17 191
1 18 186
3DL2 1 19 211
1 20 130
3DS1 0 21 300
0 22 180
3DL3 1 23 112
1 24 190
2DL5 0 25 214
0 26 191
2DP1 1 27 205
1 28 89
2DS1 0 29 102
C 0 C 796
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APPENDIX 13
List of primers for HLA typing by sequencing
PCR primers:
HLA-A: ccc aga cgc cga gga tgr csg 
HLA-A: gca ggg egg aac etc aga gtc act etc t 
HLA-B: tec cag ttc taa agt ccc cac g 
HLA-B: tcc att caa ggg agg geg ac 
HLA-C: age gag gkg ccc gee egg cga 
HLA-C: gga gat ggg gaa ggc tcc cca ct
Sequencing primers:
HLA-A: gga tct egg acc egg ag 
HLA-A: gtt tag gee aaa aat yee cc 
HLA-B: gga tct egg acc yrg ag 
HLA-B: acc egg ttt cat ttt cag ttg a 
HLA-C: cga ccc ggg ccg tc 
HLA-C: gee aaa ate ccc geg ggt tgg t
(Fwd)
(Rev)
(Fwd)
(Rev)
(Fwd)
(Rev)
exon2 Rev 
exon3 Fwd 
exon2 Rev 
exon3 Fwd 
exon2 Rev 
exon3 Fwd
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HLA sequencing Protocol
HLA class I buffer preparation (10X buffer)
Trizma base 40.568 g
Ammonium Sulphate 10.96 g 
Tween 20 5 ml
Dissolve the Trizma base in 400 ml of sterile distilled water and adjust the pH to 8.8 
with concentrated HCI
Add the ammonium sulphate into the solution and mix to dissolve 
Pass the mixture through a 22 pm filter into a clean sterile bottle 
Add Tween 20 and make up the volume to 500 ml with sterile d/water
HLA PCR
Master mix pl/rxn
Class I buffer 2.0
dNTPs (10 uM) 0.4
MgCI2 (25 mM) 1.6
Primer (F) 0.4
Primer (R) 0.4
100X B S A (optional) 0.2
DMSO (optional) 1.0
Taq polymerase 0.2
Total 6.2
DNA (150 ng) + D/w 13.8
Final volume/rxn 20
Primers
A 1: ccc aga cgc cga gga tgr csg (F)
A4: gca ggg egg aac etc aga gtc act etc t (R)
B 1: tcc cag ttc taa agt ccc cac g (F)
B4: tcc att caa ggg agg geg ac (R)
C l: age gag gkg ccc gcc egg cga (F)
C4: gga gat ggg gaa ggc tcc cca ct (R)
Amplification conditions
HLA-A locus (HLAASEQ)
1 cycle 96 °C 2:00
30 cycles 96 °C 0:25 60 °C 0:25 72 °C 1:00
1 cycle 72 °C 7:00
1 cycle 4 °C oo
HLA-B locus (HLABSEQ)
1 cycle 96 °C 2:00
40 cycles 96 °C 0:15 62 °C 0:15 72 °C 1:00
1 cycle 72 °C 7:00
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1 cycle 4 °C oo
HLA-C locus (HLACSEQ) 
1 cycle 96 °C 2:00
30 cycles 96 °C 0:25 70 °C 0:25 72 °C 1:00
1 cycle 72 °C 7:00
1 cycle 4 °C oo
EXO-SAP cleaning
Per reaction
Exo I 
SAP 
W ater
0.5 jul 
0.5 pi 
4.0 pi
PCR product 5.0 pi (10.0 if band is weak)
Add exonuclease I, SAP and sterile (XQH2O in a sterile vial and mix. Make enough for 
all the samples plus 10% to care for pipetting errors 
Dispense 5 pi of the mixture into wells of a 96-well plate
Add the PCR products, mix by pipetting up-and-down, seal with and adhesive film 
and centrifuge briefly
Place in the thermal cycler and run the EXOSAP programme
Cycling conditions (EXOSAP programme)
37 °C 1 hr 15 mins
80 °C 20 mins
Alternative PCR cleaning protocol (AMPURE)
You will need:
Freshly prepared 70% ethanol
Sterile water or TE
Tips
Multichannel pipette
Gently mix the Ampure reagent by inverting several times at room temperature
Add 18 pi of Ampure into 10 pi of PCR products
Pipette mix 10 times or vortex for 30 seconds
Allow to stand at room temperature for 5 minutes
Place on the plate magnet for up to 5 minutes
Completely aspirate the clear solution from the bottom of the well and discard while 
the plate is still on the magnet
Procedure
230
Add 200 jj I of 70% ethanol (freshly prepared) into each well and wait for 30 seconds 
(plate should still be on the magnet)
Completely aspirate the alcohol from the bottom of the well and discard while the 
plate is still on the magnet 
Repeat 7-8
Place the plate on the bench to completely air dry (15-20 minutes)
Add 40 pi of sterile water or TE to elute and pipette mix 10 times or seal and vortex 
for 30 seconds, (if smaller volume is used, make sure you vortex well to contact the 
ring of beads)
Place the plate on the magnet for 5 minutes and transfer 35 pi into a new plate.
Sequencing reaction
D/water
Vol/rxn (pi) 
5.36
5X buffer 2.07
BigDye v1.1 (or 3.1) 0.25
Primer (10 uM) 0.32
Total 8.0
PCR products 2.0
Seq Primers
A2: gga tct egg acc egg ag ex2
A3: gtt tag gcc aaa aat yee cc ex3
B2: gga tct egg acc yrg ag ex2
B3: acc egg ttt cat ttt cag ttg a ex3
C2: cga ccc ggg ccg tc ex2
C3: gcc aaa ate ccc geg ggt tgg t ex3
Add 2.0 of the PCR products to their respective wells 
Add 8.0 pi of the cocktail into each well 
Mix briefly and centrifuge briefly
Load onto the thermal cycler and run the SEQ programme 
Sequencing cycling conditions (SEQ)
96 °C 
96 °C
50 °C 5 sec 30 cycles
60  °C
4  °C oo
Making the G-50 microtiter plate
1 min 
10 sec 
sec 
4 mins
Add the G-50 powder onto the black plate (Multiscreen Column Loader), spray over
to fill in the number of wells needed using the Multiscreen Loader Scraper
Put back the excess powder into its container
Place the Multiscreen plate (M AHVN4510) in position
Turn the black plate up-side-down on the Multiscreen plate
Tap gently on the black plate to transfer G-50 powder into the corresponding wells of 
the 96-well plate
Remove the black plate and add 300 pi of water into each well containing the G-50  
powder
Allow to sit at room temp for at least 2 hours. This can be kept in the fridge for several 
days (seal to avoid evaporation)
Centrifugation
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Place the G-50 plate on a 96-well U or V  bottom plate and centrifuge at 2300 rpm for 
5 minutes to remove water from the G-50. Use frame alignment between the two 
plates if needed and make sure you balance the plates in the centrifuge 
Wash the column twice to remove particles by adding 150 pi of water and centrifuge 
as above
Add 5 pi of water into each well containing the PCR product
Label a new sequencing plate with the plate ID (this label should match with Excel 
spreadsheet to be submitted electronically)
Place the G-50 plate on the labelled sequencing plate
Gently add 11 pi of product into the G-50 plate (avoid touching the G-50 with the 
pipette tips), cover the plate and hold the two plates together by tapping their sides 
with brown adhesive tape
Centrifuge at 2300 rpm for 5 minutes (this process filters out the products into the 
corresponding well of the sequencing plate while holding back excess BDT and 
primers)
Drying of samples for sequencing
Place the sequencing plate containing the products in the thermal cycler 
Cover with a light wipe to avoid anything dropping accidentally into the wells 
DO NOT close the lid
Run the programme DRY, which is set at 90°C for 20 minutes 
Denaturation
Add 10 pi of HiDi formamide into each well containing the sequencing product 
Seal with adhesive film, vortex briefly, place in the thermal cycler and run the 
programme DENATURE, which is set at 90°C for 2 minutes 
Remove, centrifuge briefly and submit for loading into the 3130x1 DNA Analyzer 
Make a new excel file with the same name as on the sequencing plate by filling the 
“User’s template” in \\Falcon\SequenceAnalvzer
Fill in the sample IDs to match with their corresponding positions on the 96-well 
sequencing plate and submit for loading into the 3130x1 instrument.
Alternative cleaning “Cleanseq” procedure
You will need:
Freshly prepared 85% ethanol
Sterile water or TE
Tips
Multichannel pipette 
Procedure
Gently mix the CleanSeq reagent by inverting several times at room temperature 
Add 10 pi of CleanSeq into 10 pi of sequencing products
Add 42 pi of 85% ethanol into each well [or V  = 2.077 x (sample vol + 10) if different 
sample volume is used] NB: use freshly prepared 85% ethanol
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Pipette mix 7 times
Place on the magnet for 5 minutes
Completely aspirate the clear solution from the bottom of the well and discard while 
the plate is still on the magnet
Add 100 pi of 85% ethanol into each well and wait for 30 seconds (plate should still 
be on the magnet)
Completely aspirate the alcohol from the bottom of the well and discard while the 
plate is still on the magnet 
Repeat 7-8
Allow to air dry for 10 minutes at room temperature
Add 40 pi of sterile water and allow tostand on the magnet for 5 minutes, (if smaller 
volume is used, make sure you vortex well to contact the ring of beads)
Transfer 30-35 pi into the sequencing plate, seal, label and submit for analysis on the 
3130x1 instrument as usual
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Abstract
Overall, the time to AIDS after HIV-2 infection is longer than with HIV-1 and many 
individuals infected with HIV-2 vims remain healthy throughout their lives. Multiple HLA 
and KIR gene products have been implicated in the control o f HIV-1 but the effect o f variation 
at these loci on HIV-2 disease is unknown. Here we show for the first time that HLA-B* 1503 
associates significantly with poor prognosis after HIV-2 infection and HLA-B*0801 associates 
with susceptibility to infection. Interestingly, previous data indicate that HLA-B* 1503 
associates with low viral loads in HIV-1 clade B-infection, but has no significant effect on 
viral load in clade C infection. In general, alleles strongly associated with HIV-1 disease 
showed no effect in HIV-2 disease. These data emphasize the unique nature o f  the effects o f  
HLA mdHLA/KIR  combinations on HIV-2 immune responses relative to HIV-1, which could 
be related to their distinct clinical course.
Word count: 147
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Introduction
Since its first report in 1986, HIV-2 remains largely confined to West Africa (1). It 
shares between 30-60% nucleotide and amino acid homology with HIV-1 but differs greatly in 
pathogenicity and transmissibility (2). Studies on HIV-2 patients across West Africa have 
shown that some people remain uninfected despite repeated exposure (3) and a substantial 
proportion o f infected people remain relatively healthy for a very long time with low plasma 
viral load and normal CD4+ T cell counts, a characteristic o f long-term non-progressors 
(LTNPs) infected with HIV-1 (4). This is perhaps a reflection o f an effective immune 
response mounted against the virus including a vigorous CD8+ T-cell response (5), 
maintenance o f HIV-specific CD4+ T-cell function (6), and the presence o f a strong 
neutralizing antibody response in many subjects (7), features that are highly desirable for a 
successful HIV-1 vaccine. Thus, HIV-2 disease course provides a natural model for 
investigating mechanisms that control HIV infection and a better understanding o f  these 
mechanisms might inform new strategies for HIV prevention and treatment.
HLA class I molecules present antigenic epitopes to cytotoxic T cells and are central to 
the acquired immune response. A  number o f  associations between HLA class I alleles and 
HIV disease outcomes have been reported (8), the most consistent being B*57 and 5*27, 
which show strong protection across studies, and certain subtypes o f B *35, which associate 
with more rapid progression (9). While several mother-infant studies have implicated sharing 
o f certain HLA alleles in transmission o f the virus from mother to infant (10, 11), there is no 
convincing data that particular HLA class I alleles protect against HIV infection in general.
HLA class I allotypes also serve as ligands for killer cell immunoglobulin-like 
receptors (KIR), which modulate natural killer (NK) cell function. KIRs are structurally 
similar to one another and can be divided into activating and inhibitory receptors. NK cells 
are key components o f the innate immune system and constantly survey host cell surfaces for
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appropriate levels o f  HLA class I molecules through a network o f  NK cell receptors, including 
KIR (12). Upon engagement with their ligand, inhibitory KIR suppress NK cell activity, but if  
the ligand is missing or has been down regulated on target cells, the threshold for NK cell 
activation is lowered thus allowing for activation signals to dominate (13).
HLA and KIR genes are found on chromosomes 6 and 19, respectively, so they 
segregate independently. As such, the genes/alleles for the corresponding receptor/ligand pair 
must be present to confer functionality, whereas presence o f one without the other results in a 
null phenotype. A  number o f HLA and KIR gene products either individually or collectively 
has been implicated in the control o f HIV-1 (14), but nothing is known o f their role in HIV-2.
Epidemiological data from Caio and other cohorts in West Africa (15, 16) indicate that 
HIV-2 infection in a substantial proportion o f infected individuals is compatible with normal 
survival and without signs o f immunodeficiency, suggesting distinct viral pathogenic 
mechanisms and protective host factors against HIV-2 relative to HIV-1. Here we determined 
the HLA class I and KIR gene profiles o f  the Caio population (>95% Manjako) and 
investigated their effects on susceptibility to HIV-2 infection and disease progression.
Materials and Methods
Study populations
The Medical Research Council (UK) unit in The Gambia has followed up for two 
decades an open cohort o f  HIV-2, HIV-1, and dually infected adults, and a similar number o f  
age- and sex-matched uninfected controls in the rural village o f  Caio, Guinea-Bissau, a 
relatively isolated community o f the Manjako tribe, an animist tribe in which marriages 
usually occur within the community. The Caio cohort was established in 1989 and a 
demographic census and sero-survey o f the area was conducted in 1989-90, in which 7.9% o f
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the adult population was shown to be infected with HIV-2 (17). This was followed by a case- 
control study in 1991 (18), a re-survey in 1996-8, and re-examination o f  the cases and 
controls in 1996 and 2003. Our study used the samples and data collected in the 2003 study. 
The original case-control cohort was carefully recruited to match cases and controls as far as 
possible for demographic factors such as age, sex, and location in the village.
A  total o f 513 samples from HIV-2 infected and uninfected adults, predominantly o f  
the Manjako tribe, were typed for HLA class I {HLA-A, -B, and -Q  and KIR genes. Table I 
shows the characteristics o f all the study participants. There were more females than males in 
each category and females were also slightly older: this is consistent with previous 
epidemiological data from Africa, in which older women appear to be more susceptible to 
HIV infection in general and particularly to HIV-2 (19,20). The differences in age between 
categories were not statistically significant. Dually infected (HIV-1&2) individuals were 
excluded from all other analyses because o f  the potential for HIV-1 to confound our analyses. 
Precise dates o f seroconversion are unknown for most o f the infected participants in our study. 
Although it is difficult to estimate HIV exposure in the control group accurately, previous 
anthropological studies in Caio strongly suggest that the unique traditional way o f life o f the 
Manjakos in Caio lead to most adults having been exposed to sexually transmitted diseases, 
including HIV, from multiple partners during their four year initiation period into adulthood 
(21,22).
The study was approved by the Gambian Govemment/MRC joint Ethical Committee, 
the Open University’s Life and Biomolecular Sciences Management Group, UK, and the 
Office o f Human Subjects Research, National Institutes o f Health, USA.
KIR and HLA class I  genotyping
Genomic DNA was genotyped for presence or absence o f  the following KIR genes: 
2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3,
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3DS1, 2DP1, and 3DPI. Genotyping was performed using PCR amplification with two pairs 
o f primers specific for each locus (PCR-SSP) as previously described (23). HLA class I 
genotyping was done by sequencing. Briefly, locus-specific primers flanking exons 2 and 3 
were used to amplify HLA-A, -B, and -C loci. Purified PCR products were sequenced in both 
directions using exon-specific primers and BigDye Terminator version 3.1 Cycle Sequencing 
Kit (Appliedbiosystems, Foster City, USA) in an ABI-3130XL DNA Analyzer 
(Appliedbiosystems, Foster City, USA). Sequence traces were analysed using “Assign 400” 
software (Conexio genomics, Western Australia).
Statistical analysis
Allele and genotype frequencies were calculated using SPSS v l 6.0.1 (SPSS Inc, 
Chicago, USA) and STATA v9.2 (Stata Corporation, Texas, USA). Haplotype reconstruction, 
test for Hardy-Weinberg equilibrium, and haplotype frequency estimations were performed 
using Arlequin version 3.11. %2 test was used to examine differences in allele and genotype 
frequencies between Caio and other West African populations. All other statistical analyses 
were performed using SAS 9.1 (SAS Institute). PROC FREQ was used to compute 
frequencies o f individual variables. PROC LOGISTIC was used for categorical analyses to 
obtain odds ratios and 95% confidence intervals. PROC GLM was used for analysing 
continuous variables. Both logistic and linear regression models were adjusted for age and 
gender. We did not adjust for ethnicity because more than 95% o f the subjects were from the 
same ethnic group (Manjako).
Results
HLA class I  allele frequencies in Caio show significant differences compared to other West 
African populations
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We first compared the frequencies o f each HLA class I allele with data from 
neighbouring West African populations in Senegal (24), Mali (25), and The Gambia (LM 
Yindom, manuscript in preparation) (Fig. 1). Frequencies o f HLA-A, -B, and -C alleles in 
Caio (n = 513) differed significantly for some alleles from those in neighbouring countries, 
where HLA-A*3303 was more common and -A*3001 less common (Fig. la ). HLA-B*0801, - 
B*1302, -B*1503, -B*1510, were also relatively common in Caio as was -B*5801, which has 
previously been shown to be protective against HIV-1 (26) (Fig. lb ). HLA-Cw*1601 and - 
Cw*17 allele frequencies were lower, whereas HLA-Cw*0701, -Cw*0304 and -Cw*0804 were 
higher in Caio than elsewhere (Fig. lc ).
KIR genotypes in Caio contain more activating KIRs than reported in other African 
populations
We also determined KIR gene frequencies in our samples and compared their 
frequencies with neighbouring populations (Fig. 2). There were no significant differences in 
frequency between the populations for any o f the inhibitory KIR genes. On the other hand, 
activating receptors were present at higher frequencies in Caio compared to neighbouring 
populations (Fig. 2). Interestingly, KIR3DS1, which is relatively rare in people o f  African 
ancestry, was not uncommon in Caio. KIR3DS1 has previously been shown to confer 
protection against rapid progression to AIDS following HIV-1 infection in combination with 
its putative ligand HLA-B Bw4-80I (27).
HLA is associated with resistance to HIV-2 infection and predicts disease progression
In order to determine whether certain HLA class I alleles could predict HIV-2 disease 
progression, we analyzed the CD4+ T-cell counts and viral load data from 141 HIV-2 infected 
individuals who provided a blood sample in 2003. The overall mean square root (sqrt) CD4+
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T-cell count was 24.68, (SE: 0.55) and mean log HIV-2 viral load was 3.07, (SE: 0.09). 
Analysis o f HLA-B genotypes, CD4+ T-cell counts (n=131) and viral load (n=136) data from 
HIV-2 infected subjects revealed that HLA-B *15+ individuals had significantly lower mean 
sqrt CD4+ T-cell counts (22.61, SE: 0.86, p = 0.001) and higher mean log HIV-2 viral load 
(3.41, SE: 0.14, p = 0.001) compared to those without this genotype (26.27, SE: 0.69; and 
2.81, SE: 0.11, respectively) (Table II). This association appeared to be due completely to the 
frequent i? *1503 allele, which showed lower mean sqrt CD4+ T-cell counts (21.18, SE: 1.20, p 
= 0.001) and higher mean log HIV-2 viral load (3.48, SE: 0.20, p = 0.020) compared to that o f  
i?*/503-negative individuals (25.75, SE: 0.60; and 2.93, SE: 0.10, respectively). No  
susceptibility effect was seen with the other common B *1510 allele. HLA-B *49 was also 
associated with lower mean sqrt CD4+ T-cell count (21.51, SE: 1.53, p = 0.02) and a tendency 
towards a higher mean log HIV-2 viral load (Table H). Not surprisingly, HLA-Cw*02, which 
is in linkage disequilibrium with B *15, also associated with lower mean sqrt CD4+ T-cell 
count (20.43, SE: 1.46, p = 0.002) and trended towards high mean log HIV-2 viral load. Other 
alleles weakly associated with markers o f  disease progression are shown in Table II. 
Interestingly, most o f the protective effects observed in this study are mediated by relatively 
rare alleles (B*82, B*44, and B*14) as has also been observed for HIV-1 infection (28). 
However, given the limited numbers and weak effects in most o f these analyses, further 
studies will be required to verify these associations.
Next, we compared two-digit HLA class I genotype frequencies for alleles present in at 
least 2% o f the study population, between cases and controls (Table III). All three loci were 
in Hardy-Weinberg (H-W) equilibrium (p-values = 0.18517, 0.25241, and 0.10134 for HLA-A, 
-B, and -C loci respectively). Two alleles, HLA*A80 and HLA-B*08, were more frequent in 
HIV-2 infected individuals than controls (5.3% vs. 0.7%, p = 0.006, and 27.1% vs 14.6%, p =
0.003, respectively) suggesting that they are associated with susceptibility to HIV-2 infection
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in this population. Only one subtype o f A *80 (A *8001) and B *08 (B*0801) was present in 
Caio. None o f the HLA-C alleles were associated with susceptibility or resistance to HIV-2 
infection.
We also estimated haplotype frequencies using Arlequin version 3.11 (29) and the 
most frequent two- and three-locus haplotypes were HLA-B*1503-Cw*0210 (9.8%), HLA- 
A*330301-B*l510-Cw*0304 (6.2%), andHLA-A*2301-B*1503-Cw*0210 (5.3%) (data not 
shown). None o f the haplotypes had any significant influence on HIV-2 acquisition or disease 
progression.
HLA and KIR compound genotypes and resistance to HIV-2 infection
KIR molecules are known to interact with their HLA class I ligands to modulate NK  
cell activity. The ligands for KIR2DL are HLA-C alleles which are classified as C-group 1 
(C l) i f  the amino acid at position 80 is asparagine or C-group 2 (C2) if  lysine occupies that 
position. The inhibitory KIR2DL2 and 2DL3 (which are alleles o f the same locus) recognize 
C l while KIR2DL1 recognizes C2 allotypes. KIR3DL1 recognizes HLA-B Bw4 allotypes, 
particularly those with isoleucine at position 80 (30). The activating receptors KIR2DS2, 
2DS1 and 3DS1 share high sequence similarity in their extracellular domains with the 
corresponding inhibitory receptors KIR2DL2/3, 2DL1 and 3DL1, respectively. KIR2DS1 and 
2DS2 appear to bind the same set o f HLA class I ligands as their inhibitory counterparts, 
although with much lower affinity (31). Epidemiological data are consistent with a receptor- 
ligand relationship between KIR3DS1 and HLA-B Bw4-80I, but this has never been shown 
formally.
To determine the effect o f HLA/KIR genotypes on susceptibility or resistance to HIV-2 
infection, we grouped individuals based on whether they had appropriate ligands for their KIR 
genetic profile, and compared the various HLA/KIR combinations between HIV-2 infected and
uninfected groups. We also looked at HIV-2 viral load and CD4+ T-cell counts in the infected 
group. There was no significant effect o f individual KIR genes on infection or markers o f  
disease progression (data not shown). However, individuals carrying either the activating 
KIR2DS2 or the inhibitory KIR2DL2 (these two KIR genes are in very strong linkage 
disequilibrium (LD) with one another), with at least one copy o f  their corresponding HLA 
ligands (C l) were more likely to be HIV-2 negative compared to those without these 
compound genotypes, raising the possibility that the compound genotypes 2DS2:HLA-Cl/x 
and/or 2DL2:HLA-Cl/x (where x could be Cl or C2) might protect against HIV-2 acquisition 
(Table IV). Due to the strong LD between KIR2DL2 and 2DS2, it is difficult to determine 
which locus is implicated in the protective effect. Analysis o f the various HLA/KIR gene 
profiles and HIV-2 viral load and CD4+ T-cell counts found no trend indicative o f an influence 
on these markers o f disease progression.
Discussion
The HIV epidemic in West Africa is caused by two closely related retroviruses HIV-1 
and HIV-2. The latter, which is the focus o f  this study, was first reported to have infected 
healthy Senegalese prostitutes in 1985 (32) and was isolated the following year from two 
West-African patients with AIDS: one from Cape Verde Islands and the other from Guinea- 
Bissau (1). HIV-2 is structurally very similar to HIV-1 and shares between 30 to 60% 
homology at the nucleotide level.
Although both HIV-1 and HIV-2 use the same repertoire o f co-receptors and target 
similar cell populations, their rate o f  infection and the resultant pathogenesis are quite 
different. The majority o f HIV-2 infected people in Caio show high rates o f long-term non­
progression (LTNP). Indeed, recent studies in Caio have shown that the majority o f  HIV-2 
infected subjects that presented in 1991 (when viral load measurements were first made) with
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viral load below detection have maintained undetectable viral loads for at least 15 years: these 
subjects have the same mortality risk as HIV uninfected subjects (Schim van der Loeff, ms 
submitted). However, in contrast to the ancestral virus (SIVsm) infecting its natural host, the 
sooty mangabey, a significant proportion o f HIV-2-infected subjects later progress to AIDS, 
with low CD4 count, high HIV-2 viral load and clinical features that are indistinguishable 
from that observed in HIV-1 infection when CD4 count falls below 200 cells/pl (33). The 
observation that the majority o f HIV-2 infected individuals are LTNPs suggests that HIV-2 
infection presents a unique human model o f naturally attenuated HIV infection that could 
provide considerable insights into the mechanism(s) o f protective immunity needed for HIV 
vaccine development. The mechanisms underlying the attenuated course o f  HIV-2 infection 
and lack o f  disease progression in a substantial proportion o f HIV-2 infected individuals are 
yet to be uncovered, but previous studies in Caio have shown a strong correlation between T- 
cell responses to a conserved region o f HIV-2 gag and low plasma viral load (5).
Accumulating epidemiological evidence indicates that a range o f distinct viral and host 
genetics and possibly some environmental factors contribute to the observed differences in 
clinical outcome after HIV infection. Amongst the host genetic factors are the HLA and KIR 
genes that are highly polymorphic and are very important antiviral innate and adaptive 
immune response regulators in humans. Epidemiological studies have implicated certain HLA 
alleles in rate o f progression to AIDS in HIV-1 disease (8) and provided evidence that HLA 
genes are involved in the control o f viral replication (34, 35), but their role in HIV-2 infection 
and disease progression is not clear. A small study on 62 female commercial sex workers 
infected with HIV-2, using p26 antigen exposure as a surrogate marker for disease 
progression, showed that HLA-B*35 was associated with lack o f p26 antibodies and higher 
risk o f disease progression (36). However, a detailed analysis on the effects o f  HLA and KIR 
genes on susceptibility to HIV-2 and disease progression is largely missing in the literature. In
this study, we determine for the first time the frequencies o f HLA class I and KIR genes 
simultaneously from a predominantly Manjako community (>95%) in Caio, Guinea-Bissau 
and demonstrated that specific HLA alleles can influence disease progression and risk o f HIV- 
2 acquisition.
Comparison o f HLA allele frequencies between Caio and neighbouring populations 
showed distinct differences in allele frequencies that are consistent with previous 
anthropological findings suggesting that Manjakos from the Caio sector are a unique set o f  
people forming a close-knit community that tends to be isolated sexually from other ethnic 
groups in the sub region. Recent studies on sequence analysis o f the gag and nef genes in 
members o f  the Caio cohort showed uniform infection with closely related strains o f clade A  
HIV-2 (Onyango et al, Vaccine 2009 in press, Feldmann et al, manuscript in preparation). 
Preliminary results from a similar study looking at the effect o f HLA and KIR genes in a multi­
ethnic cohort in Fajara, The Gambia revealed that the Manjakos living in The Gambia exhibit 
similar HLA class I allele frequencies to those found in this study suggesting that there is little 
admixture between Manjakos and other tribes in the sub region irrespective o f  their 
geographical location (Yindom et al. manuscript in preparation).
Analysis o f our KIR gene pool comparing frequencies o f individual KIR genes with the 
scant available data from other West African populations showed that most o f  the activating 
KIR genes were present at higher frequencies in Caio (Fig. 2). KIR3DS1 which is rarely found 
in people o f  African ancestry was significantly higher in the Caio population as compared to 
other West African populations such as Senegal (37), Nigeria (38), and The Gambia (Yindom  
et al. manuscript in preparation). KIR3DS1 has previously been shown to confer protection 
against rapid progression to AIDS following HIV-1 infection in combination with its putative 
ligand HLA-B Bw4-80I (27).
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Data on specific dates o f  seroconversion were not available for this cohort, as is 
usually the case in most African cohorts. We relied on information collected on known 
markers o f HIV disease progression such as CD4 counts and viral load measurements to 
predict the effect o f  HLA class I and KIR gene variants on progression to AIDS following 
HIV-2 infection. We analysed the HLA-A, -B and -C allele and genotype data from 
individuals singly infected with HIV-2 and found that individuals carrying the common 
B*1503 allele were more likely to progress to AIDS than those without this allele. No  
susceptibility effect was seen with the other common B*15 allotype, B*1510. B*1503 and 
B*1510 differ by only 3 amino acids, all at critical sites in the peptide binding groove: 
positions 63 and 67, which reside in the alpha helix and contribute to the P2 pocket, and 
position 116, which resides on the floor o f the peptide binding groove and is part o f the P9 
pocket. A  single amino acid change at position 116 in B*3501 vs. B*3503 has previously 
been implicated in differential susceptibility to HIV-1 disease progression (9), emphasizing 
the importance o f this position in distinguishing the functional activity o f  HLA class I 
molecules. HLA-B*1503 has been associated with low viral loads in individuals infected with 
HIV-1 clade B, but no protective effect o f this allele was observed in a C clade cohort from 
Durban, South Africa (39). HLA-B*1503 and the haplotype B*1503-Cw*0210 are unique 
makers confined to populations o f Sub-Sahara African origins (40). Therefore, the effect o f  
HLA-B*1503 is more likely to be observed in these populations than in populations with a low  
frequency o f this allele. Some minor/rare alleles were found to weakly associate with high 
CD4 count and a trend towards low viral load, indicating that they may offer a protective 
effect against rapid progression to AIDS following HIV-2 infection. This supports the notion 
proposed by Trachtenberg and co workers that rare HLA alleles may have a selective 
advantage in protecting against rapid progression to AIDS in populations where HIV-1 has 
adapted to the most frequent HLA alleles (28).
Concluding remarks
Here we determined HLA class I and KIR gene profiles o f a relatively isolated 
population in Caio, Guinea-Bissau, with one o f the highest prevalence rates o f HIV-2 infection 
in the world. The HLA-B* 15 alleles B*1503 and B*1510 were observed at a relatively high 
frequency in this community compared to neighbouring populations. Furthermore, HIV-2- 
infected individuals with B*1503 (but not B*1510) had significantly higher HIV-2 viral loads 
and lower CD4 counts compared to those without this allele, suggesting that this allele might 
be linked to poor control o f  viral replication and more rapid disease progression. Notably, 
none o f  the strongest HLA associations with HIV-1 were observed in our HIV-2 cohort. The 
frequencies o f activating KIR genes were higher than reported for other populations in West 
Africa. The frequency o f  KIR3DS1, which was previously shown to be protective in HIV-1 
disease progression, was significantly higher in the Manjako group than that reported in any 
other African population. KIR2DS2 and KIR2DL2 were weakly associated with reduced risk 
o f HIV-2 infection. In general, the strongest associations in our study conferred susceptibility 
to HIV-2 outcomes, while protective factors were quite weak. This observation is contrary to 
that observed in HIV-1 disease, where the strongest HLA associations confer protection. 
Perhaps this reflects the less pathogenic nature o f HIV-2 and the ability o f most HLA class I 
allotypes to effectively control the virus, as compared to HIV-1, where most allotypes are 
unable to maintain viral restriction. Our study is the first to provide a detailed analysis o f the 
effects o f HLA and KIR genetic variation on resistance/susceptibility to HIV-2 infection and 
disease progression. It will be o f great interest to determine whether these effects can be 
validated in the other rare HIV-2 cohorts collected to date.
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Figure legends
Figure 1. HLA allele frequencies in Caio, Guinea Bissau compared to frequencies in 
neighbouring West African Countries, a) HLA-A, b) HLA-B, c) HLA-C allele frequencies 
Guinea-Bissau (513 samples) and neighbouring countries: Senegal (165 samples), The 
Gambia (592 samples), and Mali (138 samples). Alleles with frequencies o f <1% in all 
populations are not shown.*: p < 0.05; **: p < 0.001.
Figure 2. Frequencies o f activating and inhibitory KIR genes in Caio, Guinea-Bissau 
compared to those in The Gambia and Senegal. *: p<0.05; **: p<0.001.
Table I. Characteristics of the study population (n = 513), Caio, 2003-7
N  (%) Median age (IQR)
HIV-negative
Male 114(35) 36.2 (25.8-52.5)
Female 213 (65) 46.2 (30.8-62.8)
HIV-2 infected
Male 49 (32) 53.7 (43.0-62.9)
Female 102 (68) 59.5 (49.5-69.4)
HIV-1&-2 dually infected
Male 6(17) 37.0 (34.7-49.3)
Female 29 (83) 52.8 (42.8-61.7)
Age difference between males and females was not statistically significant between cases and 
controls.
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Table II. Effects of HLA-B and HLA-C on CD4+ T lymphocyte counts and viral load
HLA (n=135) Mean sqrt CD4 (n) SE p Mean logHIV-2 VL (n) SE P
B*14 (P) 26.81 (14) 1.71 0.23 2.39 (14) 0.29 0.02
B*15 (S) 22.61 (51) 0.86 0.001 3.41 (52) 0.14 0.001
B*1503 (S) 21.18(26) 1.20 0.001 3.48 (28) 0.20 0.02
B*1510 24.78 (24) 1.31 0.96 3.22 (25) 0.22 0.36
B*1516 19.75 (3) 3.68 0.16 3.55 (2) 0.78 0.51
B*44 (P) 27.01 (7) 2.42 0.36 2.27 (8) 0.38 0.04
B*49 (S) 21.51 (17) 1.53 0.02 3.39 (20) 0.24 0.12
B*57 (P) 29.82 (7) 2.37 0.03 3.30 (7) 3.30 0.51
B*82 (P) 27.71 (3) 3.68 0.43 1.70 (3) 0.61 0.03
Cw*02 (S) 20.43 (19) 1.46 0.002 3.41 (20) 0.24 0.14
Cw*07( S) 24.39 (47) 0.96 0.73 3.35 (50) 0.15 0.03
(P): Protective allele with either a mean sqt CD4+ T cell count greater than 24.7 (average 
mean sqrt CD4+ T cell counts) and/or mean logVL less than 3.1 (average mean HIV-2 VL) 
and a p-value < 0.05; (S): Susceptible allele with either a mean sqrt CD4+ T cell count less 
than 24.7 (average mean CD4+ T cell counts) and/or mean logVL greater than 3.1 (average 
mean HIV-2 VL) and a p-value < 0.05. p-values stated are uncorrected for multiple 
comparisons.
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Table III. HLA-A, -B, and -C genotypes and HIV-2 antibody status in Caio community
Allele HIV-2+ (n) HIV-negative (n) All (n) P OR 95% Cl
A*01 12.0 (18) 14.6 (45) 13.8 (63) 0.45 0.80 0.44-1.44
A*02 18.7 (28) 24.4 (75) 22.5(103) 0.20 0.73 0.45-1.18
A*03 4.7 (7) 4.9(15) 4.8 (22) 0.92 0.95 0.38 - 2.40
A*23 33.3 (50) 31.5 (97) 32.1 (147) 0.63 1.11 0.73-1.68
A*26 16.7 (25) 13.6 (42) 14.6 (67) 0.37 1.28 0.75 - 2.20
A*29 1.3 (2) 2.9 (9) 2.4 (11) 0.32 0.46 0.10-2.15
A*30 24.0 (36) 17.2 (53) 19.4 (89) 0.08 1.54 0.95 - 2.48
A*33 38.0 (57) 39.3 (121) 38.9 (178) 0.84 0.96 0.64-1.43
A*34 4.7 (7) 3.9 (12) 4.2 (19) 0.69 1.21 0.47-3.15
A*66 2.0 (3) 3.6 (11) 3.1 (14) 0.36 0.55 0.15-1.99
A*68 18.0 (26) 14.3 (45) 15.5 (71) 0.43 1.24 0.73-2.10
A*74 7.3 (10) 11.7 (37) 10.3(47) 0.09 0.53 0.26-1.10
A*80 5.3 (8) 0.7(2) 2.2 (10) 0.006 8.90 1.86-42.53
B*07 4.9 (7) 7.3 (17) 6.4 (24) 0.37 0.66 0.27-1.63
B*08 27.1 (39) 14.6 (34) 19.4 (73) 0.003 2.20 1.31 -3.71
B*13 5.6 (8) 6.1 (14) 5.8 (22) 0.88 0.93 0.38 - 2.28
B*14 10.4 (14) 7.7 (19) 8.8 (33) 0.57 1.23 0.60 - 2.54
B*15 38.2 (55) 45.1 (105) 42.4 (160) 0.22 0.77 0.50-1.17
B*18 6.3 (9) 4.3 (10) 5.0 (19) 0.39 1.51 0.60 - 3.80
8*35 13.9(20) 21.5 (50) 18.6 (70) 0.08 0.60 0.34-1.06
B*44 5.6 (8) 5.2 (12) 5.3 (20) 0.85 1.09 0.44 - 2.75
B*49 13.9 (20) 13.3 (31) 13.8 (51) 0.84 1.07 0.58-1.95
B*50 2.1 (3) 2.2 (5) 2.1 (8) 0.98 0.98 0.23-4.16
B*51 3.5 (5) 3.0 (7) 3.2 (12) 0.87 1.17 0.36 - 3.76
8*52 1.4 (2) 3.8 (9) 2.9 (11) 0.19 0.36 0.08-1.67
8*53 16.7 (23) 23.2 (55) 20.7 (78) 0.08 0.62 0.36-1.07
B*57 4.9 (7) 1.7(4) 2.9 (11) 0.09 2.95 0.85 - 10.2J
B*58 22.2 (32) 19.3(45) 20.4 (77) 0.46 1.22 0.73 - 2.03
Cw*01 8.9 (13) 7.5(21) 7.9 (34) 0.60 1.21 0.59 - 2.50
Cw*02 14.9 (22) 21.3 (60) 19.1 (82) 0.12 0.66 0.38-1.12
Cw*03 39.9 (59) 44.0 (124) 42.6 (183) 0.45 0.86 0.57-1.28
Cw*04 29.7 (43) 29.8 (85) 29.8 (128) 0.87 0.96 0.62-1.49
Cw*05 8.1 (12) 4.3 (12) 5.6 (24) 0.10 2.02 0.88 - 4.61
Cw*06 4.7(11) 3.9 (27) 4.2 (18) 0.45 0.75 0.36-1.57
Cw*07 37.8 (56) 33.7 (95) 35.1 (151) 0.35 1.22 0.81 -1.85
Cw*08 14.2 (20) 15.3 (44) 14.8 (64) 0.59 0.85 0.48-1.51
Cw*14 1.4(2) 3.9 (11) 3.0 (13) 0.16 0.34 0.07-1.55
Cw*15 5.4 (8) 3.9 (11) 4.4 (19) 0.44 1.45 0.57 - 3.69
Cw*16 5.4 (8) 7.5(21) 6.7 (29) 0.44 0.72 0.31 -1.67
Cw*17 3.4 (5) 2.1 (6) 2.6 (11) 0.43 1.62 0.48 - 5.39
Cw*18 4.1 (6) 3.5 (10) 3.7 (16) 0.78 1.16 0.41 - 3.26
All: represents the percentage o f individuals positive for the indicated allele in the community; 
n: number o f individuals carrying the allele o f interest; p: p-values uncorrected for multiple 
comparisons; OR: the odds ratio derived by comparing the number o f individuals positive for 
the indicated allele versus those without the allele between cases (HIV-2+) and controls (HIV- 
negative) groups, p value and OR are calculated by logistic regression with controlling for 
gender and ethnicity. Only alleles with population frequency o f at least 2% are shown.
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Table IV. The effects of KIR and HLA compound genotypes on HIV-2 antibody status
HIV-2+ HIV-negative OR 95% Cl P
n % n %
2DS2 66 44.00 178 54.27 2DS2 vs. others 0.67 0.45-0.98 0.04
Others 84 56.00 150 45.73
2DL2 72 48.00 195 59.45 2DL2 vs. others 0.63 0.43-0.93 0.02
Others 78 52.00 133 40.55
2DS2+/C1+ 49 33.79 124 44.93 2DS2+/C1+ vs. others 0.63 0.41-0.95 0.03
Others 96 66.21 152 55.07
2DL2+/C1+ 56 38.62 135 48.91 2DL2+/C1+ vs. others 0.66 0.44-0.99 0.04
Others 89 61.38 141 51.09
n: number o f individuals with the gene/genotype or without the gene/genotype (others); p: p- 
values uncorrected for multiple comparisons; OR: the odds ratio derived by comparing the 
number o f individuals positive for the indicated allele/genotype versus those without that 
allele or genotype between cases (HIV-2+) and controls (HIV-negative), p value and OR are 
calculated by logistic regression with adjusting for gender and ethnicity.
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